Omega-conopeptides

ABSTRACT

The invention relates to ω-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application is a continuation of U.S. patent application Ser. No. 09/910,082 filed on 23 Jul. 2001. The present application claims benefit under 35 USC §119(e) to U.S. provisional patent applications Serial No. 60/219,616 filed on 21 Jul. 2000 and Serial No. 60/265,888 filed on 5 Feb. 2001. Each of these applications are incorporated herein by reference.

[0002] This invention was made with Government support under Grant No. PO1 GM48677 awarded by the National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0003] The invention relates to ω-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.

[0004] The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference, and for convenience are referenced in the following text by author and date and are listed alphabetically by author in the appended bibliography.

[0005] Conus is a genus of predatory marine gastropods (snails) which envenomate their prey. Venomous cone snails use a highly developed projectile apparatus to deliver their cocktail of toxic conotoxins into their prey. In fish-eating species such as Conus magus the cone detects the presence of the fish using chemosensors in its siphon and when close enough extends its proboscis and fires a hollow harpoon-like tooth containing venom into the fish. This immobilizes the fish and enables the cone snail to wind it into its mouth via an attached filament. For general information on Conus and their venom see the website address http://grimwade.biochem.unimelb.edu.au/cone/referenc.html. Prey capture is accomplished through a sophisticated arsenal of peptides which target specific ion channel and receptor subtypes. Each Conus species venom appears to contain a unique set of 50-200 peptides. The composition of the venom differs greatly between species and between individual snails within each species, each optimally evolved to paralyse it's prey. The active components of the venom are small peptides toxins, typically 12-30 amino acid residues in length and are typically highly constrained peptides due to their high density of disulphide bonds.

[0006] The venoms consist of a large number of different peptide components that when separated exhibit a range of biological activities: when injected into mice they elicit a range of physiological responses from shaking to depression. The paralytic components of the venom that have been the focus of recent investigation are the α-, ω- and μ-conotoxins. All of these conotoxins act by preventing neuronal communication, but each targets a different aspect of the process to achieve this. The α-conotoxins target nicotinic ligand gated channels, the μ-conotoxins target the voltage-gated sodium channels and the ω-conotoxins target the voltage-gated calcium channels (Olivera et al., 1985; Olivera et al., 1990). For example a linkage has been established between α-, αA- & φ-conotoxins and the nicotinic ligand-gated ion channel; ω-conotoxins and the voltage-gated calcium channel; κ-conotoxins and the voltage-gated sodium channel; δ-conotoxins and the voltage-gated sodium channel; κ-conotoxins and the voltage-gated potassium channel; conantokins and the ligand-gated glutamate (NMDA) channel.

[0007] However, the structure and function of only a small minority of these peptides have been determined to date. For peptides where function has been determined, three classes of targets have been elucidated: voltage-gated ion channels; ligand-gated ion channels, and G-protein-linked receptors.

[0008] Conus peptides which target voltage-gated ion channels include those that delay the inactivation of sodium channels, as well as blockers specific for sodium channels, calcium channels and potassium channels. Peptides that target ligand-gated ion channels include antagonists of NMDA and serotonin receptors, as well as competitive and noncompetitive nicotinic receptor antagonists. Peptides which act on G-protein receptors include neurotensin and vasopressin receptor agonists. The unprecedented pharmaceutical selectivity of conotoxins is at least in part defined by a specific disulfide bond frameworks combined with hypervariable amino acids within disulfide loops (for a review see McIntosh et al., 1998).

[0009] There are drugs used in the treatment of pain, which are known in the literature and to the skilled artisan. See, for example, Merck Manual, 16th Ed. (1992). However, there is a demand for more active analgesic agents with diminished side effects and toxicity and which are non-addictive. The ideal analgesic would reduce the awareness of pain, produce analgesia over a wide range of pain types, act satisfactorily whether given orally or parenterally, produce minimal or no side effects, be free from tendency to produce tolerance and drug dependence.

[0010] Due to the high potency and exquisite selectivity of the conopeptides, several are in various stages of clinical development for treatment of human disorders. For example, two Conus peptides are being developed for the treatment of pain. The most advanced is ω-conotoxin MVIIA (ziconotide), an N-type calcium channel blocker (see Heading, C., 1999; U.S. Pat. No. 5,859,186). ω-Conotoxin MVIIA, isolated from Conus magnus, is approximately 1000 times more potent than morphine, yet does not produce the tolerance or addictive properties of opiates. ω-Conotoxin MVIIA has completed Phase III (final stages) of human clinical trials and has been approved as a therapeutic agent. ω-Conotoxin MVIIA is introduced into human patients by means of an implantable, programmable pump with a catheter threaded into the intrathecal space. Preclinical testing for use in post-surgical pain is being carried out on another Conus peptide, contulakin-G, isolated from Conus geographus (Craig et al. 1999). Contulakin-G is a 16 amino acid O-linked glycopeptide whose C-terminus resembles neurotensin. It is an agonist of neurotensin receptors, but appears significantly more potent than neurotensin in inhibiting pain in in vivo assays.

[0011] Ischemic damage to the central nervous system (CNS) may result form either global or focal ischemic conditions. Global ischemia occurs under conditions in which blood flow to the entire brain ceases for a period of time, such as may result from cardiac arrest. Focal ischemia occurs under conditions in which a portion of the brain is deprived of its normal blood supply, such as may result from thromboembolytic occlusion of a cerebral vessel, traumatic head or spinal cord injury, edema or brain or spinal cord tumors. Both global and focal ischemic conditions have the potential for widespread neuronal damage, even if the global ischemic condition is transient or the focal condition affects a very limited area.

[0012] Epilepsy is a recurrent paroxysmal disorder of cerebral function characterized by sudden brief attacks of altered consciousness, motor activity, sensory phenomena or inappropriate behavior caused by abnormal excessive discharge of cerebral neurons. Convulsive seizures, the most common form of attacks, begin with loss of consciousness and motor control, and tonic or clonic jerking of all extremities but any recurrent seizure pattern may be termed epilepsy. The term primary or idiopathic epilepsy denotes those cases where no cause for the seizures can be identified. Secondary or symptomatic epilepsy designates the disorder when it is associated with such factors as trauma, neoplasm, infection, developmental abnormalities, cerebrovascular disease, or various metabolic conditions. Epileptic seizures are classified as partial seizures (focal, local seizures) or generalized seizures (convulsive or nonconvulsive). Classes of partial seizures include simple partial seizures, complex partial seizures and partial seizures secondarily generalized. Classes of generalized seizures include absence seizures, atypical absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic-clonic seizures (grand mal) and atonic seizures. Therapeutics having anticonvulsant properties are used in the treatment of seizures. Most therapeutics used to abolish or attenuate seizures act at least through effects that reduce the spread of excitation from seizure foci and prevent detonation and disruption of function of normal aggregates of neurons. Traditional anticonvulsants that have been utilized include phenytoin, phenobarbital, primidone, carbamazepine, ethosuximide, clonazepam and valproate. Several novel and chemically diverse anticonvulsant medications recently have been approved for marketing, including lamotrigine, ferlbamate, gabapentin and topiramate. For further details of seizures and their therapy, see Rall & Schleifer (1985) and The Merck Manual (1992).

[0013] In view of a large number of biologically active substances in Conus species it is desirable to further characterize them and to identify peptides capable of treating disorders involving voltage gated ion channels, such as stroke and pain. Surprisingly, and in accordance with this invention, Applicants have discovered novel conotoxins that can be useful for the treatment of disorders involving voltage gated ion channels and could address a long felt need for a safe and effective treatment.

SUMMARY OF THE INVENTION

[0014] The present invention is directed to ω-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention is further directed to nucleic acid sequences encoding the ω-conopeptides and encoding propeptides, as well as the propeptides.

[0015] More specifically, the present invention is directed to ω-conopeptides, having the amino acid sequences set forth in Table 2 below.

[0016] The present invention is also directed to derivatives or pharmaceutically acceptable salts of the ω-conopeptides or the derivatives. Examples of derivatives include peptides in which the Arg residues may be substituted by Lys, ornithine, homoargine, nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any synthetic basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoargine, nor-Lys, or any synthetic basic amino acid; the Tyr residues may be substituted with meta-Tyr, ortho-Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any synthetic hydroxy containing amino acid; the Ser residues may be substituted with Thr or any synthetic hydroxylated amino acid; the Thr residues may be substituted with Ser or any synthetic hydroxylated amino acid; the Phe residues may be substituted with any synthetic aromatic amino acid; the Trp residues may be substituted with Trp (D), neo-Trp, halo-Trp (D or L) or any aromatic synthetic amino acid; and the Asn, Ser, Thr or Hyp residues may be glycosylated. The halogen may be iodo, chloro, fluoro or bromo; preferably iodo for halogen substituted-Tyr and bromo for halogen-substituted Trp. The Tyr residues may also be substituted with the 3-hydroxyl or 2-hydroxyl isomers (meta-Tyr or ortho-Tyr, respectively) and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic amino acid, e.g., tetrazolyl derivatives of Gly and Ala. The aliphatic amino acids may be substituted by synthetic derivatives bearing non-natural aliphatic branched or linear side chains C_(n)H_(2n+2) up to and including n=8. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L).

[0017] Examples of synthetic aromatic amino acid include, but are not limited to, nitro-Phe, 4-substituted-Phe wherein the substituent is C₁-C₃ alkyl, carboxyl, hyrdroxymethyl, sulphomethyl, halo, phenyl, —CHO, —CN, —SO₃H and —NHAc. Examples of synthetic hydroxy containing amino acid, include, but are not limited to, such as 4-hydroxymethyl-Phe, 4-hydroxyphenyl-Gly, 2,6-dimethyl-Tyr and 5-amino-Tyr. Examples of synthetic basic amino acids include, but are not limited to, N-1-(2-pyrazolinyl)-Arg, 2-(4-piperinyl)-Gly, 2-(4-piperinyl)-Ala, 2-[3-(2S)pyrrolininyl)-Gly and 2-[3-(2S)pyrrolininyl)-Ala. These and other synthetic basic amino acids, synthetic hydroxy containing amino acids or synthetic aromatic amino acids are described in Building Block Index, Version 3.0 (1999 Catalog, pages 4-47 for hydroxy containing amino acids and aromatic amino acids and pages 66-87 for basic amino acids; see also http://www.amino-acids.com), incorporated herein by reference, by and available from RSP Amino Acid Analogues, Inc., Worcester, Mass. Examples of synthetic acid amino acids include those derivatives bearing acidic functionality, including carboxyl, phosphate, sulfonate and synthetic tetrazolyl derivatives such as described by Ornstein et al. (1993) and in U.S. Pat. No. 5,331,001, each incorporated herein by reference.

[0018] Optionally, in the ω-conopeptides of the present invention, the Asn residues may be modified to contain an N-glycan and the Ser, Thr and Hyp residues may be modified to contain an O-glycan (e.g., g-N, g-S, g-T and g-Hyp). In accordance with the present invention, a glycan shall mean any N-, S- or O-linked mono-, di-, tri-, poly- or oligosaccharide that can be attached to any hydroxy, amino or thiol group of natural or modified amino acids by synthetic or enzymatic methodologies known in the art. The monosaccharides making up the glycan can include D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-galactosamine, D-glucosamine, D-N-acetyl-glucosamine (GlcNAc), D-N-acetyl-galactosamine (GalNAc), D-fucose or D-arabinose. These saccharides may be structurally modified, e.g., with one or more O-sulfate, O-phosphate, O-acetyl or acidic groups, such as sialic acid, including combinations thereof. The gylcan may also include similar polyhydroxy groups, such as D-penicillamine 2,5 and halogenated derivatives thereof or polypropylene glycol derivatives. The glycosidic linkage is beta and 1-4 or 1-3, preferably 1-3. The linkage between the glycan and the amino acid may be alpha or beta, preferably alpha and is 1-.

[0019] Core O-glycans have been described by Van de Steen et al. (1998), incorporated herein by reference. Mucin type O-linked oligosaccharides are attached to Ser or Thr (or other hydroxylated residues of the present peptides) by a GalNAc residue. The monosaccharide building blocks and the linkage attached to this first GaINAc residue define the “core glycans,” of which eight have been identified. The type of glycosidic linkage (orientation and connectivities) are defined for each core glycan. Suitable glycans and glycan analogs are described further in U.S. Ser. No. 09/420,797 filed 19 Oct. 1999 and in PCT Application No. PCT/US99/24380 filed 19 Oct. 1999 (PCT Published Application No. WO 00/23092), each incorporated herein by reference. A preferred glycan is Gal(β1→3)GalNAc(α1→).

[0020] Optionally, in the ω-conopeptides described above, pairs of Cys residues may be replaced pairwise with isoteric lactam or ester-thioether replacements, such as Ser/(Glu or Asp), Lys/(Glu or Asp) or Cys/Ala combinations. Sequential coupling by known methods (Barnay et al., 2000; Hruby et al., 1994; Bitan et al., 1997) allows replacement of native Cys bridges with lactam bridges. Thioether analogs may be readily synthesized using halo-Ala residues commercially available from RSP Amino Acid Analogues.

[0021] The present invention is further directed to a method of treating disorders associated with voltage gated ion channel disorders in a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a therapeutically effective amount of a ω-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a ω-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

[0022] More specifically, the present invention is further directed to uses of these peptides or nucleic acids as described herein, including the treatment of neurologic disorders, such as anticonvulsant agents, as neuroprotective agents, such as for treating stroke, as cardiovascular agents or for the management of pain.

[0023] More specifically, the present invention is also directed to nucleic acids which encode conopeptides of the present invention or which encodes precursor peptides for these conopeptides, as well as the precursor peptide. The nucleic acid sequences encoding the precursor peptides of other conopeptides of the present invention are set forth in Table 1. Table 1 also sets forth the amino acid sequences of these precursor peptides.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0024] The present invention is to ω-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of neurologic disorders, such as anticonvulsant agents, as neuroprotective agents, such as for treating stroke, as cardiovascular agents or for the management of pain, e.g. as analgesic agents. The invention is further directed to nucleic acid sequences encoding the ω-conopeptides and encoding propeptides, as well as the propeptides.

[0025] The present invention, in another aspect, relates to a pharmaceutical composition comprising an effective amount of an ω-conopeptides, a mutein thereof, an analog thereof, an active fragment thereof or pharmaceutically acceptable salts or solvates. Such a pharmaceutical composition has the capability of acting at voltage gated ion channels, and are thus useful for treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the partial or complete blockade of voltage gated ion channels of the central nervous system comprising the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a pharmaceutical composition of the present invention.

[0026] Voltage-gated calcium channels are present in neurons, and in cardiac, smooth, and skeletal muscle and other excitable cells, and are known to play a variety of roles in membrane excitability, muscle contraction, and cellular secretion, such as in synaptic transmission (McCleskey). In neuronal cells, voltage-gated calcium channels have been classified by their electrophysiological as well as by their biochemical (binding) properties. Six classes of physiologically distinct calcium channels have been identified to date, namely the T, L, N, P, Q, and R-type channels.

[0027] It is well known that an accumulation of calcium (calcium overload) in the brain is seen after anoxia, ischemia, migraine and other hyperactivity periods of the brain, such as after epileptic convulsions. An uncontrolled high concentration of calcium in the cells of the central nervous system (CNS) is known to cause most of the degenerative changes connected with the above diseases. Compounds which can block the calcium channels of brain cells are therefore useful in the treatment of stroke, anoxia, ischemia, migraine, psychosis, or epilepsy, any other convulsive disorder and in the prevention of the degenerative changes connected with the same.

[0028] Compounds blocking the so called L-type calcium channels in the CNS are useful for the treatment of the above disorders by directly blocking the calcium uptake in the CNS. Further, it is well known that the so called N- and P-types of calcium channels, as well as possibly other types of calcium channels, are involved in the regulation of neurotransmitter release. Compounds blocking the N- and/or P-types of calcium channels indirectly and very powerfully prevent calcium overload in the CNS after the hyperactivity periods of the brain as described above by inhibiting the enhanced neurotransmitter release seen after such hyperactivity periods of the CNS, and especially the neurotoxic, enhanced glutamate release after such hyperactivity periods of the CNS. Furthermore, blockers of the N- and/or P-types of calcium channels, as dependent upon the selectivity of the compound in question, inhibit the release of various other neurotransmitters such as aspartate, GABA, glycine, dopamine, serotonin and noradrenaline.

[0029] Thus, the pharmaceutical compositions of the present invention are useful as neuroprotectants, cardiovascular agents, anticonvulsants, analgesics or adjuvants to general anesthetics. A “neurological disorder or disease” is a disorder or disease of the nervous system including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage as in cardiac arrest or neonatal distress or epilepsy. In addition, a “neurological disorder or disease” is a disease state and condition in which a neuroprotectant, anticonvulsant, analgesic and/or as an adjunct in general anesthesia may be indicated, useful, recommended or prescribed.

[0030] More specifically, the present invention is directed to the use of these compounds for the treatment and alleviation of epilepsy and as a general anticonvulsant agent. The present invention is also directed to the use of these compounds for reducing neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events. The present invention is further directed to the use of these compounds for treating pain, including acute and chronic pain, such migraine, nociceptive and neuropathic pain. Other uses of these compounds are described in U.S. Pat. No. 5,859,186, incorporated herein by reference.

[0031] A “neuroprotectant” is a compound capable of preventing the neuronal death associated with a neurological disorder or disease. An “anticonvulsant” is a compound capable of reducing convulsions produced by conditions such as simple partial seizures, complex partial seizures, status epilepticus, and trauma-induced seizures such as occur following head injury, including head surgery. An “analgesic” is a compound capable of relieving pain by altering perception of nociceptive stimuli without producing anesthesia or loss of consciousness. A “muscle relaxant” is a compound that reduces muscular tension. A “adjunct in general anesthesia” is a compound useful in conjunction with anesthetic agents in producing the loss of ability to perceive pain associated with the loss of consciousness.

[0032] The invention relates as well to methods useful for treatment of neurological disorders and diseases, including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage such as in cardiac arrest or neonatal distress, epilepsy or other convulsive disorders without undesirable side effects.

[0033] Thus, in one embodiment, the invention provides a method of reducing/alleviating/ decreasing the perception of pain by a subject or for inducing analgesia in a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a therapeutically effective amount of a ω-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof. The pain may be acute, persistent, inflammatory or neuropathic pain.

[0034] In a second embodiment, the invention provides a method of treating stroke, head or spinal cord trauma or injury, anoxia, hypoxia-induced nerve cell damage, ischemia, migraine, psychosis, anxiety, schizophrenia, inflammation, movement disorder, epilepsy, any other convulsive disorder or in the prevention of the degenerative changes connected with the same in a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a therapeutically effective amount of a ω-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof.

[0035] The ω-conopeptides described herein are sufficiently small to be chemically synthesized. General chemical syntheses for preparing the foregoing ω-conotoxin peptides are described hereinafter. Various ones of the ω-conopeptides can also be obtained by isolation and purification from specific Conus species using the technique described in U.S. Pat. No. 4,447,356 (Olivera et al., 1984); U.S. Pat. Nos. 5,514,774; 5,719,264; and 5,591,821, as well as in PCT published application WO 98/03189, the disclosures of which are incorporated herein by reference.

[0036] Although the ω-conopeptides of the present invention can be obtained by purification from cone snails, because the amounts of ω-conopeptides obtainable from individual snails are very small, the desired substantially pure ω-conopeptides are best practically obtained in commercially valuable amounts by chemical synthesis using solid-phase strategy. For example, the yield from a single cone snail may be about 10 micrograms or less of ω-conopeptides peptide. By “substantially pure” is meant that the peptide is present in the substantial absence of other biological molecules of the same type; it is preferably present in an amount of at least about 85% purity and preferably at least about 95% purity. Chemical synthesis of biologically active ω-conopeptides peptides depends of course upon correct determination of the amino acid sequence.

[0037] The ω-conopeptides can also be produced by recombinant DNA techniques well known in the art. Such techniques are described by Sambrook et al. (1989). A gene of interest (i.e., a gene that encodes a suitable ω-conopeptides) can be inserted into a cloning site of a suitable expression vector by using standard techniques. These techniques are well known to those skilled in the art. The expression vector containing the gene of interest may then be used to transfect the desired cell line. Standard transfection techniques such as calcium phosphate co-precipitation, DEAE-dextran transfection or electroporation may be utilized. A wide variety of host/expression vector combinations may be used to express a gene encoding a conotoxin peptide of interest. Such combinations are well known to a skilled artisan. The peptides produced in this manner are isolated, reduced if necessary, and oxidized to form the correct disulfide bonds.

[0038] One method of forming disulfide bonds in the ω-conopeptides of the present invention is the air oxidation of the linear peptides for prolonged periods under cold room temperatures or at room temperature. This procedure results in the creation of a substantial amount of the bioactive, disulfide-linked peptides. The oxidized peptides are fractionated using reverse-phase high performance liquid chromatography (HPLC) or the like, to separate peptides having different linked configurations. Thereafter, either by comparing these fractions with the elution of the native material or by using a simple assay, the particular fraction having the correct linkage for maximum biological potency is easily determined. However, because of the dilution resulting from the presence of other fractions of less biopotency, a somewhat higher dosage may be required.

[0039] The peptides are synthesized by a suitable method, such as by exclusively solid-phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution couplings.

[0040] In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which constituent amino acids are added to the growing peptide chain in the desired sequence. Use of various coupling reagents, e.g., dicyclohexylcarbodiimide or diisopropylcarbonyldimidazole, various active esters, e.g., esters of N-hydroxyphthalimide or N-hydroxy-succinimide, and the various cleavage reagents, to carry out reaction in solution, with subsequent isolation and purification of intermediates, is well known classical peptide methodology. Classical solution synthesis is described in detail in the treatise, “Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden,” (1974). Techniques of exclusively solid-phase synthesis are set forth in the textbook, “Solid-Phase Peptide Synthesis,” (Stewart and Young, 1969), and are exemplified by the disclosure of U.S. Pat. No. 4,105,603 (Vale et al., 1978). The fragment condensation method of synthesis is exemplified in U.S. Pat. No. 3,972,859 (1976). Other available syntheses are exemplified by U.S. Pat. No. 3,842,067 (1974) and U.S. Pat. No. 3,862,925 (1975). The synthesis of peptides containing γ-carboxyglutamic acid residues is exemplified by Rivier et al. (1987), Nishiuchi et al. (1993) and Zhou et al. (1996).

[0041] Common to such chemical syntheses is the protection of the labile side chain groups of the various amino acid moieties with suitable protecting groups which will prevent a chemical reaction from occurring at that site until the group is ultimately removed. Usually also common is the protection of an α-amino group on an amino acid or a fragment while that entity reacts at the carboxyl group, followed by the selective removal of the α-amino protecting group to allow subsequent reaction to take place at that location. Accordingly, it is common that, as a step in such a synthesis, an intermediate compound is produced which includes each of the amino acid residues located in its desired sequence in the peptide chain with appropriate side-chain protecting groups linked to various ones of the residues having labile side chains.

[0042] As far as the selection of a side chain amino protecting group is concerned, generally one is chosen which is not removed during deprotection of the α-amino groups during the synthesis. However, for some amino acids, e.g., His, protection is not generally necessary. In selecting a particular side chain protecting group to be used in the synthesis of the peptides, the following general rules are followed: (a) the protecting group preferably retains its protecting properties and is not split off under coupling conditions, (b) the protecting group should be stable under the reaction conditions selected for removing the α-amino protecting group at each step of the synthesis, and (c) the side chain protecting group must be removable, upon the completion of the synthesis containing the desired amino acid sequence, under reaction conditions that will not undesirably alter the peptide chain.

[0043] It should be possible to prepare many, or even all, of these peptides using recombinant DNA technology. However, when peptides are not so prepared, they are preferably prepared using the Merrifield solid-phase synthesis, although other equivalent chemical syntheses known in the art can also be used as previously mentioned. Solid-phase synthesis is commenced from the C-terminus of the peptide by coupling a protected α-amino acid to a suitable resin. Such a starting material can be prepared by attaching an α-amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a benzhydrylamine (BHA) resin or paramethylbenzhydrylamine (MBHA) resin. Preparation of the hydroxymethyl resin is described by Bodansky et al. (1966). Chloromethylated resins are commercially available from Bio Rad Laboratories (Richmond, Calif.) and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart and Young (1969). BHA and MBHA resin supports are commercially available, and are generally used when the desired polypeptide being synthesized has an unsubstituted amide at the C-terminus. Thus, solid resin supports may be any of those known in the art, such as one having the formulae —O—CH₂-resin support, —NH BHA resin support, or —NH—MBHA resin support. When the unsubstituted amide is desired, use of a BHA or MBHA resin is preferred, because cleavage directly gives the amide. In case the N-methyl amide is desired, it can be generated from an N-methyl BHA resin. Should other substituted amides be desired, the teaching of U.S. Pat. No. 4,569,967 (Kornreich et al., 1986) can be used, or should still other groups than the free acid be desired at the C-terminus, it may be preferable to synthesize the peptide using classical methods as set forth in the Houben-Weyl text (1974).

[0044] The C-terminal amino acid, protected by Boc or Fmoc and by a side-chain protecting group, if appropriate, can be first coupled to a chloromethylated resin according to the procedure set forth in K. Horiki et al. (1978), using KF in DMF at about 60° C. for 24 hours with stirring, when a peptide having free acid at the C-terminus is to be synthesized. Following the coupling of the BOC-protected amino acid to the resin support, the α-amino protecting group is removed, as by using trifluoroacetic acid (TFA) in methylene chloride or TFA alone. The deprotection is carried out at a temperature between about 0° C. and room temperature. Other standard cleaving reagents, such as HCl in dioxane, and conditions for removal of specific α-amino protecting groups may be used as described in Schroder & Lubke (1965).

[0045] After removal of the α-amino-protecting group, the remaining α-amino- and side chain-protected amino acids are coupled step-wise in the desired order to obtain the intermediate compound defined hereinbefore, or as an alternative to adding each amino acid separately in the synthesis, some of them may be coupled to one another prior to addition to the solid phase reactor. Selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as a coupling reagent is N,N′-dicyclohexylcarbodiimide (DCC, DIC, HBTU, HATU, TBTU in the presence of HoBt or HoAt).

[0046] The activating reagents used in the solid phase synthesis of the peptides are well known in the peptide art. Examples of suitable activating reagents are carbodiimides, such as N,N′-diisopropylcarbodiimide and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide. Other activating reagents and their use in peptide coupling are described by Schroder & Lubke (1965) and Kapoor (1970).

[0047] Each protected amino acid or amino acid sequence is introduced into the solid-phase reactor in about a twofold or more excess, and the coupling may be carried out in a medium of dimethylformamide (DMF):CH₂Cl₂ (1:1) or in DMF or CH₂Cl₂ alone. In cases where intermediate coupling occurs, the coupling procedure is repeated before removal of the α-amino protecting group prior to the coupling of the next amino acid. The success of the coupling reaction at each stage of the synthesis, if performed manually, is preferably monitored by the ninhydrin reaction, as described by Kaiser et al. (1970). Coupling reactions can be performed automatically, as on a Beckman 990 automatic synthesizer, using a program such as that reported in Rivier et al. (1978).

[0048] After the desired amino acid sequence has been completed, the intermediate peptide can be removed from the resin support by treatment with a reagent, such as liquid hydrogen fluoride or TFA (if using Fmoc chemistry), which not only cleaves the peptide from the resin but also cleaves all remaining side chain protecting groups and also the -amino protecting group at the N-terminus if it was not previously removed to obtain the peptide in the form of the free acid. If Met is present in the sequence, the Boc protecting group is preferably first removed using trifluoroacetic acid (TFA)/ethanedithiol prior to cleaving the peptide from the resin with HF to eliminate potential S-alkylation. When using hydrogen fluoride or TFA for cleaving, one or more scavengers such as anisole, cresol, dimethyl sulfide and methylethyl sulfide are included in the reaction vessel.

[0049] Cyclization of the linear peptide is preferably affected, as opposed to cyclizing the peptide while a part of the peptido-resin, to create bonds between Cys residues. To effect such a disulfide cyclizing linkage, fully protected peptide can be cleaved from a hydroxymethylated resin or a chloromethylated resin support by ammonolysis, as is well known in the art, to yield the fully protected amide intermediate, which is thereafter suitably cyclized and deprotected. Alternatively, deprotection, as well as cleavage of the peptide from the above resins or a benzhydrylamine (BHA) resin or a methylbenzhydrylamine (MBHA), can take place at 0° C. with hydrofluoric acid (HF) or TFA, followed by oxidation as described above.

[0050] The peptides are also synthesized using an automatic synthesizer. Amino acids are sequentially coupled to an MBHA Rink resin (typically 100 mg of resin) beginning at the C-terminus using an Advanced Chemtech 357 Automatic Peptide Synthesizer. Couplings are carried out using 1,3-diisopropylcarbodimide in N-methylpyrrolidinone (NMP) or by 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and diethylisopro-pylethylamine (DIEA). The FMOC protecting group is removed by treatment with a 20% solution of piperidine in dimethylformamide(DMF). Resins are subsequently washed with DMF (twice), followed by methanol and NMP.

[0051] Muteins, analogs or active fragments, of the foregoing conotoxin peptides are also contemplated here. See, e.g., Hammerland et al. (1992). Derivative muteins, analogs or active fragments of the conotoxin peptides may be synthesized according to known techniques, including conservative amino acid substitutions, such as outlined in U.S. Pat. No. 5,545,723 (see particularly col. 2, line 50--col. 3, line 8); U.S. Pat. No. 5,534,615 (see particularly col. 19, line 45--col. 22, line 33); and U.S. Pat. No. 5,364,769 (see particularly col. 4, line 55--col. 7, line 26), each herein incorporated by reference.

[0052] The ω-conopeptides of the present invention are also useful to reduce neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal chord trauma, myocardial infarct, physical trauma, drownings, suffocation, perinatal asphyxia, or hypoglycemic events. To reduce neurotoxic injury, an ω-conopeptide should be administered in a therapeutically effective amount to the patient within 24 hours of the onset of the hypoxic, anoxic or ischemic condition in order for the ω-conopeptide to effectively minimize the CNS damage which the patient will experience.

[0053] The ω-conopeptides of the present invention are further useful in controlling pain, e.g., as analgesic agents, and the treatment of migraine, acute pain or persistent pain. They can be used prophylactically or to relieve the symptoms associated with a migraine episode, or to treat acute or persistent pain. For these uses, an ω-conopeptide is administered in a therapeutically effective amount to overcome or to ease the pain.

[0054] Pharmaceutical compositions containing a compound of the present invention as the active ingredient can be prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa.). Typically, an antagonistic amount of active ingredient will be admixed with a pharmaceutically acceptable carrier. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, parenteral or intrathecally. For examples of delivery methods see U.S. Pat. No. 5,844,077, incorporated herein by reference.

[0055] “Pharmaceutical composition” means physically discrete coherent portions suitable for medical administration. “Pharmaceutical composition in dosage unit form” means physically discrete coherent units suitable for medical administration, each containing a daily dose or a multiple (up to four times) or a sub-multiple (down to a fortieth) of a daily dose of the active compound in association with a carrier and/or enclosed within an envelope. Whether the composition contains a daily dose, or for example, a half, a third or a quarter of a daily dose, will depend on whether the pharmaceutical composition is to be administered once or, for example, twice, three times or four times a day, respectively.

[0056] The term “salt”, as used herein, denotes acidic and/or basic salts, formed with inorganic or organic acids and/or bases, preferably basic salts. While pharmaceutically acceptable salts are preferred, particularly when employing the compounds of the invention as medicaments, other salts find utility, for example, in processing these compounds, or where non-medicament-type uses are contemplated. Salts of these compounds may be prepared by art-recognized techniques.

[0057] Examples of such pharmaceutically acceptable salts include, but are not limited to, inorganic and organic addition salts, such as hydrochloride, sulphates, nitrates or phosphates and acetates, trifluoroacetates, propionates, succinates, benzoates, citrates, tartrates, fumarates, maleates, methane-sulfonates, isothionates, theophylline acetates, salicylates, respectively, or the like. Lower alkyl quaternary ammonium salts and the like are suitable, as well.

[0058] As used herein, the term “pharmaceutically acceptable” carrier means a non-toxic, inert solid, semi-solid liquid filler, diluent, encapsulating material, formulation auxiliary of any type, or simply a sterile aqueous medium, such as saline. Some examples of the materials that can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin, talc; excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol, polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline, Ringer's solution; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations.

[0059] Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. Examples of pharmaceutically acceptable antioxidants include, but are not limited to, water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; oil soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, aloha-tocopherol and the like; and the metal chelating agents such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like.

[0060] For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions or emulsions. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, WO 96/11698.

[0061] For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.

[0062] A variety of administration routes are available. The particular mode selected will depend of course, upon the particular drug selected, the severity of the disease state being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, sublingual, topical, nasal, transdermal or parenteral routes. The term “parenteral” includes subcutaneous, intravenous, epidural, irrigation, intramuscular, release pumps, or infusion.

[0063] For example, administration of the active agent according to this invention may be achieved using any suitable delivery means, including:

[0064] (a) pump (see, e.g., Luer & Hatton (1993), Zimm et al. (1984) and Ettinger et al. (1978));

[0065] (b), microencapsulation (see, e.g., U.S. Pat. Nos. 4,352,883; 4,353,888; and 5,084,350);

[0066] (c) continuous release polymer implants (see, e.g., U.S. Pat. No. 4,883,666);

[0067] (d) macroencapsulation (see, e.g., U.S. Pat. Nos. 5,284,761, 5,158,881, 4,976,859 and 4,968,733 and published PCT patent applications WO92/19195, WO 95/05452);

[0068] (e) naked or unencapsulated cell grafts to the CNS (see, e.g., U.S. Pat. Nos. 5,082,670 and 5,618,531);

[0069] (f) injection, either subcutaneously, intravenously, intra-arterially, intramuscularly, or to other suitable site; or

[0070] (g) oral administration, in capsule, liquid, tablet, pill, or prolonged release formulation.

[0071] In one embodiment of this invention, an active agent is delivered directly into the CNS, preferably to the brain ventricles, brain parenchyma, the intrathecal space or other suitable CNS location, most preferably intrathecally.

[0072] Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands. Targeting may be desirable for a variety of reasons, e.g. if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to enter the target cells.

[0073] The active agents, which are peptides, can also be administered in a cell based delivery system in which a DNA sequence encoding an active agent is introduced into cells designed for implantation in the body of the patient, especially in the spinal cord region. Suitable delivery systems are described in U.S. Pat. No. 5,550,050 and published PCT Application Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646, WO 96/40871, WO 96/40959 and WO 97/12635. Suitable DNA sequences can be prepared synthetically for each active agent on the basis of the developed sequences and the known genetic code.

[0074] The active agent is preferably administered in an therapeutically effective amount. By a “therapeutically effective amount” or simply “effective amount” of an active compound is meant a sufficient amount of the compound to treat the desired condition at a reasonable benefit/risk ratio applicable to any medical treatment. The actual amount administered, and the rate and time-course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc., is within the responsibility of general practitioners or spealists, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Parmaceutical Sciences.

[0075] Dosage may be adjusted appropriately to achieve desired drug levels, locally or systemically. Typically the active agents of the present invention exhibit their effect at a dosage range from about 0.001 mg/kg to about 250 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg of the active ingredient, more preferably from a bout 0.05 mg/kg to about 75 mg/kg. A suitable dose can be administered in multiple sub-doses per day. Typically, a dose or sub-dose may contain from about 0.1 mg to about 500 mg of the active ingredient per unit dosage form. A more preferred dosage will contain from about 0.5 mg to about 100 mg of active ingredient per unit dosage form. Dosages are generally initiated at lower levels and increased until desired effects are achieved. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Continuous dosing over, for example 24 hours or multiple doses per day are contemplated to achieve appropriate systemic levels of compounds.

[0076] For the treatment of pain, if the route of administration is directly to the CNS, the dosage contemplated is from about 1 ng to about 100 mg per day, preferably from about 100 ng to about 10 mg per day, more preferably from about 1 μg to about 100 μg per day. If administered peripherally, the dosage contemplated is somewhat higher, from about 100 ng to about 1000 mg per day, preferably from about 10 μg to about 100 mg per day, more preferably from about 100 μg to about 10 mg per day. If the conopeptide is delivered by continuous infusion (e.g., by pump delivery, biodegradable polymer delivery or cell-based delivery), then a lower dosage is contemplated than for bolus delivery.

[0077] Advantageously, the compositions are formulated as dosage units, each unit being adapted to supply a fixed dose of active ingredients. Tablets, coated tablets, capsules, ampoules and suppositories are examples of dosage forms according to the invention.

[0078] It is only necessary that the active ingredient constitute an effective amount, i.e., such that a suitable effective dosage will be consistent with the dosage form employed in single or multiple unit doses. The exact individual dosages, as well as daily dosages, are determined according to standard medical principles under the direction of a physician or veterinarian for use humans or animals.

[0079] The pharmaceutical compositions will generally contain from about 0.0001 to 99 wt. %, preferably about 0.001 to 50 wt. %, more preferably about 0.01 to 10 wt. % of the active ingredient by weight of the total composition. In addition to the active agent, the pharmaceutical compositions and medicaments can also contain other pharmaceutically active compounds. Examples of other pharmaceutically active compounds include, but are not limited to, analgesic agents, cytokines and therapeutic agents in all of the major areas of clinical medicine. When used with other pharmaceutically active compounds, the conopeptides of the present invention may be delivered in the form of drug cocktails. A cocktail is a mixture of any one of the compounds useful with this invention with another drug or agent. In this embodiment, a common administration vehicle (e.g., pill, tablet, implant, pump, injectable solution, etc.) would contain both the instant composition in combination supplementary potentiating agent. The individual drugs of the cocktail are each administered in therapeutically effective amounts. A therapeutically effective amount will be determined by the parameters described above; but, in any event, is that amount which establishes a level of the drugs in the area of body where the drugs are required for a period of time which is effective in attaining the desired effects.

[0080] The practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art. See, e.g., Maniatis et al., 1982; Sambrook et al., 1989; Ausubel et al., 1992; Glover, 1985; Anand, 1992; Guthrie and Fink, 1991; Harlow and Lane, 1988; Jakoby and Pastan, 1979; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Riott, Essential Immunology, 6th Edition, Blackwell Scientific Publications, Oxford, 1988; Hogan et al., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

EXAMPLES

[0081] The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.

Example 1 Isolation of ω-Conotoxins

[0082] Crude venom was extracted from venom ducts (Cruz et al., 1976), and the components were purified as previously described (Cartier et al., 1996). The crude extract from venom ducts was purified by reverse phase liquid chromatography (RPLC) using a Vydac C₁₈ semi-preparative column (10×250 mm). Further purification of bioactive peaks was done on a Vydac C₁₈ analytical column (4.6×220 mm). The effluents were monitored at 220 nm. Peaks were collected, and aliquots were assayed for activity. Throughout purification, HPLC fractions were assayed by means of intracerebral ventricular (i.c.v.) injection into mice (Clark et al., 1981).

[0083] The amino acid sequence of the purified peptides were determined by standard methods. The purified peptides were reduced and alkylated prior to sequencing by automated Edman degradation on an Applied Biosystems 477A Protein Sequencer with a 120A Analyzer (DNA/Peptide Facility, University of Utah) (Martinez et al., 1995; Shon et al., 1994).

[0084] In accordance with this method, the ω-conopeptides described as “isolated” in Table 1 were obtained. These ω-conopeptides, as well as the other ω-conopeptides and the ω-conopeptide precursors set forth in Table 1 are synthesized as described in U.S. Pat. No. 5,591,821.

Example 2 Isolation of DNA Encoding ω-Conopeptides

[0085] DNA coding for ω-conopeptides was isolated and cloned in accordance with conventional techniques using general procedures well known in the art, such as described in Olivera et al. (1996). Alternatively, cDNA libraries was prepared from Conus venom duct using conventional techniques. DNA from single clones was amplified by conventional techniques using primers which correspond approximately to the M13 universal priming site and the M13 reverse universal priming site. Clones having a size of approximately 300-500 nucleotides were sequenced and screened for similarity in sequence to known ω-conotoxins. The DNA sequences and encoded propeptide sequences are set forth in Table 1. DNA sequences coding for the mature toxin can also be prepared on the basis of the DNA sequences set forth in Table1. An alignment of the ω-conopeptides of the present invnetion is set forth in Table 2. TABLE 1 DNA and Amino Acid Sequences of ω-Conopeptides and Precursors Name: J410 Species: Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCATGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:1) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCATGCCCTGAGGTC GACCACCAATTTCTCCACGTTGACTCGTCGCTGCCTTTCTCCCGGATCACGATGTCA TAAGACAATGCGTAACTGCTGCACTTCATGCTCTTCATACAAAGGGAAATGTCGGCC TCGAAAATGAACCACTCATCACCTACTCCTCTGGAGGCCTCAGAGGAATTACATTGA AATAAAAGCCGCATTACAAAAAAAAAAAAAAAAA Translation: MKLTCMVIVAVLLLTACQLITADDSRGTQKHHALRSTTNFSTLTRRCLSPGSRCHKTMR (SEQ ID NO:2) NCCTSCSSYKGKCRPRK Toxin Sequence: Cys-Leu-Ser-Xaa3-Gly-Ser-Arg-Cys-His-Lys-Thr-Met-Arg-Asn-Cys-Cys-Thr-Ser-Cys-Ser-Ser- (SEQ ID NO:3) Xaa5-Lys-Gly-Lys-Cys-Arg-Xaa3-Arg-Lys-{circumflex over ( )} Name: J411 Species: Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCGTCGCCGTGCTGCTCCTGACGGTCTGT (SEQ ID NO:4) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCATGCCCTGAGGTC GACCACCAATTTCTCCACGTCGACTCGTCGCTGCAAACCTCCCGGAAGAAAATGTCT GAATAGAAAGAATGAATGCTGCAGCAAGTTTTGCAATGAACACCTACATATGTGTG GATAAATGGCTAAAAACTGAATAAAAGCCGCATTGCAAAAAAAAAAAAAAAAAAA AA Translation: MKLTCVVIVAVLLLTVCQLITADDSRGTQKHHALRSTTNFSTSTRRCKPPGRKCLNRKN (SEQ ID NO:5) ECCSKFCNEHLHMCG Toxin Sequence: Cys-Lys-Xaa3-Xaa3-Gly-Arg-Lys-Cys-Leu-Asn-Arg-Lys-Asn-Xaa1-Cys-Cys-Ser-Lys-Phe-Cys- (SEQ ID NO:6) Asn-Xaa1-His-Leu-His-Met-Cys-# Name: J413 Species: Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:7) CAACTCGTCACAGCTGATGGCTCCAGAGGTATGCAGAAGCATTATGCCCTGAGGTC GACCACCAATCTCTCCATATCGTCTCGCTGCAAACCTCCCAGAAGAAAATGTCTGAA GATTAAGGATAAATGCTGCAACTTTTGCAATACACACCTAAATATGTGTGGATAAAT GGCTAAAAACTGAATAAAAGCCGCATTGCAAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLLLTACQLVTADGSRGMQKHYALRSTTNLSISSRCKPPRRKCLKIKDK (SEQ ID NO:8) CCNFCNTHLNMCG Toxin Sequence: Cys-Lys-Xaa3-Xaa3-Arg-Arg-Lys-Cys-Leu-Lys-Ile-Lys-Asp-Lys-Cys-Cys-Asn-Phe-Cys-Asn- (SEQ ID NO:9) Thr-His-Leu-Asn-Met-Cys-# Name: J414 Species: Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGATGGCCTGT (SEQ ID NO:10) CAACTCGTCACAGCTGATGGCTCCAGAGGTATGCACAAGCATTATGCCCTGAGGTC GACCACCAAACTCTCCATGTCGACTCGCTGCGCAGGTCCAGGAACAATTTGTCCTAA TAGGGTATGCTGCGGTTATTGCAGTAAAAGAACACATCTATGTCATTCGCGAACTGG CTGATCTTCCCCCTTCTGCGCTCCATCCTTTTCTGCCTGAGTCCTCCATACCTGAGAA TGGTCATGAACCACTCAACACCTACTCCTCTGGAGGGCCTCAGAAGAGCTACATTG AAATAAAAGCCGCATTACAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLLLMACQLVTADGSRGMHKHYALRSTTKLSMSTRCAGPGTICPNRVC (SEQ ID NO:11) CGYCSKRTHLCHSRTG Toxin Sequence: Cys-Ala-Gly-Xaa3-Gly-Thr-Ile-Cys-Xaa3-Asn-Arg-Val-Cys-Cys-Gly-Xaa5-Cys-Ser-Lys-Arg- (SEQ ID NO: 12) Thr-His-Leu-Cys-His-Ser-Arg-Thr-# Name: Ar6.10 Species: arenatus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCATGGTGATCATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:13) CAACTCATTACAGGTGAGCAGAAGGACCATGCTCTGAGGTCAACTGACAAAAACTC CAAGTTGACTAGGCAGTGCTCGGCTAACGGTGGATCTTGTACTCGTCATTTTCACTG CTGCAGCCTCTATTGCAATAAAGATTCCAGTGTATGTGTGGCAACCTCATACCCGTG AGTGGCCATGAACCCCTCAATACCCTCTCCTCTGGAGGCTTCAGAGGAACTGCATTG AAATAAAACCGCATTGCAATAAAAAAAAAAAAAAAAAAA Translation: MKILTCMVIIAVLFLTACQLITGEQKDHALRSTDKNSKLTRQCSANGGSCTRHFHCCSLY (SEQ ID NO:14) CNIKDSSVCVATSYP Toxin Sequence: Xaa2-Cys-Ser-Ala-Asn-Gly-Gly-Ser-Cys-Thr-Arg-His-Phe-His-Cys-Cys-Ser-Leu-Xaa5-Cys- (SEQ ID NO:15) Asn-Lys-Asp-Ser-Ser-Val-Cys-Val-Ala-Thr-Ser-Xaa5-Xaa3-{circumflex over ( )} Name: Ar6.2 Species: arenatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGCGTGTTGATTATCGCCGTGCTGTTC (SEQ D NO: 16) CTGACGGCCTGTCAACTCATTACAGCTGAGACTTACTCCAGAGGTGAGCAGAAGCA CCATGCTCTGAGGTCAACTGACAGAAACTCCAAGTTGACCAGGACATGCAACACTC CCACTGAATATTGTACTTTGCATCGACACTGCTGCAGCGGCTACTGCCATAAAACAA TCCAGGCATGTTCATAATACCGGTGAGTGGTCATGAACCACTCAATACCCTCTCCTC TGGAGGCTTCAGAGGAACTGCATTGAAATAAAAGCCGCATTGC Translation: MKLTCVLIIAVLFLTACQLITAETYSRGEQKHHALRSTDRNSKLTRTCNTPTEYCTLHRH (SEQ ID NO:17) CCSGYCHKTIQACS Toxin Sequence: Thr-Cys-Asn-Thr-Xaa3-Thr-Xaa1-Xaa5-Cys-Thr-Leu-His-Arg-His-Cys-Cys-Ser-Gly-Xaa5-Cys- (SEQ ID NO: 18) His-Lys-Thr-Ile-Gln-Ala-Cys-Ser-{circumflex over ( )} Name: Ar6.3 Species: arenatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGCGTGTTGATCATCGCCGTGCTGTTC (SEQ ID NO:19) CTGACGGCCTGTCAACTCATTACAGCTGAGACTTACTCCAGAGGTGAGCAGATGCA CCGTGCTCTGAGGTCAACTGACAAAAACTCCAAGTTGACTAGGCAGTGCACGCCTA ACGGTGGATCTTGTTCTCGTCATTTTCACTGCTGCAGCCTCTATTGCAATAAAAGTA CTGGCGTATGTATTGCAACCTCATACCCGTGAGTGGTCATGAACCACTCAATACCCT CTCCTCTGGAGGCTTCAGAGGAACTGCATTGAAATAAAAGCCGCATTGC Translation: MKLTCVLIIAVLFLTACQLITAETYSRGEQMHRALRSTDKNSKLTRQCTPNGGSCSRHFH (SEQ ID NO:20) CCSLYCNKSTGVCIATSYP Toxin Sequence: Xaa2-Cys-Thr-Xaa3-Asn-Gly-Gly-Ser-Cys-Ser-Arg-His-Phe-His-Cys-Cys-Ser-Leu-Xaa5-Cys- (SEQ ID NO:21) Asn-Lys-Ser-Thr-Gly-Val-Cys-Ile-Ala-Thr-Ser-Xaa5-Xaa3-{circumflex over ( )} Name: Ar6.4 Species: arenatus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCATGGTGATTATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:22) CAACTCATTACAGCTGAGACTTACTCCAGAGGTGAGCAGAAGCACCATGCTCTGAG GTCAACTGACAAAAACTCCAAGTTGACCAGGACATGCAACACTCCCACCGAATATT GTACTTTGCATCAACACTGCTGCAGCGGCTACTGCCATAAAACAATCCAGGCATGTT CATAATACCGGTGAGTGGTCATGAACCACTCAATACCCTCTCCTCTGGAGGCTTCAG AGGAACTGCATTGAAATAAAACCGCATTACAAAAAAAAAAAAAAAAAAA Translation: MKLTCMVHAVLFLTACQLITAETYSRGEQKHHALRSTDKNSKLTRTCNTPTEYCTLHQH (SEQ ID NO:23) CCSGYCHKTIQACS Toxin Sequence: Thr-Cys-Asn-Thr-Xaa3-Thr-Xaa1-Xaa5-Cys-Thr-Leu-His-Gln-His-Cys-Cys-Ser-Gly-Xaa5-Cys- (SEQ ID NO:24) His-Lys-Thr-Ile-Gln-Ala-Cys-Ser-{circumflex over ( )} Name: Ar6.6 Species: arenatus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTATGGTGATCATCGCCGTACTGTTCCTGACGGCCTGT (SEQ ID NO:25) CAACTCATTACAGCTGAGACTTACTCCAGAGGTAAGCAGATGCACCGCGCTCTGAG GTCAACTGACAAAAACTCCCAGTTGACCAGGGAATGCACACCTCCCGGTGGAGCTT GTGGTTTACCTACACACTGCTGCGGGTTTTGCGATACTGCAAACAACAGATGTCTGT AAAGCTGGTCTGGCGTCTGATATTCCCCTTCTGTGCTCTATCCTCTTTGGCCTGAGTC ATCCGTACCTGTGAGTGGTCATGAACTACTCAATACCCTCTCCTCTGGAGGCTTCAG AGGAACTACAATGAAATAAAACCCGCATTGCAGAGAAAAAAAAAAAAAAAAAA Translation: MKLTCMVIIAVLFLTACQLITAETYSRGKQMHRALRSTDKNSQLTRECTPPGGACGLPT (SEQ ID NO:26) HCCGFCDTANNRCL Toxin Sequence: Xaa1-Cys-Thr-Xaa3-Xaa3-Gly-Gly-Ala-Cys-Gly-Leu-Xaa3-Thr-His-Cys-Cys-Gly-Phe-Cys- (SEQ ID NO:27) Asp-Thr-Ala-Asn-Asn-Arg-Cys-Leu-{circumflex over ( )} Name: Ar6.7 Species: arenatus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATTATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:28) CAACTCATTACAGCTGAGACTTACTCCAGAGGTGAGCAGAATCACCATGTTCTGAG GTCAACTGACAAAAACTCCAAGTTGACCAGGACATGCAACACTCCCACTGAATATT GTACTTTGCATCAACACTGCTGCAGCGGCCACTGCCATAAAACAATCCAGGCATGT GCATAATACCGGTGGGTGGTCATGAACCACTCAATACCCTCTCCTCTGGAGGCTTCA GAGGAACTGCATTGAAATAAAACCGCATTGCAATGAANAAAAAAAAAAAAAAAAA AAAAAAAA Translation: MKLTCVVIIAVLFLTACQLITAETYSRGEQNHHVLRSTDKNSKLTRTCNTPTEYCTLHQH (SEQ D NO:29) CCSGHCHKTIQACA Toxin Sequence: Thr-Cys-Asn-Thr-Xaa3-Thr-Xaa1-Xaa5-Cys-Thr-Leu-His-Gln-His-Cys-Cys-Ser-Gly-His-Cys- (SEQ ID NO:30) His-Lys-Thr-Ile-Gln-Ala-Cys-Ala-{circumflex over ( )} Name: Ar6.8 Species: arenatus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTGTGGTGATCATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:31) CAACTCACTACAGGTGAGCAGAAGGACCATGCTCTGAGGTCAACTGACAAAAACTC CAAGTTGACTAGGCAGTGCTCGCCTATCGGTGGATATTGTACTCTTCATATTCACTG CTGCAGCAACCATTGCATTAAACCTATCGGCCGATGTGTGGCAACCTGATACCCGTG CGTGGTCATGAACCCCTCAATACCCTCTCCTCTGGAGGCTTCAGAGGAACTGCATTG AAATAAAACCGCATTGCAATAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIIAVLFLTACQLTTGEQKDHALRSTDKNSKLTRQCSPIGGYCTLHTHCCSNHC (SEQ ID NO:32) IKLPIGRCVAT Toxin Sequence: Xaa2-Cys-Ser-Xaa3-Ile-Gly-Gly-Xaa5-Cys-Thr-Leu-His-Ile-His-Cys-Cys-Ser-Asn-His-Cys-Ile- (SEQ ID NO:33) Lys-Xaa3-Ile-Gly-Arg-Cys-Val-Ala-Thr-{circumflex over ( )} Name: Ar6.9 Species: arenatus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:34) CAACTCACTACAGGTGAGCAGAAGGACCATGCTCTGAGGTCAACTGACAAAAACTC CAAGTTGACTAGGCAGTGCTTGCCTAACGGTGGATATTGTACTCTTCATATTCACTG CTGCAGCGACCATTGCATTAAACCTATCGACCGATGTGTGGCAACCTGATACCCGG GCGTGGTCATGAACCCCTCAATACCCTCTCCTCTGGAGGCTTCAGAGGAACTGCATT GAAATAAAACCGCATTACAAAAAAAAAAAAAAAAA Translation: MKLTCVVIIAVLFLTACQLTTGEQKDHALRSTDKNSKLTRQCLPNGGYCTLHIHCCSDH (SEQ ID NO:35) CTKPIDRCVAT Toxin Sequence: Xaa2-Cys-Leu-Xaa3-Asn-Gly-Gly-Xaa5-Cys-Thr-Leu-His-Ile-His-Cys-Cys-Ser-Asp-His-Cys- (SEQ ID NO:36) Ile-Lys-Xaa3-Ile-Asp-Arg-Cys-Val-Ala-Thr-{circumflex over ( )} Name: Ay6.1 Species: aurisiacus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:37) ATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTTCCCTGAGCTCGGCCAC CAAACTCTCCATGTCGACTCGCTGCAAGGGTAAAGGAAAACCATGCAGTAGGATTT CGTATAACTGCTGCACCGGTTCTTGCAGATCAGGTAAATGTGGCTGATCCAGCGCCT GATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTACCTGAGAGTG GTCATGAACCACTCATCACCTGCTCCTCTGGAGGCCCCAGAGGAGCTACATTGAAAT AAAAGTCGCATTGCAAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRSLSSATKILSMSTRCKGKGKPCSRISYN (SEQ ID NO:38) CCTGSCRSGKCG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Lys-Xaa3-Cys-Ser-Arg-Ile-Ser-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:39) Ser-Gly-Lys-Cys-# Name: Ay6.2 Species: aurisiacus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:40) ATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTTCCCTGAGGTCGAAGAC CAAACTCTCCATGTCGACTGGCTGCATGGAAGCCGGATCTTATTGCGGCTCTACTAC GAGAATCTGCTGCGGTTTTTGCGCTTATTTCGGCAAAAAATGTATTGACTATCCCAG CAACTGATCTTCCCCCTACTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTACCTGA GAGTGGTCATGAACCACTCATCACCTGCTCCTCTGGAGGCCCCAGAGGAGCTACATT GAAATAAAATCGCATTGCTAAAAAAAAAAAAAAAAAAA Translation: MRLTCVVIVAVLLLTACQLITADDSRGTQKHRSLRSKTKLSMSTGCMEAGSYCGSTTRI (SEQ ID NO:41) CCGFCAYFGKKCIDYPSN Toxin Sequence: Cys-Met-Xaa1-Ala-Gly-Ser-Xaa5-Cys-Gly-Ser-Thr-Thr-Arg-Ile-Cys-Cys-Gly-Phe-Cys-Ala- (SEQ ID NO:42) Xaa5-Phe-Gly-Lys-Lys-Cys-Ile-Asp-Xaa5-Xaa3-Ser-Asn-{circumflex over ( )} Name: Ay6.3 Species: aurisiacus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:43) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTTCCCTGAGCTCGGCCACCAAACTCTCCATGTCGACTCGCTGCAAGGCTAAAGGA AAACCATGCAGTAGGATTGCGTATAACTGCTGCACCGGTTCTTGCAGATCAGGTAA ATGTGGCTGATCCAGTGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGA GTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTGCTCCTCTGGAGGCCC CAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRSLSSATKLSMSTRCKAKGKPCSRIAYN (SEQ ID NO:44) CCTGSCRSGKCG Toxin Sequence: Cys-Lys-Ala-Lys-Gly-Lys-Xaa3-Cys-Ser-Arg-Ile-Ala-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:45) Ser-Gly-Lys-Cys-# Name: Ay6.4 Species: aurisiacus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:46) CCTGACGACCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGGAGCATC GTGCCCTGAGGTCGAAGACAAAACTCTCCATGTTAACTTTGCGCTGCGCATCTTACG GAAAACCTTGTGGTATTGACAACGACTGCTGCAATGCATGCGATCCAGGAAGAAAT ATATGTACGTAGCTGATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCT GCCCGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTGCTCCCTGGA GGCCTCAGAGGAGCTACAATGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTTCQLITADDSRGTQEHRALRSKTKLSMLTLRCASYGKPCGIDND (SEQ ID NO:47) CCNACDPGRNICT Toxin Sequence: Cys-Ala-Ser-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Asp-Asn-Asp-Cys-Cys-Asn-Ala-Cys-Asp-Xaa3- (SEQ ID NO:48) Gly-Arg-Asn-Ile-Cys-Thr-{circumflex over ( )} Name: Bu6.1 Species: bullatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGCGATCGTCGCCGTGCTGCT (SEQ ID NO:49) CCTGACGGCCTGTCAGCTCATTACAGCTGAAGACTCCAGAGGTACGCATGAGCATC TTGCCCTGAAGTCGACCTCCAAAGTCTCCAAGTCGACTAGCTGCATGGAAGCCGGA TCTTATTGCGGACCTGCTACTACGAAAATCTGCTGCGATTTTTGCAGTCCATTCAGC GATAGATGTATGAACAATCCCAACAATTGATCTTCCCCCTTGTGTGCTCCATCCTTTT CTGCCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCT GGAGGCTTCAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVAIVAVLLLTACQLITAEDSRGTHEHLALKSTSKVSKSTSCMEAGSYCGPATTKI (SEQ ID NO:50) CCDFCSPFSDRCMNNPNN Toxin Sequence: Ser-Thr-Ser-Cys-Met-Xaa1-Ala-Gly-Ser-Xaa5-Cys-Gly-Xaa3-Ala-Thr-Thr-Lys-Ile-Cys-Cys- (SEQ ID NO: 51) Asp-Phe-Cys-Ser-Xaa3-Phe-Ser-Asp-Arg-Cys-Met-Asn-Asn-Xaa3-Asn-Asn-{circumflex over ( )} Name: Bu6.2 Species: bullatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:52) CCTGACGGCCTGTCAGCTCATTACAGCTGAAGACTCCAGAGGTACGCAGTTGCATC GTGCCCTGAGGAAGGCCACCAAACACCCTGTGTCGACTCGCTGCATTACTCCAGGA ACACGATGTAAGGTTCCGAGCCAATGCTGCAGAGGTCCTTGCAAGAACGGTCGTTG TACTCCATCCCCTTCTGAATGGTAAATGTGGTTGATCCAGCGCCTGATCTTCCCCCTT CGTCGTGCTCCATCCTTTTCTGCCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACC ACTCATCACCTACTCCCCTGGAGGCTTCAGAGGAGCTACATTGAAATAAAAGCCGC ATTGC Translation: MKLTCVVIVAVLLLTACQLITAEDSRGTQLHRALRKATKATKHPVSTRCITPGTRCKVPSQCC (SEQ ID NO:53) RGPCKNGRCTPSPSEW Toxin Sequence: Cys-Ile-Thr-Xaa3-Gly-Thr-Arg-Cys-Lys-Val-Xaa3-Ser-Gln-Cys-Cys-Arg-Gly-Xaa3-Cys-Lys- (SEQ ID NO: 54) Asn-Gly-Arg-Cys-Thr-Xaa3-Ser-Xaa3-Ser-Xaa1-Xaa4-{circumflex over ( )} Name: Bu6.3 Species: bullatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGCGATCGTCGCCGTGCTGCT (SEQ ID NO:55) CCTGACGGCCTGTCAGCTCATTACAGCTGAGGACTCCAGAGATACGCAGAAGCATC GTGCCCTGAGGTCGGACACCAAACTCTCCATGTTGACTTTGCGCTGCGCAACTTACG GAAAACCTTGTGGTATTCAAAACGACTGCTGCAATACATGCGATCCAGCCAGAAGG ACATGTACGTAGCTGATCCGGCGTCTTGATCCTCCGCTTCTGTGCTCCATCTTTTCTG CCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGGA GGCTTTAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVAIVAVLLLTACQLITAEDSRDTQKHRALRSDTKLSMLTLRCATYGKPCGIQND (SEQ ID NO:56) CCNTCDPARRTCT Toxin Sequence: Cys-Ala-Thr-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Gln-Asn-Asp-Cys-Cys-Asn-Thr-Cys-Asp-Xaa3- (SEQ ID NO:57) Ala-Arg-Arg-Thr-Cys-Thr-{circumflex over ( )} Name: Bu6.4 Species: bullatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGCGATCGTCGCCGTGCTGCT (SEQ ID NO:58) CCTGACGGCCTGTCAGCTCATTACAGCTGAAGACTCCAGAGGTACGCAGTTGCATC GTGCCCTGAGGAAGACCACCAAACTCTCCTTGTCGACTCGCTGCAAGGGTCCAGGA GCATCATGTATAAGGATTGCGTATAACTGCTGCAAGTATTCTTGCAGAAATGGTAAA TGTGGCTGATCCAGCGCCTGATCTTCCCCCTTGTGTGCTCCATCCTTTTCTGCCTGAG TCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGGAGGCTTC AGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVALVAVLLLTACQLITAEDSRGTQLHRALRKTTKLSLSTRCKGPGASCIRTAYNC (SEQ ID NO:59) CKYSCRNGKCG Toxin Sequence: Cys-Lys-Gly-Xaa3-Gly-Ala-Ser-Cys-Ile-Arg-Ile-Ala-Xaa5-Asn-Cys-Cys-Lys-Xaa5-Ser-Cys- (SEQ ID NO:60) Arg-Asn-Gly-Lys-Cys-# Name: Bu6.5 Species: bullatus Cloned: Yes DNA Sequence: ATCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTC (SEQ ID NO:61) CTGACGGCCTGTCAGCTCATTACAGCTGAAGACTCCAGAGGTACGCATGAGCATCTT GCCCTGAAGTCGACCTCCAAAGTCTCCAAGTCGACTAGCTGCATGGCAGCCGGATC TTATTGCGGACCTGCTACTACGAATATCTGCTGCGATTTTTGCAGTCCATTCAGCGA TAGATGTATGAAAAAGCCCAACAATTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCT GCCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGG AGGCTTCAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLITAEDSRGTHEHLALKSTSKVSKSTSCMAAGSYCGPATTNI (SEQ ID NO:62) CCDFCSPFSDRCMKKPNN Toxin Sequence: Ser-Thr-Ser-Cys-Met-Ala-Ala-Gly-Ser-Xaa5-Cys-Gly-Xaa3-Ala-Thr-Thr-Asn-Ile-Cys-Cys-Asp- (SEQ ID NO:63) Phe-Cys-Ser-Xaa3-Phe-Ser-Asp-Arg-Cys-Met-Lys-Lys-Xaa3-Asn-Asn-{circumflex over ( )} Name: Bu6.6 Species: bullatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:64) CCTGACGGCCTGTCAGCTCATTATAGCTGAGGACTCCAGAGGTACGCAGTTGCATCG TGCCCTGAGGAAGGCCACCAAACTCTCCGTGTCGACTCGCTGCAAGAGTAAAGGAT CATCATGTCATAGGACTTCGTATGACTGCTGCACGGGTTCTTGCAGAAATGGTAGAT GTGGCTGATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCCATCCTTTTCTGCCTGAGT CCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGGAGGCTTCA GAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLIIAEDSRGTQLHRALRKATKLSVSTRCKSKGSSCHRTSYDC (SEQ ID NO:65) CTGSCRNGRCG Toxin Sequence: Cys-Lys-Ser-Lys-Gly-Ser-Ser-Cys-His-Arg-Thr-Ser-Xaa5-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:66) Asn-Gly-Arg-Cys-# Name: Ca6.4 Species: caracteristicus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:67) CAACTCATTACAGGTGAGCAGAAGGACCATGCTCTGAGGTCAACTGACAAAAACTC CAAGTTGACTAGGCAGTGCTCGGCTAACGGTGGATCTTGTACTCGTCATTTTCACTG CTGCAGCCTCTATTGCAATAAAGATTCCAGTGTATGTGTGGCAACCTCATACCCGTG AGTGGCCATGAACCCCTCAATACCCTCTCCTCTGGAGGCTTCAGAGGAACTGCATTG AAATAAAACCGCATTACAAAAAAAAAAAAAAAAAAAA Translation: MKLTCVVHAVLFLTACQLITGEQKDHALRSTDKNSKLTRQCSANGGSCTRHFHCCSLYC (SEQ ID NO:68) NKDSSVCVATSYP Toxin Sequence: Xaa2-Cys-Ser-Ala-Asn-Gly-Gly-Ser-Cys-Thr-Arg-His-Phe-His-Cys-Cys-Ser-Leu-Xaa5-Cys- (SEQ ID NO:69) Asn-Lys-Asp-Ser-Ser-Val-Cys-Val-Ala-Thr-Ser-Xaa5-Xaa3-{circumflex over ( )} Name: C6.1 Species: catus Cloned: Yes DNA Sequence: Translation: CKSTGASCRRTSYDCCTGSCRSGRCG (SEQ ID NO:70) Toxin Sequence: Cys-Lys-Ser-Thr-Gly-Ala-Ser-Cys-Arg-Arg-Thr-Ser-Xaa5-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:71) Ser-Gly-Arg-Cys-# Name: C6.4 Species: catus Cloned: Yes DNA Sequence: TCGACTCGCTGCCAGGGTAGAGGAGCATCATGTCGTAAGACTATGTATAACTGCTG (SEQ ID NO:72) CAGCGGTTCTTGCAACAGAGGTAGTTGTGGCTGATCCGGCGCCTGATCTTCCCCCTT CCGTGCTCTATCCTTTTCTGCCTGATTCCTCCTTACCTGAGAGCGGTCATGAACCACT CATCACCTGCTCCTCTGGAGGCCTCAGAGGAGCTACATTGAAATAAAAGCCGCATT GC Translation: STRCQGRGASCRKTMYNCCSGSCNRGSCG (SEQ ID NO:73) Toxin Sequence: Cys-Gln-Gly-Arg-Gly-Ala-Ser-Cys-Arg-Lys-Thr-Met-Xaa5-Asn-Cys-Cys-Ser-Gly-Ser-Cys-Asn- (SEQ ID NO:74) Arg-Gly-Ser-Cys-# Name: C6.5 Species: catus Cloned: Yes DNA Sequence: TCGACACGCTGCTTGCCTGCCGGAGAGTCTTGCCTTTTTAGTAGGATTAGATGCTGC (SEQ ID NO:75) GGTACTTGCAGTTCAGTCTTAAAGTCATGTGTGAGCTGATCCAGCTGCTGATCTTCC TCCTCCTGTGCTCCATCCTTTTCTGCCTGAGTCCTCCTTATCTGAGAGTGGTCATGAA CCACTCACCACCTACTCTTCTGGAGGCTTCAGAGGAGCTACAGTGAAATAAAAGCC GCATTGC Translation: STRCLPAGESCLFSRIRCCGTCSSVLKSCVS (SEQ ID NO:76) Toxin Sequence: Cys-Leu-Xaa3-Ala-Gly-Xaa1-Ser-Cys-Leu-Phe-Ser-Arg-Ile-Arg-Cys-Cys-Gly-Thr-Cys-Ser-Ser- (SEQ ID NO:77) Val-Leu-Lys-Ser-Cys-Val-Ser-{circumflex over ( )} Name: C6.6 Species: catus Cloned: Yes DNA Sequence: TCGACACGCTGCCAGGGTAGAGGAGGACCATGTACTAAGGCTGTGTTTAACTGCTG (SEQ ID NO:78) CAGCGGTTCTTGCAACAGAGGTAGATGTGGCTGATCCAGCGCCTGATCTTCCCCCTT CTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTACTGAGAGTAGTCATGAACCACTC ATCACCTACTCCTCTGGAGGCCTCAGAGAGCTACATTGAAATAAAAGCCGCATTGC Translation: STRCQGRGGPCTKAVFNCCSGSCNRGRCG (SEQ ID NO:79) Toxin Sequence: Cys-Gln-Gly-Arg-Gly-Gly-Xaa3-Cys-Thr-Lys-Ala-Val-Phe-Asn-Cys-Cys-Ser-Gly-Ser-Cys-Asn- (SEQ ID NO:80) Arg-Gly-Arg-Cys-# Name: C6.7 Species: catus Cloned: Yes DNA Sequence: TTAACTTTGCGCTGCGCAACTTACGGAAAACCTTGTGGTATTCAAAACGACTGCTGC (SEQ ID NO:81) AATACATGCGATCCAGCCAGAAAGACATGTACGTAGCTGATCCGGCGTCTGATCTC CCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTACCTGAGAGTGGTCATG AACCACTCATCACCTGCTCCTCTGGAGGCCTCGGGGGAGCTACATTGAAATAAAAG CCGCATTGC Translation: LTLRCATYGKPCGIQNDCCNTCDPARKTCT (SEQ ID NO:82) Toxin Sequence: Cys-Ala-Thr-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Gln-Asn-Asp-Cys-Cys-Asn-Thr-Cys-Asp-Xaa3- (SEQ ID NO:83) Ala-Arg-Lys-Thr-Cys-Thr-{circumflex over ( )} Name: C6.8 Species: catus Cloned: Yes DNA Sequence: TCGACTCGCTGCCGGGGTAGAGGAGGACCATGTACTAAGGCTATGTTTAACTGCTG (SEQ ID NO:84) CAGCGGTTCTTGCAACAGAGGTAGATGTGGCTGATCCAGCGCCTGATCTTCCCCCTT CTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTAACTGAGAGTAGTCATGAACCACT CATCACCTACTCCTCTGGAGGCCTCAGAGAAGCATCATTGAAATAAAAGCCGCATT GC Translation: STRCRGRGGPCTKAMFNCCSGSCNRGRCG (SEQ ID NO:85) Toxin Sequence: Cys-Arg-Gly-Arg-Gly-Gly-Xaa3-Cys-Thr-Lys-Ala-Met-Phe-Asn-Cys-Cys-Ser-Gly-Ser-Cys- (SEQ ID NO:86) Asn-Arg-Gly-Arg-Cys-# Name: Cr6.1 Species: circumcisus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:87) CCTGACGACCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGGAGCATC GTGCCCTGAGGTCGGACACCAAACTCCCCATGTCGACTCGCTGCAAGGGTAAAGGA GCATCATGTCGTAAGACTATGTATAACTGCTGCAGCGGTTCTTGCAGCAACGGTAGA TGTGGCTGATCCAGCGCCTGATCTTCCCCCTTCTGCTGCTCTATCCTTTTCTGCCTGA GTCCTCCTTACCTGAGAGCTGGTCATGAACCACTCATCACCTGCTCCTCTGGAGGCC CAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTTCQLITADDSRGTQEHRALRSDTKIPMSTRCKGKGASCRKTMY (SEQ ID NO:88) NCCSGSCSNGRCG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Ala-Ser-Cys-Arg-Lys-Thr-Met-Xaa5-Asn-Cys-Cys-Ser-Gly-Ser-Cys-Ser- (SEQ ID NO:89) Asn-Gly-Arg-Cys-# Name: Cr6.2 Species: circumcisus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:90) CCTGACGACCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGGCCACCAAAGTCTCCAAGTCGACTAGCTGCATGGAAGCCGGA TCTTATTGCCGCTCTACTACGAGAACCTGCTGCGGTTATTGCTCTTATTTCAGCAAAA AATGTATTGACTTTCCCAGCAACTGATCTTCCCCCTACTGTGCTCTATCCTTTTCTGC CTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCCTACTCCTCTGGA GGCCCAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVTVAVLLLTTCQLITADDSRGTQKHRALRSATKVSKSTSCMEAGSYCRSTTRT (SEQ ID NO:91) CCGYCSYFSKKCDFPSN Toxin Sequence: Ser-Thr-Ser-Cys-Met-Xaa1-Ala-Gly-Ser-Xaa5-Cys-Arg-Ser-Thr-Thr-Arg-Thr-Cys-Cys-Gly- (SEQ ID NO:92) Xaa5-Cys-Ser-Xaa5-Phe-Ser-Lys-Lys-Cys-Ile-Asp-Phe-Xaa3-Ser-Asn-{circumflex over ( )} Name: Cr6.3 Species: circumcisus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:93) CCTGACGACCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGGAGCATC GTGCCCTGAGGTCGGACACCAAACTCCCCATGTCGACTCGCTGCAAGAGTAAAGGA GCAAAATGTTCAAGGCTTATGTATGACTGCTGCAGCGGTTCTTGCAGCAGGTACTCA GGTAGATGTGGCTGATCCAGCGCCTGATCTTCCCCCTTCTGCTGCTCTATCCTTTTCT GCCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGG AGGCCCAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTTCQLITADDSRGTQEHRALRSDTKLPMSTRCKSKGAKCSRLMY (SEQ ID NO:94) DCCSGSCSRYSGRCG Toxin Sequence: Cys-Lys-Ser-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Xaa5-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Ser- (SEQ ID NO: 95) Arg-Xaa5-Ser-Gly-Arg-Cys-# Name: Cr6.4 Species: circumcisus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:96) CCTGACGACCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTTCCCTGACGTCGGCCACCAAAGTCTCCAAGTCGACTGGCTGCATGAAAGCCGGA TCTTATTGCCGCTCTACTACGAGAACTTGCTGCGGTTATTGCGCTTATTTCGGCAAA AAATGTATTGACTATCCCAGCAACTGATCTTCCCCCTACTGTGCTCTATCCTTTTCTG CCTAAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCCTACTCCTCTGG AGGCCCAGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTTCQLITADDSRGTQKHRSLTSATKVSKSTGCMKAGSYCRSTTRT (SEQ ID NO:97) CCGYCAYFGKKCIDYPSN Toxin Sequence: Ser-Thr-Gly-Cys-Met-Lys-Ala-Gly-Ser-Xaa5-Cys-Arg-Ser-Thr-Thr-Arg-Thr-Cys-Cys-Gly- (SEQ ID NO:98) Xaa5-Cys-Ala-Xaa5-Phe-Gly-Lys-Lys-Cys-Ile-Asp-Xaa5-Xaa3-Ser-Asn-{circumflex over ( )} Name: Cn6.1 Species: consors Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:99) CTCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAAGTCTTACAC CAAACTCTCCATGTTAACTTTGCGCTGCGCATCTTACGGAAAACCTTGTGGTATTGA CAACGACTGCTGCAATACATGCGATCCAGCCAGAAAGACATGTACGTAGCTGATCC GGCGTCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTACCT GAGAGTGGTCAACGAACCACTCATCACCTAGCTCCTCTGGAGGCTTCAGAGGAGCTA CAATGAAATAAAACGCCATTGC Translation: MKLTCVVIVAVLLLTACQLLTADDSRGTQKHRALKSYTKLSMLTLRCASYGKPCGIDN (SEQ ID NO:100) DCCNTCDPARKTCT Toxin Sequence: Cys-Ala-Ser-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Asp-Asn-Asp-Cys-Cys-Asn-Thr-Cys-Asp-Xaa3- (SEQ ID NO:101) Ala-Arg-Lys-Thr-Cys-Thr-{circumflex over ( )} Name: Cn6.2 Species: consors Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:102) CTCACGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTCGGACAC CAAACTCTCCATGTCGACTCGCTGCAAGGGTACAGGAAAACCATGCAGTAGGATTG CGTATAACTGCTGCACCGGTTCTTGCAGATCAGGTAAATGTGGCTGATCCAGCGCCT GATCTCCCCCC Translation: MKLTCVVIVAVLLLTACQLLTADDSRGTQKHRALRSDTKLSMSTRCKGTGKPCSRIAYN (SEQ ID NO:103) CCTGSCRSGKCG Toxin Sequence: Cys-Lys-Gly-Thr-Gly-Lys-Xaa3-Cys-Ser-Arg-Ile-Ala-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:104) Ser-Gly-Lys-Cys-# Name: Cn6.3 Species: consors Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:105) ATCACAGCTGATGACTCCAAAGGTACGCAGAAGCATCGTTCCCTGAGGTCGACCAC CAAAGTCTCCAAGGCGACTGACTGCATTGAAGCCGGAAATTATTGCGGACCTACTG TTATGAAAATCTGCTGCGGCTTTTGCAGTCCATACAGCAAAATATGTATGAACTATC CCCAAAATTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTAC CTGAGAGTGGTCATGAACCACTCATCACCTCGTCCC Translation: MKLTCVVWAVLLLTACQLITADDSKGTQKHRSLRSTTKVSKATDCIIEAGNYCGPTVMK (SEQ ID NO:106) ICCGFCSPYSKICMNYPQN Toxin Sequence: Ala-Thr-Asp-Cys-Ile-Xaa1-Ala-Gly-Asn-Xaa5-Cys-Gly-Xaa3-Thr-Val-Met-Lys-Ile-Cys-Cys- (SEQ ID NO:107) Gly-Phe-Cys-Ser-Xaa3-Xaa5-Ser-Lys-Ile-Cys-Met-Asn-Xaa5-Xaa3-Gln-Asn-{circumflex over ( )} Name: Cn6.4 Species: consors Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:108) CTCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTCGGACAC CAAACTCTCCATGTCGACTCGCTGCAAAGGTAAAGGAGCATCATGTACAAGGCTTA TGTATGACTGCTGCCACGGTTCTTGCAGCAGCAGCAAGGGTAGATGTGGCTGATCC GGCGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTACCT GAGAGGTGGTCATGAACCACTCATCACCTGCTCCCCTG Translation: MKLTCVVIVAVLLLTACQLLTADDSRGTQKHRALRSDTKLSMSTRCKGKGASCTRLMY (SEQ ID NO:19) DCCHGSCSSSKGRCG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Ala-Ser-Cys-Thr-Arg-Leu-Met-Xaa5-Asp-Cys-Cys-His-Gly-Ser-Cys-Ser- (SEQ ID NO:110) Ser-Ser-Lys-Gly-Arg-Cys-# Name: Cn6.5 Species: consors Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCATGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:111) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTC GGACACCAAACTCTCCATGTCAACTCGCTGCAAGGGTAAAGGAGCATCATGTCATA GGACTTCGTATGACTGCTGCACCGGTTCTTGCAACAGAGGTAAATGTGGCTGATCCG GCGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCATCCATACCTG TGCTCGAG Translation: MKLTCMVIVAVLLLTACQLITADDSRGTQKHRALRSDTKLSMSTRCKGKGASCHRTSY (SEQ ID NO:112) DCCTGSCNRGKCG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Ala-Ser-Cys-His-Arg-Thr-Ser-Xaa5-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Asn- (SEQ ID NO:113) Arg-Gly-Lys-Cys-# Name: Cn6.6 Species: consors Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:114) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAAGTC GGACACCAAACTCTCCATGTTAACTTTGCGCTGCGCATCTTACGGAAAACCTTGTGG TATTTACAACGACTGCTGCAATACATGCGATCCAGCCAGAAAGACATGTACGTAGC TGATCCGGCGTCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCATCC ATACCTGTGCTCGAG Translation: MKLTCVVTVAVLLLTACQLITADDSRGTQKHRALKSDTKLSMLTLRCASYGKPCGIYND (SEQ ID NO:115) CCNTCDPARKTCT Toxin Sequence: Cys-Ala-Ser-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Xaa5-Asn-Asp-Cys-Cys-Asn-Thr-Cys-Asp-Xaa3- (SEQ ID NO:116) Ala-Arg-Lys-Thr-Cys-Thr-{circumflex over ( )} Name: Cn6.7 Species: consors Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:117) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTC GGACACCAAACTCTCCATGTCGACTCGCTGCAAGGGTACAGGAAAACCATGCAGTA GGGTTGCGTATAACTGCTGCACCGGTTCTTGCAGATCAGGTAAATGTGGCTGATCCA GTGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCTTACCTG AGAGTGGTCATGAACCACTCATCACCTGCTCCTCTGGAGGCTTCAGAGGAGCTACAT TGAAATAAAAGCCGCATTGCANTGNANAAAANNNNNNNNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNNNNGGAAAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSDTKLSMSTRCKGTGKPCSRVAY (SEQ ID NO:118) NCCTGSCRSGKCG Toxin Sequence: Cys-Lys-Gly-Thr-Gly-Lys-Xaa3-Cys-Ser-Arg-Val-Ala-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys- (SEQ ID NO:119) Arg-Ser-Gly-Lys-Cys-# Name: Cn6.8 Species: consors Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCATGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:120) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTTCCCTGAGGTC GACCACCAAAGTCTCCAAGTCGACTAGCTGCATGAAAGCCGGGTCTTATTGCCGCTC TACTACGAGAACCTGCTGCGGTTATTGCGCTTATTTCGGCAAATTTTGTATTGACTTT CCCAGCAACTGATCTTCCCCCTACTGTGCTCTATCCTTTTCTGCCTCTGCCTGAGTCC TCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTGCTCCCCTGGAGGCCTCAGA GGAGCTACAATGAAATAAAAGCCGCATTGCAAAAAAAAAAAAAAAAAAAA Translation: MKLTCMVIVAVLLLTACQLITADDSRGTQKHRSLRSTTKVSKSTSCMKAGSYCRSTTRT (SEQ ID NO:121) CCGYCAYFGKFCIDFPSN Toxin Sequence: Ser-Thr-Ser-Cys-Met-Lys-Ala-Gly-Ser-Xaa5-Cys-Arg-Ser-Thr-Thr-Arg-Thr-Cys-Cys-Gly- (SEQ ID NO:122) Xaa5-Cys-Ala-Xaa5-Phe-Gly-Lys-Phe-Cys-Ile-Asp-Phe-Xaa3-Ser-Asn-{circumflex over ( )} Name: Da6.8 Species: dalli Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGTTC (SEQ ID NO:123) CTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAAGTACGCAGAAGCATCG TGCTCTGAGGTCGACCATCAAACACTCCATGTTGACTAGGAGCTGCACGCCTCCCGG AGGACCTTGTGGTTATTATAATGACTGCTGCAGTCATCAATGCAATATAAGCAGAA ATAAATGCGAGTAGCTGATCCGGCATCTGATCTTCCCCTTCTGTGCTCGTCCTAACC TGAGAGTGGTCATGAACCATCATCACCTACTCCTCTGGAGGCTTCAGAGGAGCTAC ATGGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLFLTACQLITADDSRSTQKHRALRSTIKHSMLTRSCTPPGGPCGYYND (SEQ ID NO:124) CCSHQCNISRNKCE Toxin Sequence: Ser-Cys-Thr-Xaa3-Xaa3-Gly-Gly-Xaa3-Cys-Gly-Xaa5-Xaa5-Asn-Asp-Cys-Cys-Ser-His-Gln- (SEQ ID NO:125) Cys-Asn-Ile-Ser-Arg-Asn-Lys-Cys-Xaa1-{circumflex over ( )} Name: Di6.1 Species: distans Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGCGTGTTGATCATCGCCGTGCTGTTC (SEQ ID NO:126) CTGACGGCCTGTCAACTCACTAGAGGAAAGCTGGAGCGTCCTGTTCTGAGGTCGAG CGACCAAACCTCCGGGTCAACGAAGAGATGCGAAGATCCTGGTGAACCTTGCGGAA GTGATCATTCCTGCTGCGGCGGTAGTTGCAACCACAACGTCTGCGCCTGAAGCTGGT CTGGCATCTGACCATTCCCCTTCTGTACTCTATCTCTATTGCCTGAGTCATCTTTACC TGTGAGTGGTCATGAATCTCTCAATACCTTCTCCCCTGGAGGCTTCAGAAGAACTAG ATTGAAATA Translation: MKLTCVLIIAVLFLTACQLTRGKILERPVLRSSDQTSGSTKRCEDPGEPCGSDHSCCGGSC (SEQ ID NO:127) NHNVCA Toxin Sequence: Cys-Xaa1-Asp-Xaa3-Gly-Xaa1-Xaa3-Cys-Gly-Ser-Asp-His-Ser-Cys-Cys-Gly-Gly-Ser-Cys-Asn- (SEQ ID NO:128) His-Asn-Val-Cys-Ala-{circumflex over ( )} Name: E6.2 Species: ermineus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:129) ATCACAGCTGACGACTCCAGACGTACGCAGAAGCATCGTGCCCTGAGGTCGACCAC CAAACGCGCCACGTCGAATCGCCCCTGCAAGCCGAAAGGACGAAAATGTTTTCCGC ATCAGAAGGACTGCTGCAATAAAACGTGCACCAGATCAAAATGTCCCTGATCTTCC CCCTTCTGTGCTGTATCCTTTTCTGCCTGAGTCCTCCTTACCTGAGAGTGGTCAGTAA CCACTCATCACCATCTCCTCTGGAGG Translation: MKLTCVVIVAVLLLTACQLITADDSRRTQKHRALRSTTKRATSNRPCKPKGRKCFPHQK (SEQ ID NO:130) DCCNKTCTRSKCP Toxin Sequence: Xaa3-Cys-Lys-Xaa3-Lys-Gly-Arg-Lys-Cys-Phe-Xaa3-His-Gln-Lys-Asp-Cys-Cys-Asn-Lys-Thr- (SEQ ID NO:131) Cys-Thr-Arg-Ser-Lys-Cys-Xaa3-{circumflex over ( )} Name: E6.3 Species: ermineus Cloned: Yes DNA Sequence: AACTCATCACAGCTGATGACTCCAGAGGTACGCAGAACGATCGTGCCCTGAGGTCG (SEQ ID NO:132) ACCACCAAACTCTCCATGCTGACTCGGGCCTGCTGGTCTTCCGGAACACCTTGTGGT ACTGATAGTTTATGCTGCGGTGGATGCAATGTATCCAAAAGTAAATGTAACTAGCTG ATTCGGCGTCTGAACTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCCGAGTCCTCCAT ACCTGAGAATGGTCATGAACCACTCATCACCTACTCCTCTGGAGACCTCAGAAGAG CTACACTGAAATAAAAGCGCTTGC Translation: LITADDSRGTQNDRALRSTTKLSMLTRACWSSGTPCGTDSLCCGGCNVSKSKCN (SEQ ID NO:133) Toxin Sequence: Ala-Cys-Xaa4-Ser-Ser-Gly-Thr-Xaa3-Cys-Gly-Thr-Asp-Ser-Leu-Cys-Cys-Gly-Gly-Cys-Asn- (SEQ ID NO:134) Val-Ser-Lys-Ser-Lys-Cys-Asn-{circumflex over ( )} Name: G6.1 Species: geographus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:135) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGGGGTC GACCACCGAACTCTCCTTGTCGACTCGCTGCAAGTCACCCGGATCTTCATGTTCACC GACTAGTTATAATTGCTGCAGGTCTTGCAATCCATACGCCAAAAGATGTTACGGCTA ATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATCCCTTCCTGTCTGAGTCCTCCTT ACCTGAGAGTGGTCATGAACCACTCCTCACCTACTTCTCTGGAGGCTTCGGAGGAGC TACATTGAAATAAAAGCCGCATTGTAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALGSTTELSLSTRCKSPGSSCSPTSYNC (SEQ ID NO:136) CRSCNPYAKRCYG Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Ser-Ser-Cys-Ser-Xaa3-Thr-Ser-Xaa5-Asn-Cys-Cys-Arg-Ser-Cys-Asn- (SEQ ID NO:137) Xaa3-Xaa5-Ala-Lys-Arg-Cys-Xaa5-# Name: G6.2 Species: geographus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:138) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTC GTCCACCAAACTCACCTTGTCGACTCGCTGCAAATCACCCGGAACTCCATGTTCAAG GGGTATGCGTGATTGCTGCACGCCTTGCTTGTTATACAGCAACAAATGTAGGCGCTA CTAACCCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATTCCTTTCTGCCTGAGTCCTC CTTACCTGAAAGTGGTCATGAACCACTCATCACCTACTTCTCTGGAGGCTTCAGAAG AGCTACATTGAAATAAAAGCCGCATTGCAATGACAAAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSSTKLTLSTRCKSPGTPCSRGMRD (SEQ ID NO:139) CCTPCLLYSNKCRRY Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Thr-Xaa3-Cys-Ser-Arg-Gly-Met-Arg-Asp-Cys-Cys-Thr-Xaa3-Cys-Leu- (SEQ ID NO:140) Leu-Xaa5-Ser-Asn-Lys-Cys-Arg-Arg-Xaa5-{circumflex over ( )} Name: w-GVIA Species: geographus Cloned: Yes DNA Sequence: GGAATTCCGTTTCTGCGCTGCTTCCTTTGGCATCACCAAAACCATCATCAAAATGAA (SEQ ID NO:141) ACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTCATCAC AGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGGGGTCGACCACCGAAC TCTCCTTGTCGACTCGCTGCAAGTCACCCGGATCTTCATGTTCACCGACTAGTTATA ATTGCTGCAGGTCTTGCAATCCATACACCAAAAGATGTTACGGCTAATCCAGCGCCT GATCTTCCCTGCTCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACC TACTTCTCTAGGCGGTTCGGAGGAGCTACATTGAAATAAAAGCCGCATTGCAAAAA AAAAAAAAAA Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALGSTTELSLSTRCKSPGSSCSPTSYNC (SEQ ID NO:142) CRSCNPYTKRCYG Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Ser-Ser-Cys-Ser-Xaa3-Thr-Ser-Xaa5-Asn-Cys-Cys-Arg-Ser-Cys-Asn- (SEQ ID NO:143) Xaa3-Xaa5-Thr-Lys-Arg-Cys-Xaa5-# Name: w-GVIB Species: geographus Isolated: Yes Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Ser-Ser-Cys-Ser-Xaa3-Thr-Ser-Xaa5-Asn-Cys-Cys-Arg-Ser-Cys-Asn- (SEQ ID NO:144) Xaa3-Xaa5-Thr-Lys-Arg-Cys-Xaa5-Gly-# Name: w-GVIC Species: geographus Isolated: Yes Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Ser-Ser-Cys-Ser-Xaa3-Thr-Ser-Xaa5-Asn-Cys-Cys-Arg-Ser-Cys-Asn- (SEQ ID NO:145) Xaa3-Xaa5-Thr-Lys-Arg-Cys-# Name: w-GVIIA Species: geographus Isolated: Yes Cloned: Yes DNA Sequence: CATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTCGTCCA (SEQ ID NO:146) CCAAACTCACCTTGTCGACTCGCTGCAAATCACCCGGAACTCCATGTTCAAGGGGTA TGCGTGATTGCTGCACGTCTTGCTTGTTATACAGCAACAAATGTAGGCGCTACTAAC CCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATTCCTTTCTGCCTGAGTCCTCCTTAC CTGAAAGTGGTCATGAACCACTCATCACCTACTTCTCTGGAGGCTTCAGAAGAGCTA CATTGAAATAAAAGCCGCATTGCAATGAC Translation: ITADDSRGTQKHRALRSSTKLTLSTRCKSPGTPCSRGMRDCCTSCLLYSNKCRRY (SEQ ID NO:147) Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Thr-Xaa3-Cys-Ser-Arg-Gly-Met-Arg-Asp-Cys-Cys-Thr-Ser-Cys-Leu- (SEQ ID NO:148) Leu-Xaa5-Ser-Asn-Lys-Cys-Arg-Arg-Xaa5-# Name: w-GVIIB Species: geographus Isolated: Yes Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Thr-Xaa3-Cys-Ser-Arg-Gly-Met-Arg-Asp-Cys-Cys-Thr-Ser-Cys-Leu- (SEQ ID NO:149) Ser-Xaa5-Ser-Asn-Lys-Cys-Arg-Arg-Xaa5-# Name: La6.1 Species: laterculatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:150) CCTGACGGCCTGTCAACTCATCACCGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGACCACCAATCTCTCCATGCTGACTCGGAAGTGCTGGCCTTCCG GAAGCTATTGTCGTGCGAATAGTAAATGCTGCAGTGGATGCGATCGGAACAGAAAT AAATGTTACTAGCTGATTCGGCGTCTGAACTTCCTCCTTCTGTGCTCTATCCTTTTCT GCCCGAGTCCTCCATACCTGAGAGTGGTCATGAACCACTCAACTCCTACTCCTCTGG AGGCCTCAGAAGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSTTNLSMLTRKCWPSGSYCRANS (SEQ ID NO:151) KCCSGCDRNRNKCY Toxin Sequence: Lys-Cys-Xaa4-Xaa3-Ser-Gly-Ser-Xaa5-Cys-Arg-Ala-Asn-Ser-Lys-Cys-Cys-Ser-Gly-Cys-Asp- (SEQ ID NO:152) Arg-Asn-Arg-Asn-Lys-Cys-Xaa5-{circumflex over ( )} Name: La6.2 Species: laterculatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:153) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGACCACCAAACTCTCCATATCGACTCGCTGCCTTCCTCCCGGAT CATATTGTAAGGCGACAACGGAAGTCTGCTGCTCTTCTTGCCTTCAATTCGCTCAGA TATGTTCGGGTTGATCTTCCCTCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCAT ACCTGAGAATGGTCATGAACCACTCAACATCTACTCCTCTGGAGGCCTCAGAAGAG CTATATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSTTKLSISTRCLPPGSYCKATTEVC (SEQ ID NO:154) CSSCLQFAQICSG Toxin Sequence: Cys-Leu-Xaa3-Xaa3-Gly-Ser-Xaa5-Cys-Lys-Ala-Thr-Thr-Xaa1-Val-Cys-Cys-Ser-Ser-Cys-Leu- (SEQ ID NO:155) Gln-Phe-Ala-Gln-Ile-Cys-Ser-# Name: La6.3 Species: laterculatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:156) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGACCACCAATCTCTCCATGTCGACTCGCTGCAAGTCTCCCGGAT CATCATGTAGCGTGTCTATGCGTAACTGCTGCACTTCTTGCAATTCACGCACCAAGA AATGTACGCGACGTGGCTGAACTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCCGAGT CCTCCATACCTGAGAGTGGTCATGAACCACTCAACATCTACTCCTCTGGAGGCCTCA GAAGAGCTATATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSTTNLSMSTRCKSPGSSCSVSMRN (SEQ ID NO:157) CCTSCNSRTKKCTRRG Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Ser-Ser-Cys-Ser-Val-Ser-Met-Arg-Asn-Cys-Cys-Thr-Ser-Cys-Asn-Ser- (SEQ ID NO:158) Arg-Thr-Lys-Lys-Cys-Thr-Arg-Arg-# Name: La6.4 Species: laterculatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:159) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGACAACCAAACTCTCCATGCTGACTCGGACCTGCTGGCCTTCCG GAACAGCTTGTGGTATTGATAGTAACTGCTGCAGTGGATGCAATGTATCCAGAAGT AAATGTAACTAGCTGATTCGGCGTCTAAACTTCCTCCTTCTGCCTGAGTCCTCCATA CCTGAGAGTGGTCATGAACCACATCATCACCTCATCTCTGGAGGCCTC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSTTKLSMLTRTCWPSGTACGIDSN (SEQ ID NO:160) CCSGCNVSRSKCN Toxin Sequence: Thr-Cys-Xaa4-Xaa3-Ser-Gly-Thr-Ala-Cys-Gly-Ile-Asp-Ser-Asn-Cys-Cys-Ser-Gly-Cys-Asn-Val- (SEQ ID NO:161) Ser-Arg-Ser-Lys-Cys-Asn-{circumflex over ( )} Name: La6.5 Species: laterculatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:162) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGACCACCAATCTCTCCATGCTGACTCGGAAGTGCTGGCCTTCCG GAAGCTATTGTCGTGCGAATAGTAAATGCTGCAGTGGATGCGATCGGAACAGAAGT AAATGTAACTAGCTGATTCGGCGTCTAAACTTCCTCCTTCTGCCTGAGTCCTCCATA CCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGGAGGCCTCAAAGGAGCT ACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVTVAVLLLTACQLITADDSRGTQKHRALRSTTNLSMLTRKCWPSGSYCRANS (SEQ ID NO:163) KCCSGCDRNRSKCN Toxin Sequence: Lys-Cys-Xaa4-Xaa3-Ser-Gly-Ser-Xaa5-Cys-Arg-Ala-Asn-Ser-Lys-Cys-Cys-Ser-Gly-Cys-Asp- (SEQ ID NO:164) Arg-Asn-Arg-Ser-Lys-Cys-Asn-{circumflex over ( )} Name: Lp6.1 Species: leopardus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTAGCTGTGCTGTTCCTGACGGCCTGTCAACTC (SEQ ID NO:165) ACTACAGCTGACATCTCCAGAGGTACGCGGAAGCGTCGTGCTCTGAGGTCGACCAC CAAACTCTCCAGGTCGCTCTTTGAGTGCGCGCCTTCCGGTGGACGTTGTGGTTTTTTA AAGTCCTGCTGCGAAGGATATTGCGATGGGGAAAGCACTTCATGTGTGAGTGGCCC ATACAGCATCTGATCTTCCCGCCTTCAGTGCTCTATCCTTTTCTGCCTGAGTCCTCCA TACCTCTGAGCGGTCATGAACCACTCAACACCTACTCCTCTGGAGGCTTCAGGGAAC TATATTAAAATAAAGCCGCATTGCAACGAAANAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLFLTACQLTTADISRGTRKRRALRSTTKLSRSLFECAPSGGRCGFLKSC (SEQ ID NO:166) CEGYCDGESTSCVSGPYSI Toxin Sequence: Ser-Leu-Phe-Xaa1-Cys-Ala-Xaa3-Ser-Gly-Gly-Arg-Cys-Gly-Phe-Leu-Lys-Ser-Cys-Cys-Xaa1- (SEQ ID NO:167) Gly-Xaa5-Cys-Asp-Gly-Xaa1-Ser-Thr-Ser-Cys-Val-Ser-Gly-Xaa3-Xaa5-Ser-Ile-{circumflex over ( )} Name: Lp6.2 Species: leopardus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCTGTGCTGTTCCTGACGGCCTGTCAACTC (SEQ ID NO:168) ACTACAGCTGACATCTCCAGAGGTACGTGGAAGCATCGTGGTGTGGGGTCGACCAC CGGACTCTCCCCGTGGCCCTTGGACTGCACGGCTCCCAGTCAACCTTGTGGTTATTT TCCTAGGTGCTGTGGACATTGCGATGTACGCAGGGTATGTACGAGTGGCTGATCCG GCGTCTGATCTTTCCGCCTTCTGTGCTGTATCCTTTTCTGCCTGAGTCCTCCATACCC GTGAGTGGTCATGAACCACTCAACACCTACTCCTCTGGAGGCTTCAGAGGAACTAT ATTAAAATAAAGCCGCATTGCAATG Translation: MKLTCVVIVAVLFLTACQLTTADISRGTWKHRGVGSTTGLSPWPLDCTAPSQPCGYFPR (SEQ ID NO:169) CCGHCDVRRVCTSG Toxin Sequence: Xaa4-Xaa3-Leu-Asp-Cys-Thr-Ala-Xaa3-Ser-Gln-Xaa3-Cys-Gly-Xaa5-Phe-Xaa3-Arg-Cys-Cys- (SEQ ID NO:170) Gly-His-Cys-Asp-Val-Arg-Arg-Val-Cys-Thr-Ser-# Name: Lp6.3 Species: leopardus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCTGTGCTGTTCCTGACGGCCTGTCAACTC (SEQ ID NO:171) ACTACAGCTGACATCTCCAGAGGTACGCGGAAGCATCGTGCTCTGAGGTCGACCAC CAAACTCTCCAGGTCGCCCTCTAGGTGCATGTCTCCCGGTGGAATTTGTGGTGATTT TGGTGACTGCTGCGAAATTTGCAATGTGTACGGTATATGTGTGAGTGACTTACCCGG CATCTGATCTTTCCGCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCCTCCATACCCCT GAGTGGTCATGGACCACTCAACACCTACTCCTCTGGAGGCTTCAGAGGAACTACATT AAAATAAAGCCGCATTGCAAAAAAAAAAAAAAAAAAAA Translation: MKLTCVVTVAVLFLTACQLTTADISRGTRKHRALRSTTKLSRSPSRCMSPGGICGDFGDC (SEQ ID NO:172) CEICNVYGICVSDLPGI Toxin Sequence: Cys-Met-Ser-Xaa3-Gly-Gly-Ile-Cys-Gly-Asp-Phe-Gly-Asp-Cys-Cys-Xaa1-Ile-Cys-Asn-Val- (SEQ ID NO:173) Xaa5-Gly-Ile-Cys-Val-Ser-Asp-Leu-Xaa3-Gly-Ile-{circumflex over ( )} Name: Lp6.4 Species: leopardus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCTGTGCTGTTCCTGACGGCCTGTCAACTC (SEQ ID NO:174) ACTACAGCTGATGATTCCAGAGGTACACGGAAGCATCGTGCTCTGAGGTCAACCAC CAAACTCTCCAGGTGGCCCAGGTACTGCGCGCCTCCCGGTGGAGCTTGTGGGTTTTT TGATCACTGCTGCGGATATTGCGAAACGTTTTACAATACGTGTAGATGAGTTGGCTG ATCCGGCGCTTGATCTTTCCGCCTTCTGTTGCTCTATCTTTTTCTGCCTGAGTCCTCCC ATACCCCGTTGAGTGGTCCATGAACCACTCCAACACCTACTCCCTCCTTGGAAGCTT CCAAAGGAAACGACATTTAAAATAAATTCCCCATTGCAATTGGAAAAAAAAAAAAA AAAAA Translation: MKLTCVVTVAVLFLTACQLTTADDSRGTRKHRALRSTTKLSRWPRYCAPPGGACGFFD (SEQ ID NO:175) HCCGYCETFYNTCR Toxin Sequence: Xaa5-Cys-Ala-Xaa3-Xaa3-Gly-Gly-Ala-Cys-Gly-Phe-Phe-Asp-His-Cys-Cys-Gly-Xaa5-Cys- (SEQ ID NO:176) Xaa1-Thr-Phe-Xaa5-Asn-Thr-Cys-Arg-{circumflex over ( )} Name: L6.1 Species: lynceus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:177) ATCACAGCTGATGACTCCAGACGTACACAGAAGCATCGTGCCCTGAGGTCGACCAC CAATCTCTCCATGTCGACTCGCTGCAAGTCTCCCGGATCACCATGTAGTGTGACATC GTATAACTGCTGCACTTTTTGCTCTTCATACACTAAGAAATGTCGGGCCTCTTTATGA ACCACTCATCACCTACTCCTCTGGAGGCCTCAGAAGAGCTACACTGAAATAAAAGC CGCATTGG Translation: MKLTCVVIVAVLLLTACQLITADDSRRTQKHRALRSTTNLSMSTRCKSPGSPCSVTSYN (SEQ ID NO:178) CCTFCSSYTKKCRASL Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Ser-Xaa3-Cys-Ser-Val-Thr-Ser-Xaa5-Asn-Cys-Cys-Thr-Phe-Cys-Ser- (SEQ ID NO:179) Ser-Xaa5-Thr-Lys-Lys-Cys-Arg-Ala-Ser-Leu-{circumflex over ( )} Name: L6.2 Species: lynceus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGTCAACTC (SEQ ID NO:180) ATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTCGACCAC CAAACTATCCATGTATACTCGCTGCGCAGGTCCAGGAGCAATTTGTCCTAATAGGGT ATGCTGCGGTTATTGCAGTAAAAGAACACATCTATGTCATTCGCGAACTGGCTGATC TTCCCCCTTCTGTGCTCTATCCTTTTTCTGCCTGAGTCCTCCATACCTGAGAATGGTC ATGAACCACTCATCACCTACTCCTCTTGGAGACCTCAGAGGAGCTACACTGAAATA AAAGCCGCATTGGC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSTTKLSMYTRCAGPGAICPNRVCC (SEQ ID NO:181) GYCSKRTHLCHSRTG Toxin Sequence: Cys-Ala-Gly-Xaa3-Gly-Ala-Ile-Cys-Xaa3-Asn-Arg-Val-Cys-Cys-Gly-Xaa5-Cys-Ser-Lys-Arg- (SEQ ID NO:182) Thr-His-Leu-Cys-His-Ser-Arg-Thr-# Name: L6.3 Species: lynceus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCTGCTAGCGGCCTGTCAACTA (SEQ ID NO:183) CTACACGCTGATGACTCCAGAGGTACGCAGAAGACTGCTGCCCGAGGTCGACCACC AAAACTCTCCATGCTGACTCGGGCCTGCTGGTCTTCCGGAACACCTTGTGGTACTGA TAGTTTATGCTGCGGTGGATGCAATGTATCCAAAAGTAAATGTAACTAGCTGATTCG GCGTCTGAACTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCCGAGTCCTCCATACCTG AGAATGGTCATGAACCACTCATCACCTACTCCTCTGGAGACCTCAGAAGAGCTACA CTGAAATAAAAGCGCATTGC Translation: MKLTCVVIVAVLLLAACQLLHADDSRGTQKTAARGRPPKLSMLTRACWSSGTPCGTDS (SEQ ID NO:184) LCCGGCNVSKSKCN Toxin Sequence: Ala-Cys-Xaa4-Ser-Ser-Gly-Thr-Xaa3-Cys-Gly-Thr-Asp-Ser-Leu-Cys-Cys-Gly-Gly-Cys-Asn- (SEQ ID NO:185) Val-Ser-Lys-Ser-Lys-Cys-Asn-{circumflex over ( )} Name: L6.4 Species: lynceus Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGAGCTACTCCTAACGGCCTGTCAACTC (SEQ ID NO:186) ATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCGTGCCCTGAGGTCGACCAC CAATCTCTCCATGCTGACTCGGAAGTGCTGGTCTCCCGGAACCTATTGTCGTGCGCA TAGTAAATGCTGCCGTGGATGCGATCAGAACAGAAATAAATGTTACTAGCTGATTC GGCGTCTGAACTTCCTCCTTCTGTGCTCTATCCTTTTTCTGCCTGAGTCCTCCATACC TGAGAATGGTCATGAACCACTCATCACCTACTCCTCTGGAGGCCTCAGAGGAGCCT ACACTGAAATAAAAGCCGCATTGG Translation: MKLTCVVIVAELLLTACQLITADDSRGTQKHRALRSTTNLSMLTRKCWSPGTYCRAHSK (SEQ ID NO:187) CCRGCDQNRNKCY Toxin Sequence: Lys-Cys-Xaa4-Ser-Xaa3-Gly-Thr-Xaa5-Cys-Arg-Ala-His-Ser-Lys-Cys-Cys-Arg-Gly-Cys-Asp- (SEQ ID NO:188) Gln-Asn-Arg-Asn-Lys-Cys-Xaa5-{circumflex over ( )} Name: M6.1 Species: magus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:189) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGGACACCAAACTCTCCATGTCGACTCGCTGCAAGGGTACAGGA AAACCATGCAGTAGGATTGCGTATAACTGCTGCACCGGTTCTTGCAGATCAGGTAA ATGTGGCTGATCCAGTGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTTCTGCCTG AGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCA Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSDTKLSMSTRCKGTGKPCSRIAYN (SEQ ID NO:190) CCTGSCRSGKCG Toxin Sequence: Cys-Lys-Gly-Thr-Gly-Lys-Xaa3-Cys-Ser-Arg-Ile-Ala-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:191) Ser-Gly-Lys-Cys-# Name: M6.2 Species: magus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:192) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAAGTCGGACACCAAACTCTCCATGTTAACTTTGCGCTGCGCATCTTACG GAAAACCTTGTGGTATTTACAACGACTGCTGCAATACATGCGATCCAGCCAGAAAG ACATGTACGTAGCTGATCCGGCGTCTGATCTTCC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALKSDTKISMLTLRCASYGKPCGIYND (SEQ ID NO:193) CCNTCDPARKTCT Toxin Sequence: Cys-Ala-Ser-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Xaa5-Asn-Asp-Cys-Cys-Asn-Thr-Cys-Asp-Xaa3- (SEQ ID NO:194) Ala-Arg-Lys-Thr-Cys-Thr-{circumflex over ( )} Name: w-MVIIB Species: magus Isolated: Yes Cloned: Yes DNA Sequence: GAATTTTCAGCATCACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATC (SEQ ID NO:195) GTCGCCGTGCTGCTCCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGT ACGCAGAAGCATCGTGCCCTGAGGTCGGACACCAAACTCTCCATGTCAACTCGCTG CAAGGGTAAAGGAGCATCATGTCATAGGACTTCGTATGACTGCTGCACCGGTTCTTG CAACAGAGGTAAATTTGGCTGATCCGCC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSDTKISMSTRCKGKGASCHRTSY (SEQ ID NO:196) DCCTGSCNRGKLFG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Ala-Ser-Cys-His-Arg-Thr-Ser-Xaa5-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Asn- (SEQ ID NO:197) Arg-Gly-Lys-Cys-# Name: Mi6.1 Species: miles Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCATCGCCATGCTGTTCCTGACAGCCTAT (SEQ ID NO:198) CAACTCGCTACAGCTGCGAGCTACGCCAAAGGTAAACAGAAGCATCGTGCTCTGAG GCCAGCTGACAAACACCTCAGGTTGACCAAGCGTTGCAATGATCGCGGTGGAGGTT GCAGTCAACATCCTCACTGCTGCGGTGGAACTTGCAATAAGCTTATTGGCGTATGTC TGTAAAGCTGGTCTGCCGTCTGATATTCCCTTTCTGTGCTTCATCCTCTTTTGCCTGA GTCATCCATACCTGTGAATGGTTAAGAGCCACTCAATACCTATTCCTCTGGGGGCTT CAGAGGAACTACTTTAC Translation: MKLTCVVIIAMLFLTAYQLATAASYAKGKQKHRALRPADKHLRLTKRCNDRGGGCSQ (SEQ ID NO:199) HPHCCGGTCNKLIGVCL Toxin Sequence: Cys-Asn-Asp-Arg-Gly-Gly-Gly-Cys-Ser-Gln-His-Xaa3-His-Cys-Cys-Gly-Gly-Thr-Cys-Asn- (SEQ ID NO:200) Lys-Leu-Ile-Gly-Val-Cys-Leu-{circumflex over ( )} Name: Mn6.1 Species: monachus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGAGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:201) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGGACACCAAACTCTCCATATCGACTCGCTGCAAGTCTACAGGA AAATCATGCAGTAGGATTGCGTATAACTGCTGCACCGGTTCTTGCAGATCAGGTAA ATGTGGCTGATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGA GTCCTCCTTA Translation: MKLTSVVIVAVLLLTACQLITADDSRGTQKHRALRSDTKLSISTRCKSTGKSCSRIAYNC (SEQ ID NO:202) CTGSCRSGKCG Toxin Sequence: Cys-Lys-Ser-Thr-Gly-Lys-Ser-Cys-Ser-Arg-Ile-Ala-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:203) Ser-Gly-Lys-Cys-# Name: Mn6.2 Species: monachus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGAGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:204) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGGACACCAACCTCTCCATGTCGACTCGCTGCAAGGGTAAAGGA TCTTCATGTAGTAGGACCATGTATAACTGCTGCACCGGTTCTTGCAACAGAGGTAAA TGTGGCTGATCCAGCGCCTGATCTTCCCCCTTC Translation: MKLTSVVIVAVLLLTACQLITADDSRGTQKHRALRSDTNLSMSTRCKGKGSSCSRTMYN (SEQ ID NO:205) CCTGSCNRGKCG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Ser-Ser-Cys-Ser-Arg-Thr-Met-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys-Asn- (SEQ ID NO:206) Arg-Gly-Lys-Cys-# Name: O6.1 Species: obscurus Cloned: Yes DNA Sequence: ctctctctctctctgctggacAGGTCGCCTCCCTGCATGAAAGGCGGATCGTCATGCCGCGGTACT (SEQ ID NO:207) ACGGGAGTCTGTTGCGGTTTTTGCAGTGATTTCGGCTATAAATGTAGGGACTATCCC CAAAACTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGTCCGAGTCCTCCTGACCT GAGAGTGGTCATGAACCACTCATCACCTACCCCTCTGGGGCTTCACAGGATCTACAT TGAAATAAAAGCCGCATTGC Translation: LLDRSPPCMKGGSSCRGTTGVCCGFCSDFGYKCRDYPQN (SEQ ID NO:208) Toxin Sequence: Ser-Xaa3-Xaa3-Cys-Met-Lys-Gly-Gly-Ser-Ser-Cys-Arg-Gly-Thr-Thr-Gly-Val-Cys-Cys-Gly- (SEQ ID NO:209) Phe-Cys-Ser-Asp-Phe-Gly-Xaa5-Lys-Cys-Arg-Asp-Xaa5-Xaa3-Gln-Asn-{circumflex over ( )} Name: O6.2 Species: obscurus Cloned: Yes DNA Sequence: ctctctctctctctgctggacAGGTCGACTCGCTGCTTGCCTGACGGAACGTCTTGCCTTTTTAGT (SEQ ID NO:210) AGGATCAGATGCTGCGGTACTTGCAGTTCAATCTTAAAGTCATGTGTGAGCTGATCC AGCGGTTGATCTTCCTCCCTCTGTGCTCCATCCTTTTCTGCCTGAGTTCTCCTTACCT GAGAGTGGTCATGAACCACTCATCACCTACTCTTCTGGAGGCTTCAGAGGAGCTAC ATTGAAATAAAAGCCGCATTGC Translation: RSTRCLPDGTSCLFSRIRCCGTCSSILKSCVS (SEQ ID NO:211) Toxin Sequence: Cys-Leu-Xaa3-Asp-Gly-Thr-Ser-Cys-Leu-Phe-Ser-Arg-Ile-Arg-Cys-Cys-Gly-Thr-Cys-Ser-Ser- (SEQ ID NO:212) Ile-Leu-Lys-Ser-Cys-Val-Ser-{circumflex over ( )} Name: Pu6.2 Species: pulicarius Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCATCGCCGTGCTGTTCCTGACGGCCTGTCAACTC (SEQ ID NO:213) ATTACAGCTGAGACTTACTCCAGAGGTAAGCAGAAGCACCGTGCTTTGAGGTCAAC TGACAAAAACTCCAAGTTGACTAGGCAGTGCTCGCCTAACGGTGGATCTTGTTCTCG TCATTTTCACTGCTGCAGCCTCTATTGCAATAAAAATACTGGCGTATGTATTGCAAC CTAATACCCGTGTGTGGTCATGAACCACTCAATACCCTCTCCTCTGGAGGCTTCAGA GGAACTGCATTGAAATAAAACTGCATTGCNTTGACCAAAAAAAAAA Translation: MKLTCVVIIAVLFLTACQLITAETYSRGKQKHRALRSTDKNSKLTRQCSPNGGSCSRHFH (SEQ ID NO:214) CCSLYCNKNTGVCIAT Toxin Sequence: Xaa2-Cys-Ser-Xaa3-Asn-Gly-Gly-Ser-Cys-Ser-Arg-His-Phe-His-Cys-Cys-Ser-Leu-Xaa5-Cys- (SEQ ID NO:215) Asn-Lys-Asn-Thr-Gly-Val-Cys-Ile-Ala-Thr-{circumflex over ( )} Name: P6.1 Species: purpurascens Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGTTCCTGACGGCCTGTCAACTC (SEQ ID NO:216) ATCACAGCTGATGACTCCAGACGTACGCAGAAGCATCGTGCCCTGAGGTCGACCAC CAAAGGCGCCACGTCGAATCGCCCCTGCAAGACACCCGGACGAAAATGTTTTCCGC ATCAGAAGGACTGCTGCGGTCGAGCGTGCATCATCACAATATGTCCCTGATCTTCCC CCTTCTGTGCTGTATCCTTTTCTGCCTGAGTCTCCTTACCTGAGAGTGGTCATGAA Translation: MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKGATSNRPCKTPGRKCFPHQK (SEQ ID NO:217) DCCGRACIITICP Toxin Sequence: Xaa3-Cys-Lys-Thr-Xaa3-Gly-Arg-Lys-Cys-Phe-Xaa3-His-Gln-Lys-Asp-Cys-Cys-Gly-Arg-Ala- (SEQ ID NO:218) Cys-Ile-Ile-Thr-Ile-Cys-Xaa3-{circumflex over ( )} Name: P6.2 Species: purpurascens Isolated: Yes Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:219) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGACCACCAAACTCTTCACGTCGAAAAGCTGCAAGCTTCCCGGA GCATATTGTAATGCAGAAGATTATGACTGCTGCCTTAGATGCAAAGTTGGAGGTAC ATGTGGCTGATCCAGTGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGA GTCCTCCTTACCTAAGAGTGGTCATGAACCACTCATCACCTTCTCCTCTGGAGGCTT C Translation: MKLTCVVTVAVLLLTACQLITADDSRGTQKHRALRSTTKIFTSKSCKLPGAYCNAEDYD (SEQ ID NO:220) CCLRCKVGGTCG Toxin Sequence: Ser-Cys-Lys-Leu-Xaa3-Gly-Ala-Xaa5-Cys-Asn-Ala-Xaa1-Asp-Xaa5-Asp-Cys-Cys-Leu-Arg- (SEQ ID NO:221) Cys-Lys-Val-Gly-Gly-Thr-Cys-# Name: P6.3 Species: purpurascens Cloned: Yes DNA Sequence: ATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGTTCCTGACGGCCTGTCAACTC (SEQ ID NO:222) ATCACAGCTGATGACTCCAGACGTACGCAGAAGCATCGTGCCCTGAGGTCGACCAC CAAACGCGCCACGTCGAATCGCCCCTGCAAGAAAACCGGACGAAAATGTTTTCCGC ATCAGAAGGACTGCTGCGGTCGAGCGTGCATCATCACAATATGTCCCTGATCTTCCC CCTTCTGTGCTGTATCCTTTTCTGCCTGAGTCCTCCTTACCTGAGAGTGGTCATGAAC CACTCATCACCTTCTCCTCTGGAGGCTTCAGAG Translation: MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKRATSNRPCKKTGRKCFPHQK (SEQ ID NO:223) DCCGRACIITICP Toxin Sequence: Xaa3-Cys-Lys-Lys-Thr-Gly-Arg-Lys-Cys-Phe-Xaa3-His-Gln-Lys-Asp-Cys-Cys-Gly-Arg-Ala- (SEQ ID NO:224) Cys-Ile-Ile-Thr-Ile-Cys-Xaa3-{circumflex over ( )} Name: R6.1 Species: radiatus Cloned: Yes DNA Sequence: GCTGATGCCTGATCTTCATCGTTCTTCCCTGTCTCCTTTGGCATCACCAAAACCATCA (SEQ ID NO:225) TCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGGTCCTGACGGCCTGTC AACTCATCACAGCTGATGACTCCAGAGGTATGCAGAAACATCATGCCCTGGGGTCG ATCAGCAGTCTCTTTAAGTCGACCCGTCATGGCTGCAAACCCCTCAAACGTCGTTGT TTCAATGATAAAGAATGCTGCAGCAAATTTTGCAATTCAGTCCGAAAGCAGTGTGG ATAAATGGCTAAAAAACTGAATAAAAGCCGCATTGCAAAAAAAA Translation: MKLTCVVIVAVLVLTACQLITADDSRGMQKHHALGSISSLFKSTRHGCKPLKRRCFNDK (SEQ ID NO:226) ECCSKFCNSVRKQCG Toxin Sequence: His-Gly-Cys-Lys-Xaa3-Leu-Lys-Arg-Arg-Cys-Phe-Asn-Asp-Lys-Xaa1-Cys-Cys-Ser-Lys-Phe- (SEQ ID NO:227) Cys-Asn-Ser-Val-Arg-Lys-Gln-Cys-# Name: R6.2 Species: radiatus Cloned: Yes DNA Sequence: GAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGGTCCTGACGGCCTGTCA (SEQ ID NO:228) ACTCATCACAGCTGATGACTCCAGAGGTATGCAGAAACATCATGCCCTGGGGTCGA TCAGCAGTCTCTTTAAGTCGACCCGTCGTGGCTGCAAACCCCTCAAACGTCGTTGTT TCAATGATAAAGAATGCTGCAGCAAATTTTGCAATTCAGTCCGAAACCAGTGTGGA TAAATGGCTAAAAACTGAATAAAAG Translation: MKITCVVIVAVLVLTACQLITADDSRGMQKHHALGSISSLFKSTRRGCKPLKRRCFNDK (SEQ ID NO:229) ECCSKFCNSVRNQCG Toxin Sequence: Arg-Gly-Cys-Lys-Xaa3-Leu-Lys-Arg-Arg-Cys-Phe-Asn-Asp-Lys-Xaa1-Cys-Cys-Ser-Lys-Phe- (SEQ ID NO:230) Cys-Asn-Ser-Val-Arg-Asn-Gln-Cys-# Name: w-RVIA Species: radiatus Cloned: Yes DNA Sequence: GGAATTCCGCTTGCACGGCGAACCTGACTTCATCTTTCTTCCCTGCCTCCTTTGGCAT (SEQ ID NO:231) CACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGG TCCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTATGCAGAAGCAT CATGCCCTGAGGTCGATCACCAAACTCTCCCTGTCGACTCGCTGCAAACCTCCCGGA TCACCATGTAGAGTTTCTTCGTATAACTGCTGCTCTTCTTGCAAATCATACAACAAG AAATGTGGCTGAACTTCCCCTTCTGTGCTCTATCCTTTTCCTGCCCGAGTCCTCCATA CCTGAGAGTAGTCATGAACCACTGATTACCTACTCCTCTGGAGGGCCTCAGAGGAG CTACTTTGAAATAAAAGCCCGCATTGCAAAAAAAAAA Translation: MKLTCVVTVAVLVLTACQLITADDSRGMQKHHALRSITKLSLSTRCKPPGSPCRVSSYNC (SEQ ID NO:232) CSSCKSYNKKCG Toxin Sequence: Cys-Lys-Xaa3-Xaa3-Gly-Ser-Xaa3-Cys-Arg-Val-Ser-Ser-Xaa5-Asn-Cys-Cys-Ser-Ser-Cys-Lys- (SEQ ID NO:233) Ser-Xaa5-Asn-Lys-Lys-Cys-Gly-# Name: Ra6.1 Species: rattus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCATGGTGATCATCGCCGTGCTGTTCCTGACAGCCTGT (SEQ ID NO:234) CAATTCGATACAGCTGCGAGCTACGACAAAGGTAAGCAGAAACCTCCTACTCTGAG GCCAGCTGACAAACACATCAGGTTGACCAAGCGTTGCAATGCTCGCAATGATGGTT GCAGTCAACATTCTCAATGCTGCAGTGGATCTTGCAATAAGACTGCAGGCGTATGTC TGTAAAGCTGGTCTGCCGTCTGATATTCCCTTTCTGTGCTTTATCCTCTTTTGCCTGA GTCATCCATACCTGTGAATGGTTAAGAGCCACTCAATACCTACTCCTCTGGGGGCTT CAGAGGAACTACATTAAATAAAGCCACATTGCAAAAAAAAAAAAAAAAAAA Translation: MKLTCMVIIAVLFLTACQFDTAASYDKGKQKPPTLRPADKHIRLTKRCNARNDGCSQHS (SEQ ID NO:235) QCCSGSCNKTAGVCL Toxin Sequence: Cys-Asn-Ala-Arg-Asn-Asp-Gly-Cys-Ser-Gln-His-Ser-Gln-Cys-Cys-Ser-Gly-Ser-Cys-Asn-Lys (SEQ ID NO:236) Thr-Ala-Gly-Val-Cys-Leu-{circumflex over ( )} Name: Ra6.2 Species: rattus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATCATCGCCGTGCTGTTCCTGACAGCCTGT (SEQ ID NO:237) CAACTCGATGCAGCTGCGAGCTACGACAAAGGTAAGCAGAAACCTCCTACTCTGAG GCCAGCTGACAAACACTTCAGGTTGATCAAGCGTTGCAATGCTCGCAATAGTGGTT GCAGTCAACATCCTCAATGCTGCAGTGGATCTTGCAATAAGACTGCAGGCGTATGTC TGTAAAGCTGGTCTGCCGTCTGATATTCCCTTTCTGTGCTTTATCCTCTTTTGCCTGA GTCATCCATACCTGTGAATGGTTAAGAGCCACTCAATACCTACTCCTCTGGGGGCTT CAGAGGAACTACATTAAATAAAGCCACATTGCAACGAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIIAVLFLTACQLDAAASYDKGKQKPPTLRPADKHFRLIKRCNARNSGCSQHP (SEQ ID NO:238) QCCSGSCNIKTAGVCL Toxin Sequence: Cys-Asn-Ala-Arg-Asn-Ser-Gly-Cys-Ser-Gln-His-Xaa3-Gln-Cys-Cys-Ser-Gly-Ser-Cys-Asn-Lys- (SEQ ID NO:239) Thr-Ala-Gly-Val-Cys-Leu-{circumflex over ( )} Name: Ra6.3 Species: rattus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTGTGGTGATCATCGCCGTGCTGTTCCTGACAGCCTGT (SEQ ID NO:240) CAATTCGATACAGCTGCGAGCTACGACAAAGGTAAGCAGAAACCTCCTACTCTGAG GCCAGCTGACAAACACTTCAGGTTGATCAAGCGTTGCAATGCTCGCAATAGTGGTT GCAGTCAACATCCTCAATGCTGCAGTGGATCTTGCAATAAGACTTTGGGCGTATGTC TGTAAAGCTGGTCTGCCGTCTGATATTCCCTTTCTGTGCTTTATCCTCTTTTGCCTGA GTCATCCATACCTGTGAATGGTTAAGAGCCACTCAATACCTACTCCTCTGGGGGCTT CAGAGGAACTACATTAAATAAAGCCACATTGAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIIAVLFLTACQFDTAASYDKGKQKPPTLRPADKHFRLIKRCNARNSGCSQHP (SEQ ID NO:241) QCCSGSCNKTLGVCL Toxin Sequence: Cys-Asn-Ala-Arg-Asn-Ser-Gly-Cys-Ser-Gln-His-Xaa3-Gln-Cys-Cys-Ser-Gly-Ser-Cys-Asn-Lys- (SEQ ID NO:242) Thr-Leu-Gly-Val-Cys-Leu-{circumflex over ( )} Name: Sm6.1 Species: stercusmuscarum Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:243) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGAAGACCAAACTCTCCATGTCGACTCGCTGCAAGAGTAAAGGA GCAAAATGTTCAAGGCTTATGTATGACTGCTGCAGCGGTTCTTGCAGCGGCTACACA GGTAGATGTGGCTGATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTG CCTGGGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGGA GGCCTCAGAGGAGTTACAATGAAATAAAAGCCGCATTGC Translation: MRLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSKTKLSMSTRCKSKGAKCSRLMY (SEQ ID NO:244) DCCSGSCSGYTGRCG Toxin Sequence: Cys-Lys-Ser-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Xaa5-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Ser- (SEQ ID NO:245) Gly-Xaa5-Thr-Gly-Arg-Cys-# Name: Sm6.2 Species: stercusmuscarum Isolated: Yes Toxin Sequence: Thr-Thr-Ser-Cys-Met-Gln-Ala-Gly-Ser-Xaa5-Cys-Gly-Ser-Thr-Thr-Arg-Ile-Cys-Cys-Gly-Xaa5- (SEQ ID NO:246) Cys-Ala-Xaa5-Phe-Gly-Lys-Lys-Cys-Ile-Asp-Xaa5-Xaa3-Ser-Asn-{circumflex over ( )} Name: Sm6.3 Species: stercusmuscarum Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:247) CCTGACGACCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGGAGCATC GTGCCCTGAGGTCGAAGACCAAACTCTCCATGTTAACTTTGCGCTGCGCATCTTACG GAAAACCTTGTGGTATTGACAACGACTGCTGCAATGCATGCGATCCAGCCAGAAAT ATATGTACGTAGCTGATCCGGCGTCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCT GCCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCATCTACTCTCCTGG AGGCCTCAGAGGAGCTACAATGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTTCQLITADDSRGTQEHRALRSKTKLSMLTLRCASYGKPCGIDND (SEQ ID NO:248) CCNACDPARNICT Toxin Sequence: Cys-Ala-Ser-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Asp-Asn-Asp-Cys-Cys-Asn-Ala-Cys-Asp-Xaa3- (SEQ ID NO:249) Ala-Arg-Asn-Ile-Cys-Thr-{circumflex over ( )} Name: Sm6.4 Species: stercusmuscarum Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTGTGGTGATTGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:250) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGGAGCATCGTGCCCTGAGGTC GAAGACCAAACTCTCCATGTTAACTTTGCGCTGCGTATCTTACGGAAAACCTTGTGG TATTGACAACGACTGCTGCAATGCATGCGATCCAGCCAGAAATATATGTACGTAGC TGATCCGGCGTCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGGGTCCTCC TTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGGAGGCCTCAGAGGA GTTACAATGAAATAAAAGCCGCATTGCAAAAAAAAAAAAAAAAAAAA Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQEHRALRSKTKLSMLTLRCVSYGKPCGIDND (SEQ ID NO:251) CCNACDPARNICT Toxin Sequence: Cys-Val-Ser-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Asp-Asn-Asp-Cys-Cys-Asn-Ala-Cys-Asp-Xaa3- (SEQ ID NO:252) Ala-Arg-Asn-Ile-Cys-Thr-{circumflex over ( )} Name: S6.1 Species: striatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:253) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTTCCCTGAGGTCGACCACCAAAGTCTCCAAGGCGACTGACTGCATTGAAGCCGGA AATTATTGCGGACCTACTGTTATGAAAATCTGCTGCGGCTTTTGCAGTCCATACAGC AAAATATGTATGAACTATCCCAAAAATTGATCTTCCCCC Translation: MKLTCVVWAVLLLTACQLITADDSRGTQKHRSLRSTTKVSKATDCIEAGNYCGPTVMK (SEQ ID NO:254) ICCGFCSPYSKICMNYPKN Toxin Sequence: Ala-Thr-Asp-Cys-Ile-Xaa1-Ala-Gly-Asn-Xaa5-Cys-Gly-Xaa3-Thr-Val-Met-Lys-Ile-Cys-Cys- (SEQ ID NO:255) Gly-Phe-Cys-Ser-Xaa3-Xaa5-Ser-Lys-Ile-Cys-Met-Asn-Xaa5-Xaa3-Lys-Asn-{circumflex over ( )} Name: S6.2 Species: striatus Cloned: Yes DNA Sequence: GTCGACTCGCTGCAAGCTTAAAGGACAATCATGTCGTAGGACTATGTATGACTGCTG (SEQ ID NO:256) CAGCGGTTCTTGCGGCAGGAGAGGTAAATGTGGCTGATCCAGCGCCTGATCTCCCC CCTTCTGTGCTCTATCCTTTTCTGCCTGGGTCCTCCTTACCTGAGAGTGGTCATGAAC CACTCATCACCTACTCCTCTGGAGGCCTCAGAGGAGCTACAATGAAATAAAAGCCG CATTGC Translation: STRCKLKGQSCRRTMYDCCSGSCGRRGKCG (SEQ ID NO:257) Toxin Sequence: Cys-Lys-Leu-Lys-Gly-Gln-Ser-Cys-Arg-Arg-Thr-Met-Xaa5-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Gly- (SEQ ID NO:258) Arg-Arg-Gly-Lys-Cys-# Name: S6.3 Species: striatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:259) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATC GTGCCCTGAGGTCGGACACCAAACTCTCCATGTCGACTCGCTGCAAGGCTGCAGGA AAATCATGCAGTAGGATTGCGTATAACTGCTGCACCGGTTCTTGCAGATCAGGTAA ATGCGGCTGATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTCTGCCTGAG TCCTCTTACCTGAGAGTGGTCATGAACC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQKHRALRSDTKLSMSTRCKAAGKSCSRIAYN (SEQ ID NO:260) CCTGSCRSGKCG Toxin Sequence: Cys-Lys-Ala-Ala-Gly-Lys-Ser-Cys-Ser-Arg-Ile-Ala-Xaa5-Asn-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:261) Ser-Gly-Lys-Cys-# Name: S6.6 Species: striatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:262) CCTGACGGCCTGTCAACTCATCACAGCTGATGACTCCAGAGGTACGCAGGAGCATC GTGCCCTGAGGTCGGACACCAAACTCTCCATGTTAACTTTGCGCTGCGAATCTTACG GAAAACCTTGTGGTATTTACAACGACTGCTGCAATGCATGCGATCCAGCCAAAAAG ACATGTACGTAGCTGATCCGGCGTCTGATCT Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQEHRALRSDTKLSMLTLRCESYGKLPCGIYND (SEQ ID NO:263) CCNACDPAKKTCT Toxin Sequence: Cys-Xaa1-Ser-Xaa5-Gly-Lys-Xaa3-Cys-Gly-Ile-Xaa5-Asn-Asp-Cys-Cys-Asn-Ala-Cys-Asp- (SEQ ID NO:264) Xaa3-Ala-Lys-Lys-Thr-Cys-Thr-{circumflex over ( )} Name: w-SVIA Species: striatus Cloned: Yes DNA Sequence: ACTAGGTCCTCCGGCAGCCCCTGTGGTGTTACTAGTATATGCTGTGGTAGATGCTAT (SEQ ID NO:265) AGGGGTAAATGTACGTAGCTCATCGGGCGTCTGATCTTCCCCCTTCTGTGCTCCATC CTTTTCTGCCTGAGTCCTCCTTACCTGAGAGTGGTCGTGAACCACTCATCGCCTACTC CTCTGGAGGCTTCAGAGGGGCTACACTAAAATAAAAGCTATATTGCAATGAAAAAA A Translation: CRSSGSPCGVTSICCGRCYRGKCT (SEQ ID NO:266) Toxin Sequence: Cys-Arg-Ser-Ser-Gly-Ser-Xaa3-Cys-Gly-Val-Thr-Ser-Ile-Cys-Cys-Gly-Arg-Cys-Xaa5-Arg-Gly- (SEQ ID NO:267) Lys-Cys-Thr-# Name: w-SVIB Species: striatus Isolated: Yes Toxin Sequence: Cys-Lys-Leu-Lys-Gly-Gln-Ser-Cys-Arg-Lys-Thr-Ser-Xaa5-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Gly- (SEQ ID NO:268) Arg-Ser-Gly-Lys-Cys-# Name: Sx6.1 Species: striolatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGTCTTGCTGCTC (SEQ ID NO:269) CTGACGACCTGTCGTCTCATCACAGCTGATGACTCCAGAGGTACGCAGAAGCATCG TTCCCTGAGGTCGACTACTAAAGTCTCCATGTCGACTCGCTGCAAGGGTAAAGGAG CATCATGTCTTAGGACTGCGTATGACTGCTGCACCGGTTCTTGCAACAGAGGTAGAT GTGGCTGATCCAGCGTCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCTTGAGT CCTCCTTA Translation: MKLTCVVIVVLLLLTTCRLITADDSRGTQKHRSLRSTTKVSMSTRCKGKGASCLRTAYD (SEQ ID NO:270) CCTGSCNRGRCG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Ala-Ser-Cys-Leu-Arg-Thr-Ala-Xaa5-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Asn- (SEQ ID NO:271) Arg-Gly-Arg-Cys-# Name: Sx6.2 Species: striolatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTTCTGCTG (SEQ ID NO:272) ACGGCGTGTCAACTCATCACAGCTGAGGACTCCAGAGGTACACAGAAGCATCGTAC CCTGAGGTCGACCGTCAGACGCTCCAAGTCCGAGTTGACTACGAGATGCAGGCCTT CAGGATCCAACTGTGGTAATATTAGTATCTGCTGTGGTAGATGCGTTAACAGAAGAT GTACGTAGCTCATCGGGCGTCTGATCTTTCCCC Translation: MKLTCVVTVAVLLTACQLITAEDSRGTQKHRTLRSTVRRSKSELTTRCRPSGSNCGMSIC (SEQ ID NO:273) CGRCVNRRCT Toxin Sequence: Cys-Arg-Xaa3-Ser-Gly-Ser-Asn-Cys-Gly-Asn-Ile-Ser-Ile-Cys-Cys-Gly-Arg-Cys-Val-Asn-Arg- (SEQ ID NO:274) Arg-Cys-Thr-{circumflex over ( )} Name: Sx6.3 Species: striolatus Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTTCTGTTC (SEQ ID NO:275) CTGACGGCGTGTCAACTCATCACAGCTGAGGACTCCAGAGGTACACAGAAGCATCG TTCCCTGAGGTCGACTACCAAAGTCTCCAAGTCGACTAGCTGCATGAAAGCCGGGT CTTATTGCGTCGCTACTACGAGAATCTGCTGCGGTTATTGCGCTTATTTCGGCAAAA TATGTATTGACTATCCCAAAAACTGATCTTCCCCCTACTGTGCTCTATCCTTTT Translation: MKLTCVVIVAVLFLTACQLITAEDSRGTQKHRSLRSTTKVSKSTSCMKAGSYCVATTRIC (SEQ ID NO:276) CGYCAYFGKICIDYPKN Toxin Sequence: Ser-Thr-Ser-Cys-Met-Lys-Ala-Gly-Ser-Xaa5-Cys-Val-Ala-Thr-Thr-Arg-Ile-Cys-Cys-Gly-Xaa5- (SEQ ID NO:277) Cys-Ala-Xaa5-Phe-Gly-Lys-Ile-Cys-Ile-Asp-Xaa5-Xaa3-Lys-Asn-{circumflex over ( )} Name: Tx6.15 Species: textile Cloned: Yes DNA Sequence: GTTGACTCGGTACTGCACGCCTCATGGAGGACATTGTGGTTATCATAATGACTGCTG (SEQ ID NO:278) CAGTCATCAATGCAATATAAACAGAAATAAATGTGAGTAGCTGATCTGGCATCTGA TCTGTGCTCGTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGG AGGC Translation: LTRYCTPHGGHCGYHNDCCSHQCNINRNKCE (SEQ ID NO:279) Toxin Sequence: Xaa5-Cys-Thr-Xaa3-His-Gly-Gly-His-Cys-Gly-Xaa5-His-Asn-Asp-Cys-Cys-Ser-His-Gln-Cys- (SEQ ID NO:280) Asn-Ile-Asn-Arg-Asn-Lys-Cys-Xaa1-{circumflex over ( )} Name: w-Tx Species: textile Isolated: Yes Toxin Sequence: Xaa5-Cys-Thr-Xaa3-Xaa5-Gly-Gly-His-Cys-Gly-Xaa5-His-Asn-Asp-Cys-Cys-Ser-His-Gln-Cys- (SEQ ID NO:281) Asn-Ile-Asn-Arg-Asn-Lys-Cys-Xaa1-{circumflex over ( )} Name: C.tulipa w2 Species: tulipa Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:282) CCTGACGGCCTGTCAGCTCATCACAGCTCTGCACTCCAGAGGTACGCAGAAGCATC GTGCCCTGGGGCGGACCACCAAACTCACCTTGTCGACTCGCTGCAAATCACCCGGA TCTCCATGTTCACCGACTAGTTATAATTGCTGCTGGTCTTGCAGTCCATACAGAAAA AAATGTAGGGGCTAATCCAGCGCCTGATTTTCCCCCTTCTGTGCTCTATTCCTTTCTG CCTGAGTCCTCCTTACCTGAAAGTGGTCATGAACCACTCATCACCTACTTCTCTGGA GGCTTCGGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLITALHSRGTQKHRALGRTTKLTLSTRCKSPGSPCSPTSYNC (SEQ ID NO:283) CWSCSPYRKKCRG Toxin Sequence: Cys-Lys-Ser-Xaa3-Gly-Ser-Xaa3-Cys-Ser-Xaa3-Thr-Ser-Xaa5-Asn-Cys-Cys-Xaa4-Ser-Cys-Ser- (SEQ ID NO:284) Xaa3-Xaa5-Arg-Lys-Lys-Cys-Arg-# Name: w-TVIA Species: tulipa Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:285) CCTGACGGCCTGTCAGCTCATCACAGCTCTGCACTCCAGAGGTACGCAGAAGCATC GTGCCCTGGGGTCGACCACCAAACTCACCTTGTCGACTCGCTGCTTGTCACCCGGAT CTTCATGTTCACCGACTAGTTATAATTGCTGCAGGTCTTGCAATCCATACAGCAGAA AATGTAGGGGCTAATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCTATTCCTTTCTGC CTGAGTCCTCCTTACCTGAAAGTGGTCATGAACCACTCATCACCTACTTCTCTGGAG GCTTCGGAGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLITALHSRGTQKHRALGSTTKILTLSTRCLSPGSSCSPTSYNC (SEQ ID NO:286) CRSCNPYSRKCRG Toxin Sequence: Cys-Leu-Ser-Xaa3-Gly-Ser-Ser-Cys-Ser-Xaa3-Thr-Ser-Xaa5-Asn-Cys-Cys-Arg-Ser-Cys-Asn- (SEQ ID NO:287) Xaa3-Xaa5-Ser-Arg-Lys-Cys-Arg-# Name: Vi6.1 Species: viola Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:288) CCTGACGGCCTGTCAGCTCATTACAGCTGATGACTCCAGAGGTACGCAGTTGCATCG TGCCCTGAGGAAGGCCACCAAACTCCCCGTGTCGACTCGCTGCATTACTTTAGGAAC ACGATGTAAGGTTCCGAGTCAATGCTGCAGATCTTCTTGCAAGAACGGTCGTTGTGC TCCATCCCCTGAAGAATGGTAAATGTGGCTGATCCAGCGCCTGATCTTCCCCCTTCT GACTGTCTCCGACCTTTTCTGCCTGAGTCCTCCTTACCTGAGAGGTGTCATGAACCA CTCATCACCTACTCCCCTGGAAGCTTCAGAGGAGCTACATTGAAATAAAAGCCGCA TTGC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQLHRALRKATKLPVSTRCITLGTRCKVPSQCC (SEQ ID NO:289) RSSCKNGRCAPSPEEW Toxin Sequence: Cys-Ile-Thr-Leu-Gly-Thr-Arg-Cys-Lys-Val-Xaa3-Ser-Gln-Cys-Cys-Arg-Ser-Ser-Cys-Lys-Asn- (SEQ ID NO:290) Gly-Arg-Cys-Ala-Xaa3-Ser-Xaa3-Xaa1-Xaa1-Xaa4-{circumflex over ( )} Name: Vi6.2 Species: viola Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:291) CCTGACGGCCTGTCAGCTCATTATAGCTGGGGACTCCAGAGGTACGCAGTTGCATCG TGCCCTGAGGAAGGCCACCAAACTCTCCGTGTCGACTCGCTGCAAGAGTAGAGGAT CATCATGTCGTAGGACTTCGTATGACTGCTGCACGGGTTCTTGCAGAAATGGTAAAT GTGGCTGATCCAGCGCCTGATCTTCCCCCTTCTGTGCTCCATCCTTTTCTGCCTGAGT CCTCCTTACCTGAGAGTGGGCATGAACCACTCATCACCTACTCCCTGGAAGCTTCAG AGGAGCTACATTGAAATAAAAGCCGCATTGC Translation: MKLTCVVIVAVLLLTACQLHAGDSRGTQLHRALRKATKLSVSTRCKSRGSSCRRTSYDC (SEQ ID NO:292) CTGSCRNGKCG Toxin Sequence: Cys-Lys-Ser-Arg-Gly-Ser-Ser-Cys-Arg-Arg-Thr-Ser-Xaa5-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg- (SEQ ID NO:293) Asn-Gly-Lys-Cys-# Name: Vi6.3 Species: viola Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGCGATCGTCGCCGTGCTGCT (SEQ ID NO:294) CCTGACGGCCTGTCAGCTCATTACAGCTGAAGACTCCAGAGGTACGCATGAGCATC TTGCCCTGAAGTCGACCTCCAAAGTCTCCAAGTCGACTAGCTGCATGGAAGCCAGA TCTTATTGCGGACCTGCTACTACGAAAATCTGCTGCGATTTTTGCAGTCCATTCAGC GATAGATGTATGAACAATCCCAACAATTGATCTTCCCCCTTGTGTGCTCCATCTTTTC TGCCTGAGTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTG GAGGCTTCAGAGGAGTTACATTGAAATAAAAGCCGCATGC Translation: MKLTCVAIVAVLLLTACQLITAEDSRGTHEHLALKSTSKVSKSTSCMEARSYCGPATTKI (SEQ ID NO:295) CCDFCSPFSDRCMNNPNN Toxin Sequence: Ser-Thr-Ser-Cys-Met-Xaa1-Ala-Arg-Ser-Xaa5-Cys-Gly-Xaa3-Ala-Thr-Thr-Lys-Ile-Cys-Cys- (SEQ ID NO:296) Asp-Phe-Cys-Ser-Xaa3-Phe-Ser-Asp-Arg-Cys-Met-Asn-Asn-Xaa3-Asn-Asn-{circumflex over ( )} Name: Vi6.4 Species: viola Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGCT (SEQ ID NO:297) CCTGACGGCCTGTCAGCTCATTACAGCTGAGGACTCCAGAGGTACGCAGTTGCATC GTGCCCTGAGGAAGACCACCAAACTCTCCTTGTCGACTCGCTGCAAGGGTCCAGGA GCCATATGTATAAGGATTGCGTATAACTGCTGCAAGTATTCTTGCGGAAATGGTAAA TGTGGCTGATCCAGCGCCTGATCTTCCCCCTTGTGTGCTCCATCCTTTTTCTGCCTGA GTCCTCCTTACCTGAGAGTGGTCATGAACCACTCATCACCTACTCCTCTGGAGGCTT CAGAGGAGCTACATTGAAATAAAAGCCGCATGC Translation: MKLTCVVIVAVLLLTACQLITAEDSRGTQLHRALRKTTKLSLSTRCKGPGAICIRIAYNCC (SEQ ID NO:298) KYSCGNGKCG Toxin Sequence: Cys-Lys-Gly-Xaa3-Gly-Ala-Ile-Cys-Ile-Arg-Ile-Ala-Xaa5-Asn-Cys-Cys-Lys-Xaa5-Ser-Cys-Gly- (SEQ ID NO:299) Asn-Gly-Lys-Cys-# Name: Vi6.5 Species: viola Cloned: Yes DNA Sequence: ACCAAAACCATCATCAAAATGAAACTGACGTGTGTGGTGATCGTCGCCGTGCTGTTC (SEQ ID NO:300) CTGACGGCCTGTCAATTCATCACAGCTGATGACTCCAGAAGTACGCAGAAGCATCG TGCCCTGAGGTCGACCACCAAACACTTTATGTTGACTTGGTACTGCACGCCTTATGG AGGACATTGTGGTTATTATAATGACTGCTGCAGTCATCAATGCAATATAAACAGAA ATAAATGTGAGTAGCTGATCCGGCATCTGATCTGTGCTCGCCCTAACCTGAGAGTGG TCATGAACCACTCATCATCTACTCCTCTGGAGGCTTCAGAGGAGCTACATGGAAATA AAAGCCGCATTGC Translation: MKLTCVVIVAVLFLTACQFITADDSRSTQKHRALRSTTKHFMLTWYCTPYGGHCGYYN (SEQ ID NO:301) DCCSHQCNINRNKCE Toxin Sequence: Xaa5-Cys-Thr-Xaa3-Xaa5-Gly-Gly-His-Cys-Gly-Xaa5-Xaa5-Asn-Asp-Cys-Cys-Ser-His-Gln- (SEQ ID NO:302) Cys-Asn-Ile-Asn-Arg-Asn-Lys-Cys-Xaa1-{circumflex over ( )} Name: Pu6.4 Species: pulicarius Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATTATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:303) CAACTCATTACAGCTGAGACTTACTCCAGAGGTAAGCAGATGCACCGTGCTCTGAG GTCAACTGACAAAAACTCCAAGTTGACCAGGGAATGCACACCTCCAGATGGAGCTT GTGGTTTACCTACACACTGCTGCGGGTTTTGCGATATGGCAAACAACAGATGTCTGT AAAGCGTCTGATATTCCCCTTCTGTGCTCTATCCTCTTTGGCCTGAGTCATCCATACC TGTGCTCGAG Translation: MKLTCVVIIAVLFLTACQLITAETYSRGKQMHRALRSTDKNSKLTRECTPPDGACGLPTH (SEQ ID NO:304) CCGFCDMANNRCL Toxin Sequence: Xaa1-Cys-Thr-Xaa3-Xaa3-Asp-Gly-Ala-Cys-Gly-Leu-Xaa3-Thr-His-Cys-Cys-Gly-Phe-Cys- (SEQ ID NO:305) Asp-Met-Ala-Asn-Asn-Arg-Cys-Leu-{circumflex over ( )} Name: Pu6.6 Species: pulicarius Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGCGTGGTGATTATCGCCGTGCTGTTCCTGACGGCCTGT (SEQ ID NO:306) CAACTCATTACAGCTGAGACTTACTCCAGAGGTAAGCAGATGCACCGTGCTCTGAG GTCAACTGACAAAAACTCCCAGTTGACCAGGGAATGCACACCTCCAGGTGGAGCTT GTGGTTTACCTACACACTGCTGCGGGTTTTGCGATATGGCAAACAACAGATGTCTGT AAAGCGTCTGATATTCCCCTTCTGTGCTCTATCCTCTTTGGCCTGAGTCATCCATACC TGTGCTCGAG Translation: MKLTCVVIIAVLFLTACQLITAETYSRGKQMHRALRSTDKNSQLTRECTPPGGACGLPTH (SEQ ID NO:307) CCGFCDMANNRCL Toxin Sequence: Xaa1-Cys-Thr-Xaa3-Xaa3-Gly-Gly-Ala-Cys-Gly-Leu-Xaa3-Thr-His-Cys-Cys-Gly-Phe-Cys- (SEQ ID NO:308) Asp-Met-Ala-Asn-Asn-Arg-Cys-Leu-{circumflex over ( )} Name: Ra6.4 Species: rattus Cloned: Yes DNA Sequence: GGATCCATGAAACTGACGTGTGTGGTGATCATCGCCGTGCTGTTCCTGGCAGCCTGT (SEQ ID NO:309) CAACCTGTTACAACTGAGACTTTCTCCAGAGGTAAGGAGAAGCGTCGTGCTCTGAG GTCAACTGACGGCAACTCCCGGTTGACCAGGGCATGCACGCCTGAAGGTGGAGCCT GTAGTAGTGGGCGTCACTGCTGCGGCTTTTGCGATAACGTGTCCCACACGTGCTATG GTGAAACACCATCTCTCCACTGATGTTTCCCCTTCTGTGCTCTATCTTCTTTTGCCTG AGTCATCCATACCTGTGCTCGAG Translation: MKLTCVVIIAVLFLAACQPVTTETFSRGKEKRRALRSTDGNSRLTRACTPEGGACSSGRH (SEQ ID NO:310) CCGFCDNVSHTCYGETPSLH Toxin Sequence: Ala-Cys-Thr-Xaa3-Xaa1-Gly-Gly-Ala-Cys-Ser-Ser-Gly-Arg-His-Cys-Cys-Gly-Phe-Cys-Asp- (SEQ ID NO:311) Asn-Val-Ser-His-Thr-Cys-Xaa5-Gly-Xaa1-Thr-Xaa3-Ser-Leu-His-{circumflex over ( )} Name: Sm6.7 Species: stercusmuscarum Cloned: Yes DNA Sequence: AGATCCATGAAACTGACGTGCGTGGTGATCGTCGCCGTGCTGCTCCTGACGGCCTGT (SEQ ID NO:312) CAACTCATCACAGCTGATGACTCCAGAGGTACGCAGGAGCATCGTGCCCTGAGGTC GGACACCAAACTCCCCATATCGACTCGCTGCAAGGGTAAAGGAGCATCATGTCATA AGACTATGTATGACTGCTGCAGCGGTTCCTGCACCAGAGGTAGATGTGGCTGATCC AGCGCCTGATCTTCCCCCTTCTGTGCTCTATCCTTTTCTGCCTGAGTCATCATACCTG TGCTCGAGCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGGCGTAATCATAAA ANC Translation: MKLTCVVIVAVLLLTACQLITADDSRGTQEHRALRSDTKLPISTRCKGKGASCHKTMYD (SEQ ID NO:313) CCSGSCTRGRCG Toxin Sequence: Cys-Lys-Gly-Lys-Gly-Ala-Ser-Cys-His-Lys-Thr-Met-Xaa5-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Thr- (SEQ ID NO:314) Arg-Gly-Arg-Cys-#

[0086] TABLE 2 Alignment of ω-Conopeptides (SEQ ID NO:) Ar6.10 (F170) ---QCSANGGSC-TRHFH---CCSLYCNKDSSVCVATSYP{circumflex over ( )} (315) Ar6.2 (F074) ---TCNTPTEYC-TLHRH---CCSGYCHKTIQACS{circumflex over ( )} (316) Ar6.3 ---QCTPNGGSC-SRHFH---CCSLYCNKSTGVCIATSYP{circumflex over ( )} (317) Ar6.4 (F009) ---TCNTPTEYC-TLHQH---CCSGYCHKTIQACS{circumflex over ( )} (318) Ar6.6 (F069) ---ECTPPGGACGLPT-H---CC-GFCDTANNRCL{circumflex over ( )} (319) Ar6.7 (F073) ---TCNTPTEYC-TLHQH---CCSGHCHKTIQACA{circumflex over ( )} (320) Ar6.8 (F169) ---QCSPIGGYC-TLHIH---CCSNHCIKPIGRCVAT{circumflex over ( )} (321) Ar6.9 (F171) ---QCLPNGGYC-TLHIH---CCSDHCIKPIDRCVAT{circumflex over ( )} (322) Ay6.1 (A653) ----CKGKGKPCSRISYN---CCTGSCRS--GKC# (323) Ay6.2 (A654) ----CMEAGSYCG-STTR--ICC-GFCAYFGKKCIDYPSN{circumflex over ( )} (324) Ay6.3 (J419) ----CKAKGKPCSRIAYN---CCTGSCRS--GKC# (325) Ay6.4 ----CASYGKPCGIDN-D---CCNA-CDPGRNICT{circumflex over ( )} (326) Bu6.1 -STSCMEAGSYCGPATTK--ICC-DFCSPFSDRCMNNPNN{circumflex over ( )} (327) Bu6.2 ----CITPGTRCKVPS-Q---CCRGPCKNGR--CTPSPSEW{circumflex over ( )} (328) Bu6.3 ----CATYGKPCGIQN-D---CC-NTCDPARRTCT{circumflex over ( )} (329) Bu6.4 ----CKGPGASCIRIAYN---CCKYSCRN--GKC# (330) Bu6.5 -STSCMAAGSYCGPATTN--ICC-DFCSPFSDRCMKKPNN{circumflex over ( )} (331) Bu6.6 ----CKSKGSSCHRTSYD---CCTGSCRN--GRC# (332) C6.1 ----CKSTGASCRRTSYD---CCTGSCRS--GRC# (333) C6.4 ----CQGRGASCRKTMYN---CCSGSCN--RGSC# (334) C6.5 ----CLPAGESCLFSRIR---CC-GTCSSVLKSCVS{circumflex over ( )} (335) C6.6 ----CQGRGGPCTKAVFN---CCSGSCN--RGRC# (336) C6.7 ----CATYGKPCGIQN-D---CC-NTCDPARKTCT{circumflex over ( )} (337) C6.8 ----CRGRGGPCTKAMFN---CCSGSCN--RGRC# (338) Ca6.4 (F168) ---QCSANGGSC-TRHFH---CCSLYCNKDSSVCVATSYP (339) Cn6.1 ----CASYGKPCGIDN-D---CC-NTCDPARKTCT{circumflex over ( )} (340) Cn6.2 (I583) ----CKGTGKPCSRIAYN---CCTGSCRS--GKC# (341) Cn6.3 -ATDCIEAGNYCGPTVMK--ICC-GFCSPYSKICMNYPQN{circumflex over ( )} (342) Cn6.4 ----CKGKGASCTRLMYD---CCHGSCSSSKGRC# (343) Cn6.5 (I590) ----CKGKGASCHRTSYD---CCTGSCN--RGKC# (344) Cn6.6 (I584) ----CASYGKPCGIYN-D---CC-NTCDPARKTCT{circumflex over ( )} (345) Cn6.7 (J409) ----CKGTGKPCSRVAYN---CCTGSCRS--GKC# (346) Cn6.8 (J407) -STSCMKAGSYCR-STTR--TCC-GYCAYFGKFCIDFPSN{circumflex over ( )} (347) Cr6.1 ----CKGKGASCRKTMYN---CCSGSCSN--GRC# (348) Cr6.2 -STSCMEAGSYCR-STTR--TCC-GYCSYFSKKCIDFPSN{circumflex over ( )} (349) Cr6.3 ----CKSKGAKCSRLMYD---CCSGSCSRYSGRC# (350) Cr6.4 -STGCMKAGSYCR-STTR--TCC-GYCAYFGKKCIDYPSN{circumflex over ( )} (351) Da6.8 ---SCTPPGGPCGYYN-D---CCSHQCNISRNKCE{circumflex over ( )} (352) Di6.1 ----CEDOGEOCGSDH-S---CCGGSCN--HNVCA{circumflex over ( )} (353) E6.2 ---PCKPKGRKCFPHQKD---CCNKTCT--RSKCP{circumflex over ( )} (354) E6.3 ---ACWSSGTPCGTDS-L---CCGG-CNVSKSKCN{circumflex over ( )} (355) G6.1 (J420) ----CKSPGSSCSPTSYN---CCR-SCNPYAKRCY# (356) G6.2 (J423) ----CKSPGTPCSRGMRD---CCT-PCLLYSNKC-R--RY{circumflex over ( )} (357) J410 ----CLSPGSRCHKTMRN---CCT-SCSSYKGKCRP--RK{circumflex over ( )} (358) J411 ----CKPPGRKCLNRKNE---CCSKFCNEHLHMC# (359) J413 ----CKPPRRKCLKIKDK---CC-NFCNTHLNMC# (360) J414 ----CAGPGTIC--PNRV---CC-GYCSKRTHLCHS---RT# (361) La6.1 ---KCWPSGSYCRANS-K---CCSG-CDRNRNKCY{circumflex over ( )} (362) La6.2 ----CLPPGSYCK-ATTE--VCCS-SCLQFAQIC-----S# (363) L6.1 ----CKSPGSPCSVTSYN---CCT-FCSSYTKKCRA--SL{circumflex over ( )} (364) L6.2 ----CAGPGAIC--PNRV---CC-GYCSKRTHLCHS---RT# (365) L6.3 ---ACWSSGTPCGTDS-L---CCGG-CNVSKSKCN{circumflex over ( )} (366) L6.4 ---KCWSPGTYCRAHS-K---CCRG-CDQNRNKCY{circumflex over ( )} (367) La6.3 ----CKSPGSSCSVSMRN---CCT-SCNSRTKKCTR--R# (368) La6.4 ---TCWPSGTACGIDS-N---CCSG-CNVSRSKCN{circumflex over ( )} (369) La6.5 ---KCWPSGSYCRANS-K---CCSG-CDRNRSKCN{circumflex over ( )} (370) Lp6.1 (JG4) SLFECAPSGGRCGFLK-S---CCEGYCDGESTSCVSGPYSI{circumflex over ( )} (371) Lp6.2 (JG5) WPLDCTAPSQPCGYFP-R---CCG-HCDV-RRVCTS# (372) Lp6.3 (JG7) ----CMSPGGICGDFG-D---CCE-ICNV-YGICVSDLPGI{circumflex over ( )} (373) Lp6.4 (JG15) ---YCAPPGGACGFFD-H---CC-GYCETFYNTC-R{circumflex over ( )} (374) M6.1 ----CKGTGKPCSRIAYN---CCTGSCRS--GKC# (375) M6.2 ----CASYGKPCGIYN-D---CC-NTCDPARKTCT{circumflex over ( )} (376) Mi6.1 (F157) ----CNDRGGGC-SQHPH---CCGGTCNKLIGVCL{circumflex over ( )} (377) Mn6.1 ----CKSTGKSCSRIAYN---CCTGSCRS--GKC# (378) Mn6.2 ----CKGKGSSCSRTMYN---CCTGSCN--RGKC# (379) O6.1 -SPPCMKGGSSCR-GTTG--VCC-GFCSDFGYKCRDYPQN{circumflex over ( )} (380) O6.2 ----CLPDGTSCLFSRIR---CC-GTCSSILKSCVS{circumflex over ( )} (381) P6.1 ---OCKTOGRKCFOHQKD---CCGRACI--ITICP{circumflex over ( )} (382) P6.2 ---SCKLOGAYCNAXDYD---CCLR-CKV-GGTC# (383) P6.3 ---PCKKTGRKCFPHQKD---CCGRACI--ITICP{circumflex over ( )} (384) Pu6.2 (JG28) ---QCSPNGGSC-SRHFH---CCSLYCNKNTGVCIAT{circumflex over ( )} (385) Pu6.4 (AA678) ---ECTPPDGACGLPT-H---CC-GFCDMANNRCL{circumflex over ( )} (386) Pu6.6 (AA681) ---ECTPPGGACGLPT-H---CC-GFCDMANNRCL{circumflex over ( )} (387) R6.1 --HGCKPLKRRCFNDKE----CCSKFCNSVRKQC# (388) R6.2 --RGCKPLKRRCFNDKE----CCSKFCNSVRNQC# (389) Ra6.1 (F206) ----CNARNDGC-SQHSQ---CCSGSCNKTAGVCL{circumflex over ( )} (390) Ra6.2 (F205) ----CNARNSGC-SQHPQ---CCSGSCNKTAGVCL{circumflex over ( )} (392) Ra6.3 (F207) ----CNARNSGC-SQHPQ---CCSGSCNKTLGVCL{circumflex over ( )} (393) Ra6.4 (AA688) ---ACTPEGGACSSGR-H---CC-GFCDNVSHTCYGETPSLH{circumflex over ( )} (394) S6.1 -ATDCIEAGNYCGPTVMK--ICC-GFCSPYSKICMNYPKN{circumflex over ( )} (395) S6.2 ----CKLKGQSCRRTMYD---CCSGSCGR-RGKC# (396) S6.3 ----CKAAGKSCSRIAYN---CCTGSCRS--GKC# (397) S6.6 ----CESYGKPCGIYN-D---CC-NACDPAKKTCT{circumflex over ( )} (398) Sm6.1 (J428) ----CKSKGAKCSRLMYD---CCSGSCSGYTGRC# (399) Sm6.2 -TTSCMQAGSYCG-STTR--ICC-GYCAYFGKKCIDYPSN{circumflex over ( )} (400) Sm6.3 (J429) ----CASYGKPCGIDN-D---CC-NACDPARNICT{circumflex over ( )} (401) Sm6.4 (J431) ----CVSYGKPCGIDN-D---CC-NACDPARNICT{circumflex over ( )} (402) Sm6.7 (AA689) ----CKGKGASCHKTMYD---CCSGSCTRG--RC# (403) Sx6.1 ----CKGKGASCLRTAYD---CCTGSCN--RGRC# (404) Sx6.2 ----CRPSGSNCGNIS-I---CCGR-CVN--RRCT{circumflex over ( )} (405) Sx6.3 -STSCMKAGSYCV-ATTR--ICC-GYCAYFGKICIDYPKN{circumflex over ( )} (406) Tx6.15 ---YCTPHGGHC-GYHND---CCSHQCNINRNKCE{circumflex over ( )} (407) Vi6.1 ----CITLGTRCKVPS-Q---CCRSSCKN--GRCAPSPEEW{circumflex over ( )} (408) Vi6.2 ----CKSRGSSCRRTSYD---CCTGSCRN--GKC# (409) Vi6.3 -STSCMEARSYCGPATTK--ICC-DFCSPFSDRCMNNPNN{circumflex over ( )} (410) Vi6.4 ----CKGPGAICIRIAYN---CCKYSCGN--GKC# (411) Vi6.5 ---YCTPYGGHCGYYN-D---CCSHQCNINRNKCE{circumflex over ( )} (412) ω-Tx ----CTPYGGHCGYNH-D---CCSHQCNINRNKCE{circumflex over ( )} (413) C. tulipa ω2 ----CKSWGSOCSOTSTN---CCW-SCSPYRKKC-R# (414)

Example 3 In Vivo Activity of ω-Conopeptide Frings Audiogenic Seizure Susceptible Mice

[0087] In vivo anticonvulsant activity of ω-conopeptides is analyzed in Frings audiogenic seizure susceptible mice as described by White et al. (1992). The ω-conopeptides are found to have anticonvulsant activity in this assay.

Example 4 In Vivo Activity of ω-Conopeptides in CF No. 1 Mice

[0088] In vivo anticonvulsant activity of ωconopeptides is analyzed in CF No. 1 mice as described by White et al. (1995), using the maximal electroshock, subcutaneous pentylenetetrazole (Metrazol) seizure threshold and threshold tonic extension test. ω-Conopeptides are found to have anticonvulsant activity.

Example 5 In Vivo Activity of ω-Conopeptides in Pentylenetetrazole-Induced Threshold Seizure Model

[0089] The in vivo activity of ω-conopeptides is analyzed using timed intravenous infusion of pentylenetetrazole (White et al., 1995). At time to peak effect, the convulsant solution (0.5% pentylenetetrazole in 0.9% saline containing 10 U.S.P. units/ml heparin sodium) is infused into the tail vein at a constant rate of 0.34 ml/min. The time in seconds from the start of the infusion to the appearance of the first twitch and the onset of clonus is recorded for each drug treated or control animal. The times to each endpoint are converted to mg/kg of pentylenetetrazole for each mouse, and mean and standard error of the mean are calculated. It is found that ω-conopeptides elevate the i.v. pentylenetetrazole seizure threshold.

Example 6 In Vivo Activity of ω-Conopeptides in Pain Models

[0090] The anti-pain activity of ω-conopeptides is shown in several animal models. These models include the nerve injury model (Chaplan, et al., 1997), the nocioceptive response to s.c. formalin injection in rats (Codene, 1993) and an NMDA-induced persistent pain model (Liu, et al., 1997). In each of these models it is seen that the ω-conopeptides and ω-conopeptides derivatives have analgesic properties.

[0091] More specifically, this study evaluates the effect of intrathecal administration of ω-conopeptides in mice models of nocioceptive and neuropathic pain. For nocioceptive pain, the effect of the ω-conopeptides is studied in two different tests of inflammatory pain. The first is the formalin test, ideal because it produces a relatively short-lived, but reliable pain behavior that is readily quantified. There are two phases of pain behavior, the second of which is presumed to result largely from formalin-evoked inflammation of the hind paw. An ω-conopeptide is administered 10 minutes prior to injection of formalin. The number of flinches and/or the duration of licking produced by the injection is monitored. Since the first phase is presumed to be due to direct activation of primary afferents, and thus less dependent on long term changes in the spinal cord, ω-conopeptides are presumed to have greatest effect on the magnitude of pain behavior in the second phase.

[0092] The mechanical and thermal thresholds in animals that received an injection of complete Freund's adjuvant into the hind paw are also studied. This produces a localized inflammation including swelling of the hind paw and a profound decrease in mechanical and thermal thresholds, that are detected within 24 hours after injection. The changes in thresholds in rats that receive ω-conopeptides are compared with those of rats that receive vehicle intrathecal injections.

[0093] An important issue is whether the drugs are effective when administered after the pain model has been established, or whether they are effective only if used as a pretreatment. Clearly, the clinical need is for drugs that are effective after the pain has developed. To address this issue, animals are studied in which ω-conopeptides are administered repeatedly, after the inflammation (CFA) or nerve injury has been established. In these experiments, an ω-conopeptide is injected daily by the intrathecal (i.t.) route. The mechanical and thermal thresholds (measured, respectively, with von Frey hairs in freely moving animals and with the Hargreave's test, also in freely moving animals) are repeated for a 2 to 4 week period after the injury is induced and the changes in pain measured monitored over time.

Example 7 Effect of ω-Conotoxins in a Pain Model

[0094] Analgesic activity of ω-conotoxins is also tested in pain models as follows.

[0095] Persistent pain (formalin test). Intrathecal (it) drug injections are performed as described by Hylden and Wilcox (1980). An ω-conopeptide or vehicle is administered in a volume of 5 l. Fifteen minutes after the i.t. injection, the right hindpaw is injected with 20 l of 5% formalin. Animals are placed in clear plexiglass cylinders backed by mirrors to facilitate observation. Animals are closely observed for 2 minutes per 5 minute period, and the amount of time the animal spent licking the injected paw is recorded in this manner for a total of 45-50 minutes. Results are expressed as licking time in seconds per five minutes. At the end of the experiment, all animals are placed on an accelerating rotorod and the latency to first fall was recorded. ω-Conopeptides are found to be active in this model which is predictive of efficacy for treating neuropathic pain.

[0096] Acute pain (tail-flick). An ω-conopeptide or saline is administered intrathecally (i.t.) according to the method of Hylden and Wilcox (1980) in a constant volume of 5 μl. Mice are gently wrapped in a towel with the tail exposed. At various time-points following the i.t. injection, the tail is dipped in a water bath maintained at 54 C. and the time to a vigorous tail withdrawal is recorded. If there is no withdrawal by 8 seconds, the tail is removed to avoid tissue damage.

[0097] Neuropathic pain. The partial sciatic nerve ligation model is used to assess the efficacy of Mar1 in neuropathic pain. Nerve injury is produced according to the methods of Malmberg and Basbaum (1998). Animals are anesthetized with a ketamine/xylazine solution, the sciatic nerve is exposed and tightly ligated with 8-0 silk suture around ⅓ to ½ of the nerve. In sham-operated mice the nerve is exposed, but not ligated. Animals are allowed to recover for at least 1 week before testing is performed. On the testing day, mice are placed in plexiglass cylinders on a wire mesh frame and allowed to habituate for at least 60 minutes. Mechanical allodynia is assessed with calibrated von Frey filaments using the up-down method as described by Chaplan et al. (1994), and the 50% withdrawal threshold is calculated. Animals that did not respond to any of the filaments in the series are assigned a maximal value of 3.6 grams, which is the filament that typically lifted the hindlimb without bending, and corresponds to approximately {fraction (1/10)} the animal's body weight.

[0098] The data obtained demonstrate that ω-conopeptides have potent analgesic properties in three commonly used models of pain: acute, persistent/inflammatory and neuropathic pain models.

Example 8 Calcium-Channel Antagonist Activity: Inhibition of Ionic Currents

[0099] Ionic currents through calcium channels are examined in cells that are voltage-clamped by a single patch-clamp electrode. These whole-cell patch-clamp studies are performed mainly on N1E115 mouse neuroblastoma cells, although a variety of cell types, including human neuroblastoma cell line IMR-32, are also examined.

[0100] Most measurements are obtained using a bath saline that allowed examination of the calcium currents in the absence of other ionic currents. These solutions contained 80 mM NMDG (as a sodium replacement), 30 mM TEACl (to block potassium currents), 10 mM BaCl₂ (as a charge-carrier through the calcium channels), and 10 mM HEPES at pH 7.3. Some solutions also contained 2 mM quinidine (to block potassium currents) and 3 μM tetrodotoxin (to block sodium currents). Normal bath saline is (mM): 140 NaCl, 10 glucose, 3 KCl, 2 CaCl₂, 1 MgCl₂, 10 mM HEPES pH 7.3. Intracellular solutions contained (mM): 150 CsCl, 0.5 CaCl₂, 5 EGTA, 5 MgCl₂, 2 K₂ATP at pH 7.3-7.4. Bath saline and all internal solutions are filtered before use.

[0101] Pipets are made from Corning 7052 glass (Garner Glass Company, Claremont, Calif. 91711), coated with Sylgard (Dow Corning, Midland, Mich. 48640) and fire-polished before use. Bubble numbers are typically 5 to 6, with pipet resistances typically 2-5 MOhms. Corning 8161, Kimble, and other glasses are also used without noticeable effect on the calcium currents observed.

[0102] Recordings are carried out at room temperature with an Axopatch 1-C amplifier (Axon Instruments, Foster City, Calif. 94404) and analyzed with pCLAMP software (Axon Instruments). Data are filtered at 1000 Hz for a typical sampling rate of 0.1 kHz; in all cases data are filtered at a frequency at most ⅕ of the sampling rate to avoid biasing. Data are collected on-line by the software. Analysis is performed on-screen with print-out via a Hewlett-Packard LaserJet Printer (Hewlett-Packard, Palo Alto, Calif. 94306).

[0103] The typical experiment is conducted as follows: after seal formation followed by series resistance compensation and capacitative transient cancellation, a voltage clamp protocol is performed wherein the cell potential is stepped from the holding potential (typically −100 mV) to test potentials that ranged from −60 mV to +20 mV in 10 mV increments. The cell is held at the holding potential for 5 seconds between pulses. Protocols starting from other holding potentials usually covered the same range of test potentials. ω-Conopeptides are found to have calcium channel blocking activity in such cell lines.

[0104] It will be appreciated that the methods and compositions of the instant invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.

Bibliography

[0105] Abiko, H. et al. (1986). Brain Res. 38:328-335.

[0106] Aldrete, J. A. et al. (1979). Crit. Care Med. 7:466-470.

[0107] Barnay, G. et al. (2000). J. Med. Chem.

[0108] Bitan, G. et al. (1997). J. Peptide Res. 49:421-426.

[0109] Bodansky et al. (1966). Chem. Ind. 38:1597-98.

[0110] Cartier, G. E. et al. (1996). J. Biol. Chem. 271:7522-7528.

[0111] Chandler, P. et al. (1993). J. Biol. Chem. 268:17173-17178.

[0112] Chaplan S. R. (1997). J Pharmacol. Exp. Ther. 280:829-838.

[0113] Clark, C. et al. (1981). Toxicon 19:691-699.

[0114] Codere, T. J. (1993). Eur. J. Neurosci. 5:390-393.

[0115] Cruz, L. J. at al. (1976). Verliger 18:302-308.

[0116] Ettinger, L. J. et al. (1978). Cancer 41:1270-1273.

[0117] Hammerland et al. (1992). Eur. J. Pharmacol. 226:239-244.

[0118] Heading, C. (1999). Curr. Opin. CPNS Invest. Drugs 1:153-166

[0119] Horiki, K. et al. (1978). Chemistry Letters 165-68.

[0120] Hubry, V. et al. (1994). Reactive Polymers 22:231-241.

[0121] Hylden, J. L. K. and Wilcox, G. (1980). Eur. J. Pharmacol. 67:313-316.

[0122] Kaiser et al. (1970). Anal. Biochem. 34:595.

[0123] Kapoor (1970). J. Pharm. Sci. 59:1-27.

[0124] Kornreich, W. D. et al. (1986). U.S. Pat. No. 4,569,967.

[0125] Luer, M. S. & Hatton, J. (1993). Annals Pharmcotherapy 27:912-921.

[0126] Liu, H. et al. (1997). Nature 386:721-724.

[0127] Martinez, J. S. et al. (1995). Biochem. 34:14519-14526.

[0128] McIntosh, J. M. et al. (1998). Methods Enzymol. 294:605-624.

[0129]The Merck Manual of Diagnosis and Therapy, 16 Ed., Berkow, R. et al., eds., Merck Research Laboratories, Rahway, N.J., pp. 1436-1445 (1992).

[0130]Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden, E. Wunsch (Ed.), Georg Thieme Verlag, Stuttgart, Ger. (1974).

[0131] Nehlig, A. et al. (1990). Effects of phenobarbital in the developing rat brain. In Neonatal Seizures, Wasterlain, C. G. and Vertt, P. (eds.), Raven Press, New York, pp. 285-194.

[0132] Nishiuchi, Y. et al. (1993). Int. J. Pept. Protein Res. 42:533-538.

[0133] Olivera, B. M. et al. (1984). U.S. Pat. No. 4,447,356.

[0134] Olivera, B. M. et al. (1985). Science 230:1338-1343.

[0135] Olivera, B. M. et al. (1990). Science 249:257-263.

[0136] Olivera, B. M. et al. (1996). U.S. Pat. No. 5,514,774.

[0137] Omstein, et al. (1993). Biorganic Medicinal Chemistry Letters 3:43-48.

[0138] Rall T. W. and Schleifer, L. S. in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Seventh Ed., Gilman, A. G. et al., eds., Macmillan Publishing Co., New York, pp. 446-472 (1985).

[0139]Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa.).

[0140] Rivier, J. R. et al. (1978). Biopolymers 17:1927-38.

[0141] Rivier, J. R. et al. (1987). Biochem. 26:8508-8512.

[0142] Sambrook, J. et al. (1989). Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

[0143] Shon, K.-J. et al. (1994). Biochemistry 33:11420-11425.

[0144] Stewart and Young, Solid-Phase Peptide Synthesis, Freeman & Co., San Francisco, Calif. (1969).

[0145] Vale et al. (1978). U.S. Pat. No. 4,105,603.

[0146] Troupin, A. S. et al. (1986). MK-801. In New Anticonvulsant Drugs, Current Problems in Epilepsy 4, Meldrum, B. S. and Porter, R. J. (eds.), John Libbey, London, pp. 191-202.

[0147] Van de Steen, P. et al. (1998). Critical Rev. in Biochem. and Mol. Biol. 33:151-208.

[0148] White, H. S., et al. (1992). Epilepsy Res. 12:217-226.

[0149] White, H. S., et al. (1995). Experimental Selection, Quantification, and Evaluation of Antiepileptic Drugs. In Antiepileptic Drugs, 4th Ed., Levy, R. H., eds., Raven Press, N.Y., pp. 99-110.

[0150] Wong, E. H. P. et al. (1986). Proc. Natl. Acad. Sci. USA 83:7104-7108.

[0151] Zhou L. M., et al. (1996). J. Neurochem. 66:620-628.

[0152] Zimm, S. et al. (1984). Cancer Res. 44:1698-1701.

[0153] U.S. Pat. No. 3,842,067.

[0154] U.S. Pat. No. 3,862,925.

[0155] U.S. Pat. No. 3,972,859.

[0156] U.S. Pat. No. 5,514,774.

[0157] U.S. Pat. No. 5,550,050.

[0158] U.S. Pat. No. 5,591,821.

[0159] U.S. Pat. No. 5,719,264.

[0160] U.S. Pat. No. 5,844,077 (1998).

[0161] Published PCT Application WO 92/19195.

[0162] Published PCT Application WO 94/25503.

[0163] Published PCT Application WO 95/01203.

[0164] Published PCT Application WO 95/05452.

[0165] Published PCT Application WO 96/02286.

[0166] Published PCT Application WO 96/02646.

[0167] Published PCT Application WO 96/40871.

[0168] Published PCT Application WO 96/40959.

[0169] Published PCT Application WO 97/12635.

[0170] Published PCT Application WO 98/03189.

[0171] Published PCT Application WO 00/23092.

1 413 1 318 DNA Unknown unknown Conus species 1 ggatccatga aactgacgtg catggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc atgccctgag gtcgaccacc 120 aatttctcca cgttgactcg tcgctgcctt tctcccggat cacgatgtca taagacaatg 180 cgtaactgct gcacttcatg ctcttcatac aaagggaaat gtcggcctcg aaaatgaacc 240 actcatcacc tactcctctg gaggcctcag aggaattaca ttgaaataaa agccgcatta 300 caaaaaaaaa aaaaaaaa 318 2 76 PRT Unknown unknown Conus species 2 Met Lys Leu Thr Cys Met Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His His 20 25 30 Ala Leu Arg Ser Thr Thr Asn Phe Ser Thr Leu Thr Arg Arg Cys Leu 35 40 45 Ser Pro Gly Ser Arg Cys His Lys Thr Met Arg Asn Cys Cys Thr Ser 50 55 60 Cys Ser Ser Tyr Lys Gly Lys Cys Arg Pro Arg Lys 65 70 75 3 30 PRT Unknown unknown Conus species 3 Cys Leu Ser Xaa Gly Ser Arg Cys His Lys Thr Met Arg Asn Cys Cys 1 5 10 15 Thr Ser Cys Ser Ser Xaa Lys Gly Lys Cys Arg Xaa Arg Lys 20 25 30 4 283 DNA Unknown unknown Conus species 4 ggatccatga aactgacgtg cgtggtgatc gtcgccgtgc tgctcctgac ggtctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc atgccctgag gtcgaccacc 120 aatttctcca cgtcgactcg tcgctgcaaa cctcccggaa gaaaatgtct gaatagaaag 180 aatgaatgct gcagcaagtt ttgcaatgaa cacctacata tgtgtggata aatggctaaa 240 aactgaataa aagccgcatt gcaaaaaaaa aaaaaaaaaa aaa 283 5 74 PRT Unknown unknown Conus species 5 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Val 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His His 20 25 30 Ala Leu Arg Ser Thr Thr Asn Phe Ser Thr Ser Thr Arg Arg Cys Lys 35 40 45 Pro Pro Gly Arg Lys Cys Leu Asn Arg Lys Asn Glu Cys Cys Ser Lys 50 55 60 Phe Cys Asn Glu His Leu His Met Cys Gly 65 70 6 27 PRT Unknown unknown Conus species 6 Cys Lys Xaa Xaa Gly Arg Lys Cys Leu Asn Arg Lys Asn Xaa Cys Cys 1 5 10 15 Ser Lys Phe Cys Asn Xaa His Leu His Met Cys 20 25 7 275 DNA Unknown unknown Conus species 7 ggatccatga aactgacgtg cgtggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcgtcacag ctgatggctc cagaggtatg cagaagcatt atgccctgag gtcgaccacc 120 aatctctcca tatcgtctcg ctgcaaacct cccagaagaa aatgtctgaa gattaaggat 180 aaatgctgca acttttgcaa tacacaccta aatatgtgtg gataaatggc taaaaactga 240 ataaaagccg cattgcaaaa aaaaaaaaaa aaaaa 275 8 72 PRT Unknown unknown Conus species 8 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Val Thr Ala Asp Gly Ser Arg Gly Met Gln Lys His Tyr 20 25 30 Ala Leu Arg Ser Thr Thr Asn Leu Ser Ile Ser Ser Arg Cys Lys Pro 35 40 45 Pro Arg Arg Lys Cys Leu Lys Ile Lys Asp Lys Cys Cys Asn Phe Cys 50 55 60 Asn Thr His Leu Asn Met Cys Gly 65 70 9 26 PRT Unknown unknown Conus species 9 Cys Lys Xaa Xaa Arg Arg Lys Cys Leu Lys Ile Lys Asp Lys Cys Cys 1 5 10 15 Asn Phe Cys Asn Thr His Leu Asn Met Cys 20 25 10 377 DNA Unknown unknown Conus species 10 ggatccatga aactgacgtg tgtggtgatc gtcgccgtgc tgctcctgat ggcctgtcaa 60 ctcgtcacag ctgatggctc cagaggtatg cacaagcatt atgccctgag gtcgaccacc 120 aaactctcca tgtcgactcg ctgcgcaggt ccaggaacaa tttgtcctaa tagggtatgc 180 tgcggttatt gcagtaaaag aacacatcta tgtcattcgc gaactggctg atcttccccc 240 ttctgcgctc catccttttc tgcctgagtc ctccatacct gagaatggtc atgaaccact 300 caacacctac tcctctggag ggcctcagaa gagctacatt gaaataaaag ccgcattaca 360 aaaaaaaaaa aaaaaaa 377 11 74 PRT Unknown unknown Conus species 11 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Met Ala 1 5 10 15 Cys Gln Leu Val Thr Ala Asp Gly Ser Arg Gly Met His Lys His Tyr 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Ser Met Ser Thr Arg Cys Ala Gly 35 40 45 Pro Gly Thr Ile Cys Pro Asn Arg Val Cys Cys Gly Tyr Cys Ser Lys 50 55 60 Arg Thr His Leu Cys His Ser Arg Thr Gly 65 70 12 28 PRT Unknown unknown Conus species 12 Cys Ala Gly Xaa Gly Thr Ile Cys Xaa Asn Arg Val Cys Cys Gly Xaa 1 5 10 15 Cys Ser Lys Arg Thr His Leu Cys His Ser Arg Thr 20 25 13 323 DNA Conus arenatus 13 ggatccatga aactgacgtg catggtgatc atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcattacag gtgagcagaa ggaccatgct ctgaggtcaa ctgacaaaaa ctccaagttg 120 actaggcagt gctcggctaa cggtggatct tgtactcgtc attttcactg ctgcagcctc 180 tattgcaata aagattccag tgtatgtgtg gcaacctcat acccgtgagt ggccatgaac 240 ccctcaatac cctctcctct ggaggcttca gaggaactgc attgaaataa aaccgcattg 300 caataaaaaa aaaaaaaaaa aaa 323 14 73 PRT Conus arenatus 14 Met Lys Leu Thr Cys Met Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Gly Glu Gln Lys Asp His Ala Leu Arg Ser Thr 20 25 30 Asp Lys Asn Ser Lys Leu Thr Arg Gln Cys Ser Ala Asn Gly Gly Ser 35 40 45 Cys Thr Arg His Phe His Cys Cys Ser Leu Tyr Cys Asn Lys Asp Ser 50 55 60 Ser Val Cys Val Ala Thr Ser Tyr Pro 65 70 15 33 PRT Conus arenatus PEPTIDE (1)..(33) Xaa at residue 1 is Gln or pyro-Glu; Xaa at residue 33 is Pro or Hyp; Xaa at residue 19 and 32 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo- Tyr, O-sulpho-Tyr or O-phospho-Tyr 15 Xaa Cys Ser Ala Asn Gly Gly Ser Cys Thr Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Xaa Cys Asn Lys Asp Ser Ser Val Cys Val Ala Thr Ser Xaa 20 25 30 Xaa 16 326 DNA Conus arenatus 16 accaaaacca tcatcaaaat gaaactgacg tgcgtgttga ttatcgccgt gctgttcctg 60 acggcctgtc aactcattac agctgagact tactccagag gtgagcagaa gcaccatgct 120 ctgaggtcaa ctgacagaaa ctccaagttg accaggacat gcaacactcc cactgaatat 180 tgtactttgc atcgacactg ctgcagcggc tactgccata aaacaatcca ggcatgttca 240 taataccggt gagtggtcat gaaccactca ataccctctc ctctggaggc ttcagaggaa 300 ctgcattgaa ataaaagccg cattgc 326 17 74 PRT Conus arenatus 17 Met Lys Leu Thr Cys Val Leu Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Glu Gln Lys His 20 25 30 His Ala Leu Arg Ser Thr Asp Arg Asn Ser Lys Leu Thr Arg Thr Cys 35 40 45 Asn Thr Pro Thr Glu Tyr Cys Thr Leu His Arg His Cys Cys Ser Gly 50 55 60 Tyr Cys His Lys Thr Ile Gln Ala Cys Ser 65 70 18 28 PRT Conus arenatus PEPTIDE (1)..(28) Xaa at residue 7 is Glu or gamma-carboxy Glu; Xaa at residue 5 is Pro or Hyp; Xaa at residue 8 and 19 is Tyr, 125I-Tyr, mono-iodo-Tyr, di- iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 18 Thr Cys Asn Thr Xaa Thr Xaa Xaa Cys Thr Leu His Arg His Cys Cys 1 5 10 15 Ser Gly Xaa Cys His Lys Thr Ile Gln Ala Cys Ser 20 25 19 332 DNA Conus arenatus 19 accaaaacca tcatcaaaat gaaactgacg tgcgtgttga tcatcgccgt gctgttcctg 60 acggcctgtc aactcattac agctgagact tactccagag gtgagcagat gcaccgtgct 120 ctgaggtcaa ctgacaaaaa ctccaagttg actaggcagt gcacgcctaa cggtggatct 180 tgttctcgtc attttcactg ctgcagcctc tattgcaata aaagtactgg cgtatgtatt 240 gcaacctcat acccgtgagt ggtcatgaac cactcaatac cctctcctct ggaggcttca 300 gaggaactgc attgaaataa aagccgcatt gc 332 20 79 PRT Conus arenatus 20 Met Lys Leu Thr Cys Val Leu Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Glu Gln Met His 20 25 30 Arg Ala Leu Arg Ser Thr Asp Lys Asn Ser Lys Leu Thr Arg Gln Cys 35 40 45 Thr Pro Asn Gly Gly Ser Cys Ser Arg His Phe His Cys Cys Ser Leu 50 55 60 Tyr Cys Asn Lys Ser Thr Gly Val Cys Ile Ala Thr Ser Tyr Pro 65 70 75 21 33 PRT Conus arenatus PEPTIDE (1)..(33) Xaa at residue 1 is Gln or pyro-Glu; Xaa at residue 4 and 33 is Pro or Hyp; Xaa at residue 19 and 32 is Tyr, 125I-Tyr, mono-iodo-Tyr, di- iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 21 Xaa Cys Thr Xaa Asn Gly Gly Ser Cys Ser Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Xaa Cys Asn Lys Ser Thr Gly Val Cys Ile Ala Thr Ser Xaa 20 25 30 Xaa 22 332 DNA Conus arenatus 22 ggatccatga aactgacgtg catggtgatt atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcattacag ctgagactta ctccagaggt gagcagaagc accatgctct gaggtcaact 120 gacaaaaact ccaagttgac caggacatgc aacactccca ccgaatattg tactttgcat 180 caacactgct gcagcggcta ctgccataaa acaatccagg catgttcata ataccggtga 240 gtggtcatga accactcaat accctctcct ctggaggctt cagaggaact gcattgaaat 300 aaaaccgcat tacaaaaaaa aaaaaaaaaa aa 332 23 74 PRT Conus arenatus 23 Met Lys Leu Thr Cys Met Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Glu Gln Lys His 20 25 30 His Ala Leu Arg Ser Thr Asp Lys Asn Ser Lys Leu Thr Arg Thr Cys 35 40 45 Asn Thr Pro Thr Glu Tyr Cys Thr Leu His Gln His Cys Cys Ser Gly 50 55 60 Tyr Cys His Lys Thr Ile Gln Ala Cys Ser 65 70 24 28 PRT Conus arenatus PEPTIDE (1)..(28) Xaa at residue 7 is Glu or gamma-carboxy Glu; Xaa at residue 5 is Pro or Hyp; Xaa at residue 8 and 19 is Tyr, 125I-Tyr, mono-iodo-Tyr, di- iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 24 Thr Cys Asn Thr Xaa Thr Xaa Xaa Cys Thr Leu His Gln His Cys Cys 1 5 10 15 Ser Gly Xaa Cys His Lys Thr Ile Gln Ala Cys Ser 20 25 25 394 DNA Conus arenatus 25 ggatccatga aactgacgtg tatggtgatc atcgccgtac tgttcctgac ggcctgtcaa 60 ctcattacag ctgagactta ctccagaggt aagcagatgc accgcgctct gaggtcaact 120 gacaaaaact cccagttgac cagggaatgc acacctcccg gtggagcttg tggtttacct 180 acacactgct gcgggttttg cgatactgca aacaacagat gtctgtaaag ctggtctggc 240 gtctgatatt ccccttctgt gctctatcct ctttggcctg agtcatccgt acctgtgagt 300 ggtcatgaac tactcaatac cctctcctct ggaggcttca gaggaactac aatgaaataa 360 aacccgcatt gcagagaaaa aaaaaaaaaa aaaa 394 26 73 PRT Conus arenatus 26 Met Lys Leu Thr Cys Met Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Lys Gln Met His 20 25 30 Arg Ala Leu Arg Ser Thr Asp Lys Asn Ser Gln Leu Thr Arg Glu Cys 35 40 45 Thr Pro Pro Gly Gly Ala Cys Gly Leu Pro Thr His Cys Cys Gly Phe 50 55 60 Cys Asp Thr Ala Asn Asn Arg Cys Leu 65 70 27 27 PRT Conus arenatus PEPTIDE (1)..(27) Xaa at residue 1 is Glu or gamma-carboxy Glu; Xaa at residue 4, 5 and 12 is Pro or Hyp 27 Xaa Cys Thr Xaa Xaa Gly Gly Ala Cys Gly Leu Xaa Thr His Cys Cys 1 5 10 15 Gly Phe Cys Asp Thr Ala Asn Asn Arg Cys Leu 20 25 28 345 DNA Conus arenatus misc_feature (1)..(345) n may be any nucldeotide 28 ggatccatga aactgacgtg cgtggtgatt atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcattacag ctgagactta ctccagaggt gagcagaatc accatgttct gaggtcaact 120 gacaaaaact ccaagttgac caggacatgc aacactccca ctgaatattg tactttgcat 180 caacactgct gcagcggcca ctgccataaa acaatccagg catgtgcata ataccggtgg 240 gtggtcatga accactcaat accctctcct ctggaggctt cagaggaact gcattgaaat 300 aaaaccgcat tgcaatgaan aaaaaaaaaa aaaaaaaaaa aaaaa 345 29 74 PRT Conus arenatus 29 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Glu Gln Asn His 20 25 30 His Val Leu Arg Ser Thr Asp Lys Asn Ser Lys Leu Thr Arg Thr Cys 35 40 45 Asn Thr Pro Thr Glu Tyr Cys Thr Leu His Gln His Cys Cys Ser Gly 50 55 60 His Cys His Lys Thr Ile Gln Ala Cys Ala 65 70 30 28 PRT Conus arenatus PEPTIDE (1)..(28) Xaa at residue 7 is Glu or gamma-carboxy Glu; Xaa at residue 5 is Pro or Hyp; Xaa at residue 8 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 30 Thr Cys Asn Thr Xaa Thr Xaa Xaa Cys Thr Leu His Gln His Cys Cys 1 5 10 15 Ser Gly His Cys His Lys Thr Ile Gln Ala Cys Ala 20 25 31 322 DNA Conus arenatus 31 ggatccatga aactgacgtg tgtggtgatc atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcactacag gtgagcagaa ggaccatgct ctgaggtcaa ctgacaaaaa ctccaagttg 120 actaggcagt gctcgcctat cggtggatat tgtactcttc atattcactg ctgcagcaac 180 cattgcatta aacctatcgg ccgatgtgtg gcaacctgat acccgtgcgt ggtcatgaac 240 ccctcaatac cctctcctct ggaggcttca gaggaactgc attgaaataa aaccgcattg 300 caataaaaaa aaaaaaaaaa aa 322 32 70 PRT Conus arenatus 32 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Thr Thr Gly Glu Gln Lys Asp His Ala Leu Arg Ser Thr 20 25 30 Asp Lys Asn Ser Lys Leu Thr Arg Gln Cys Ser Pro Ile Gly Gly Tyr 35 40 45 Cys Thr Leu His Ile His Cys Cys Ser Asn His Cys Ile Lys Pro Ile 50 55 60 Gly Arg Cys Val Ala Thr 65 70 33 30 PRT Conus arenatus PEPTIDE (1)..(30) Xaa at residue 1 is Gln or pyro-Glu; Xaa at residue 4 and 23 is Pro or Hyp; Xaa at residue 8 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 33 Xaa Cys Ser Xaa Ile Gly Gly Xaa Cys Thr Leu His Ile His Cys Cys 1 5 10 15 Ser Asn His Cys Ile Lys Xaa Ile Gly Arg Cys Val Ala Thr 20 25 30 34 318 DNA Conus arenatus 34 ggatccatga aactgacgtg cgtggtgatc atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcactacag gtgagcagaa ggaccatgct ctgaggtcaa ctgacaaaaa ctccaagttg 120 actaggcagt gcttgcctaa cggtggatat tgtactcttc atattcactg ctgcagcgac 180 cattgcatta aacctatcga ccgatgtgtg gcaacctgat acccgggcgt ggtcatgaac 240 ccctcaatac cctctcctct ggaggcttca gaggaactgc attgaaataa aaccgcatta 300 caaaaaaaaa aaaaaaaa 318 35 70 PRT Conus arenatus 35 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Thr Thr Gly Glu Gln Lys Asp His Ala Leu Arg Ser Thr 20 25 30 Asp Lys Asn Ser Lys Leu Thr Arg Gln Cys Leu Pro Asn Gly Gly Tyr 35 40 45 Cys Thr Leu His Ile His Cys Cys Ser Asp His Cys Ile Lys Pro Ile 50 55 60 Asp Arg Cys Val Ala Thr 65 70 36 30 PRT Conus arenatus PEPTIDE (1)..(30) Xaa at residue 1 is Gln or pyro-Glu; Xaa at residue 4 and 23 is Pro or Hyp; Xaa at residue 8 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 36 Xaa Cys Leu Xaa Asn Gly Gly Xaa Cys Thr Leu His Ile His Cys Cys 1 5 10 15 Ser Asp His Cys Ile Lys Xaa Ile Asp Arg Cys Val Ala Thr 20 25 30 37 374 DNA Conus aurisiacus 37 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcatc 60 acagctgatg actccagagg tacgcagaag catcgttccc tgagctcggc caccaaactc 120 tccatgtcga ctcgctgcaa gggtaaagga aaaccatgca gtaggatttc gtataactgc 180 tgcaccggtt cttgcagatc aggtaaatgt ggctgatcca gcgcctgatc ttcccccttc 240 tgtgctctat ccttttctgc ctgagtcctc cttacctgag agtggtcatg aaccactcat 300 cacctgctcc tctggaggcc ccagaggagc tacattgaaa taaaagtcgc attgcaaaaa 360 aaaaaaaaaa aaaa 374 38 71 PRT Conus aurisiacus 38 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Ser Ser Ala Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Lys Pro Cys Ser Arg Ile Ser Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Arg Ser Gly Lys Cys Gly 65 70 39 25 PRT Conus aurisiacus PEPTIDE (1)..(25) Xaa at residue 7 is Pro or Hyp; Xaa at res idue 13 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 39 Cys Lys Gly Lys Gly Lys Xaa Cys Ser Arg Ile Ser Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 40 380 DNA Conus aurisiacus 40 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcatc 60 acagctgatg actccagagg tacgcagaag catcgttccc tgaggtcgaa gaccaaactc 120 tccatgtcga ctggctgcat ggaagccgga tcttattgcg gctctactac gagaatctgc 180 tgcggttttt gcgcttattt cggcaaaaaa tgtattgact atcccagcaa ctgatcttcc 240 ccctactgtg ctctatcctt ttctgcctga gtcctcctta cctgagagtg gtcatgaacc 300 actcatcacc tgctcctctg gaggccccag aggagctaca ttgaaataaa atcgcattgc 360 taaaaaaaaa aaaaaaaaaa 380 41 77 PRT Conus aurisiacus 41 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Arg Ser Lys Thr Lys Leu Ser Met Ser Thr Gly Cys Met Glu 35 40 45 Ala Gly Ser Tyr Cys Gly Ser Thr Thr Arg Ile Cys Cys Gly Phe Cys 50 55 60 Ala Tyr Phe Gly Lys Lys Cys Ile Asp Tyr Pro Ser Asn 65 70 75 42 32 PRT Conus aurisiacus PEPTIDE (1)..(32) Xaa at residue 3 is Glu or gamma-carboxy Glu; Xaa at residue 30 is Pro or Hyp; Xaa at residue and 29 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 42 Cys Met Xaa Ala Gly Ser Xaa Cys Gly Ser Thr Thr Arg Ile Cys Cys 1 5 10 15 Gly Phe Cys Ala Xaa Phe Gly Lys Lys Cys Ile Asp Xaa Xaa Ser Asn 20 25 30 43 373 DNA Conus aurisiacus 43 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgttccctg 120 agctcggcca ccaaactctc catgtcgact cgctgcaagg ctaaaggaaa accatgcagt 180 aggattgcgt ataactgctg caccggttct tgcagatcag gtaaatgtgg ctgatccagt 240 gcctgatctt cccccttctg tgctctatcc ttttctgcct gagtcctcct tacctgagag 300 tggtcatgaa ccactcatca cctgctcctc tggaggcccc agaggagcta cattgaaata 360 aaagccgcat tgc 373 44 71 PRT Conus aurisiacus 44 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Ser Ser Ala Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Ala 35 40 45 Lys Gly Lys Pro Cys Ser Arg Ile Ala Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Arg Ser Gly Lys Cys Gly 65 70 45 25 PRT Conus aurisiacus PEPTIDE (1)..(25) Xaa at residue 7 is Pro or Hyp; Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo- Tyr, O-sulpho-Tyr or O-phospho-Ty 45 Cys Lys Ala Lys Gly Lys Xaa Cys Ser Arg Ile Ala Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 46 379 DNA Conus aurisiacus 46 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acgacctgtc aactcatcac agctgatgac tccagaggta cgcaggagca tcgtgccctg 120 aggtcgaaga caaaactctc catgttaact ttgcgctgcg catcttacgg aaaaccttgt 180 ggtattgaca acgactgctg caatgcatgc gatccaggaa gaaatatatg tacgtagctg 240 atccagcgcc tgatcttccc ccttctgtgc tctatccttt tctgcccgag tcctccttac 300 ctgagagtgg tcatgaacca ctcatcacct gctccctgga ggcctcagag gagctacaat 360 gaaataaaag ccgcattgc 379 47 72 PRT Conus aurisiacus 47 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Thr 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Glu His Arg 20 25 30 Ala Leu Arg Ser Lys Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Ala 35 40 45 Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn Ala Cys 50 55 60 Asp Pro Gly Arg Asn Ile Cys Thr 65 70 48 26 PRT Conus aurisiacus PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 48 Cys Ala Ser Xaa Gly Lys Xaa Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Xaa Gly Arg Asn Ile Cys Thr 20 25 49 382 DNA Conus bullatus 49 accaaaacca tcatcaaaat gaaactgacg tgtgtggcga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgaagac tccagaggta cgcatgagca tcttgccctg 120 aagtcgacct ccaaagtctc caagtcgact agctgcatgg aagccggatc ttattgcgga 180 cctgctacta cgaaaatctg ctgcgatttt tgcagtccat tcagcgatag atgtatgaac 240 aatcccaaca attgatcttc ccccttgtgt gctccatcct tttctgcctg agtcctcctt 300 acctgagagt ggtcatgaac cactcatcac ctactcctct ggaggcttca gaggagctac 360 attgaaataa aagccgcatt gc 382 50 78 PRT Conus bullatus 50 Met Lys Leu Thr Cys Val Ala Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr His Glu His Leu 20 25 30 Ala Leu Lys Ser Thr Ser Lys Val Ser Lys Ser Thr Ser Cys Met Glu 35 40 45 Ala Gly Ser Tyr Cys Gly Pro Ala Thr Thr Lys Ile Cys Cys Asp Phe 50 55 60 Cys Ser Pro Phe Ser Asp Arg Cys Met Asn Asn Pro Asn Asn 65 70 75 51 36 PRT Conus bullatus PEPTIDE (1)..(36) Xaa at residue 6 is Glu or gamma-carboxy Glu; Xaa at residue 13, 25 and 34 is Pro or Hyp; Xaa at residue 10 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 51 Ser Thr Ser Cys Met Xaa Ala Gly Ser Xaa Cys Gly Xaa Ala Thr Thr 1 5 10 15 Lys Ile Cys Cys Asp Phe Cys Ser Xaa Phe Ser Asp Arg Cys Met Asn 20 25 30 Asn Xaa Asn Asn 35 52 400 DNA Conus bullatus 52 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgaagac tccagaggta cgcagttgca tcgtgccctg 120 aggaaggcca ccaaacaccc tgtgtcgact cgctgcatta ctccaggaac acgatgtaag 180 gttccgagcc aatgctgcag aggtccttgc aagaacggtc gttgtactcc atccccttct 240 gaatggtaaa tgtggttgat ccagcgcctg atcttccccc ttcgtcgtgc tccatccttt 300 tctgcctgag tcctccttac ctgagagtgg tcatgaacca ctcatcacct actcccctgg 360 aggcttcaga ggagctacat tgaaataaaa gccgcattgc 400 53 76 PRT Conus bullatus 53 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr Gln Leu His Arg 20 25 30 Ala Leu Arg Lys Ala Thr Lys His Pro Val Ser Thr Arg Cys Ile Thr 35 40 45 Pro Gly Thr Arg Cys Lys Val Pro Ser Gln Cys Cys Arg Gly Pro Cys 50 55 60 Lys Asn Gly Arg Cys Thr Pro Ser Pro Ser Glu Trp 65 70 75 54 31 PRT Conus bullatus PEPTIDE (1)..(31) Xaa at residue 30 is Glu or gamma-carboxy Glu; Xaa at residue 4, 11, 18, 26 and 28 is Pro or Hyp; Xaa at residue 31is Trp or Bromo-Trp 54 Cys Ile Thr Xaa Gly Thr Ala Cys Lys Val Xaa Ser Gln Cys Cys Arg 1 5 10 15 Gly Xaa Cys Lys Asn Gly Arg Cys Thr Xaa Ser Xaa Ser Xaa Xaa 20 25 30 55 379 DNA Conus bullatus 55 accaaaacca tcatcaaaat gaaactgacg tgtgtggcga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgaggac tccagagata cgcagaagca tcgtgccctg 120 aggtcggaca ccaaactctc catgttgact ttgcgctgcg caacttacgg aaaaccttgt 180 ggtattcaaa acgactgctg caatacatgc gatccagcca gaaggacatg tacgtagctg 240 atccggcgtc ttgatcctcc gcttctgtgc tccatctttt ctgcctgagt cctccttacc 300 tgagagtggt catgaaccac tcatcaccta ctcctctgga ggctttagag gagctacatt 360 gaaataaaag ccgcattgc 379 56 72 PRT Conus bullatus 56 Met Lys Leu Thr Cys Val Ala Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Asp Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Ala 35 40 45 Thr Tyr Gly Lys Pro Cys Gly Ile Gln Asn Asp Cys Cys Asn Thr Cys 50 55 60 Asp Pro Ala Arg Arg Thr Cys Thr 65 70 57 26 PRT Conus bullatus PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 57 Cys Ala Thr Xaa Gly Lys Xaa Cys Gly Ile Gln Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Xaa Ala Arg Arg Thr Cys Thr 20 25 58 373 DNA Conus bullatus 58 accaaaacca tcatcaaaat gaaactgacg tgtgtggcga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgaagac tccagaggta cgcagttgca tcgtgccctg 120 aggaagacca ccaaactctc cttgtcgact cgctgcaagg gtccaggagc atcatgtata 180 aggattgcgt ataactgctg caagtattct tgcagaaatg gtaaatgtgg ctgatccagc 240 gcctgatctt cccccttgtg tgctccatcc ttttctgcct gagtcctcct tacctgagag 300 tggtcatgaa ccactcatca cctactcctc tggaggcttc agaggagcta cattgaaata 360 aaagccgcat tgc 373 59 71 PRT Conus bullatus 59 Met Lys Leu Thr Cys Val Ala Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr Gln Leu His Arg 20 25 30 Ala Leu Arg Lys Thr Thr Lys Leu Ser Leu Ser Thr Arg Cys Lys Gly 35 40 45 Pro Gly Ala Ser Cys Ile Arg Ile Ala Tyr Asn Cys Cys Lys Tyr Ser 50 55 60 Cys Arg Asn Gly Lys Cys Gly 65 70 60 25 PRT Conus bullatus PEPTIDE (1)..(25) Xaa at residue 4 is Pro or Hyp; Xaa at residue 13 and 18 is Tyr, 125I-Tyr, mono-iodo-Tyr, di- iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 60 Cys Lys Gly Xaa Gly Ala Ser Cys Ile Arg Ile Ala Xaa Asn Cys Cys 1 5 10 15 Lys Xaa Ser Cys Arg Asn Gly Lys Cys 20 25 61 382 DNA Conus bullatus 61 atcaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgaagac tccagaggta cgcatgagca tcttgccctg 120 aagtcgacct ccaaagtctc caagtcgact agctgcatgg cagccggatc ttattgcgga 180 cctgctacta cgaatatctg ctgcgatttt tgcagtccat tcagcgatag atgtatgaaa 240 aagcccaaca attgatcttc ccccttctgt gctctatcct tttctgcctg agtcctcctt 300 acctgagagt ggtcatgaac cactcatcac ctactcctct ggaggcttca gaggagctac 360 attgaaataa aagccgcatt gc 382 62 78 PRT Conus bullatus 62 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr His Glu His Leu 20 25 30 Ala Leu Lys Ser Thr Ser Lys Val Ser Lys Ser Thr Ser Cys Met Ala 35 40 45 Ala Gly Ser Tyr Cys Gly Pro Ala Thr Thr Asn Ile Cys Cys Asp Phe 50 55 60 Cys Ser Pro Phe Ser Asp Arg Cys Met Lys Lys Pro Asn Asn 65 70 75 63 36 PRT Conus bullatus PEPTIDE (1)..(36) Xaa at residue 13, 25 and 34 is Pro or Hyp; Xaa at residue 10 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 63 Ser Thr Ser Cys Met Ala Ala Gly Ser Xaa Cys Gly Xaa Ala Thr Thr 1 5 10 15 Asn Ile Cys Cys Asp Phe Cys Ser Xaa Phe Ser Asp Arg Cys Met Lys 20 25 30 Lys Xaa Asn Asn 35 64 373 DNA Conus bullatus 64 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattat agctgaggac tccagaggta cgcagttgca tcgtgccctg 120 aggaaggcca ccaaactctc cgtgtcgact cgctgcaaga gtaaaggatc atcatgtcat 180 aggacttcgt atgactgctg cacgggttct tgcagaaatg gtagatgtgg ctgatccagc 240 gcctgatctt cccccttctg tgctccatcc ttttctgcct gagtcctcct tacctgagag 300 tggtcatgaa ccactcatca cctactcctc tggaggcttc agaggagcta cattgaaata 360 aaagccgcat tgc 373 65 71 PRT Conus bullatus 65 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Ile Ala Glu Asp Ser Arg Gly Thr Gln Leu His Arg 20 25 30 Ala Leu Arg Lys Ala Thr Lys Leu Ser Val Ser Thr Arg Cys Lys Ser 35 40 45 Lys Gly Ser Ser Cys His Arg Thr Ser Tyr Asp Cys Cys Thr Gly Ser 50 55 60 Cys Arg Asn Gly Arg Cys Gly 65 70 66 25 PRT Conus bullatus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 66 Cys Lys Ser Lys Gly Ser Ser Cys His Arg Thr Ser Xaa Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Asn Gly Arg Cys 20 25 67 321 DNA Conus caracteristicus 67 ggatccatga aactgacgtg cgtggtgatc atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcattacag gtgagcagaa ggaccatgct ctgaggtcaa ctgacaaaaa ctccaagttg 120 actaggcagt gctcggctaa cggtggatct tgtactcgtc attttcactg ctgcagcctc 180 tattgcaata aagattccag tgtatgtgtg gcaacctcat acccgtgagt ggccatgaac 240 ccctcaatac cctctcctct ggaggcttca gaggaactgc attgaaataa aaccgcatta 300 caaaaaaaaa aaaaaaaaaa a 321 68 73 PRT Conus caracteristicus 68 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Gly Glu Gln Lys Asp His Ala Leu Arg Ser Thr 20 25 30 Asp Lys Asn Ser Lys Leu Thr Arg Gln Cys Ser Ala Asn Gly Gly Ser 35 40 45 Cys Thr Arg His Phe His Cys Cys Ser Leu Tyr Cys Asn Lys Asp Ser 50 55 60 Ser Val Cys Val Ala Thr Ser Tyr Pro 65 70 69 33 PRT Conus caracteristicus PEPTIDE (1)..(33) Xaa at residue 1 is Gln or pyro-Glu; Xaa at residue 33 is Pro or Hyp; Xaa at residue 19 and 32 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo- Tyr, O-sulpho-Tyr or O-phospho-Tyr 69 Xaa Cys Ser Ala Asn Gly Gly Ser Cys Thr Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Xaa Cys Asn Lys Asp Ser Ser Val Cys Val Ala Thr Ser Xaa 20 25 30 Xaa 70 26 PRT Conus catus 70 Cys Lys Ser Thr Gly Ala Ser Cys Arg Arg Thr Ser Tyr Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Arg Cys Gly 20 25 71 25 PRT Conus catus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 71 Cys Lys Ser Thr Gly Ala Ser Cys Arg Arg Thr Ser Xaa Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Arg Cys 20 25 72 229 DNA Conus catus 72 tcgactcgct gccagggtag aggagcatca tgtcgtaaga ctatgtataa ctgctgcagc 60 ggttcttgca acagaggtag ttgtggctga tccggcgcct gatcttcccc cttccgtgct 120 ctatcctttt ctgcctgatt cctccttacc tgagagcggt catgaaccac tcatcacctg 180 ctcctctgga ggcctcagag gagctacatt gaaataaaag ccgcattgc 229 73 29 PRT Conus catus 73 Ser Thr Arg Cys Gln Gly Arg Gly Ala Ser Cys Arg Lys Thr Met Tyr 1 5 10 15 Asn Cys Cys Ser Gly Ser Cys Asn Arg Gly Ser Cys Gly 20 25 74 25 PRT Conus catus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 74 Cys Gln Gly Arg Gly Ala Ser Cys Arg Lys Thr Met Xaa Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Asn Arg Gly Ser Cys 20 25 75 235 DNA Conus catus 75 tcgacacgct gcttgcctgc cggagagtct tgccttttta gtaggattag atgctgcggt 60 acttgcagtt cagtcttaaa gtcatgtgtg agctgatcca gctgctgatc ttcctcctcc 120 tgtgctccat ccttttctgc ctgagtcctc cttatctgag agtggtcatg aaccactcac 180 cacctactct tctggaggct tcagaggagc tacagtgaaa taaaagccgc attgc 235 76 31 PRT Conus catus 76 Ser Thr Arg Cys Leu Pro Ala Gly Glu Ser Cys Leu Phe Ser Arg Ile 1 5 10 15 Arg Cys Cys Gly Thr Cys Ser Ser Val Leu Lys Ser Cys Val Ser 20 25 30 77 28 PRT Conus catus PEPTIDE (1)..(28) Xaa at residue 6 is Glu or gamma-carboxy Glu; Xaa at residue 3 is Pro or Hyp 77 Cys Leu Xaa Ala Gly Xaa Ser Cys Leu Phe Ser Arg Ile Arg Cys Cys 1 5 10 15 Gly Thr Cys Ser Ser Val Leu Lys Ser Cys Val Ser 20 25 78 227 DNA Conus catus 78 tcgacacgct gccagggtag aggaggacca tgtactaagg ctgtgtttaa ctgctgcagc 60 ggttcttgca acagaggtag atgtggctga tccagcgcct gatcttcccc cttctgtgct 120 ctatcctttt ctgcctgagt cctccttact gagagtagtc atgaaccact catcacctac 180 tcctctggag gcctcagaga gctacattga aataaaagcc gcattgc 227 79 29 PRT Conus catus 79 Ser Thr Arg Cys Gln Gly Arg Gly Gly Pro Cys Thr Lys Ala Val Phe 1 5 10 15 Asn Cys Cys Ser Gly Ser Cys Asn Arg Gly Arg Cys Gly 20 25 80 25 PRT Conus catus PEPTIDE (1)..(25) Xaa at residue 7 is Pro or Hyp 80 Cys Gln Gly Arg Gly Gly Xaa Cys Thr Lys Ala Val Phe Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Asn Arg Gly Arg Cys 20 25 81 236 DNA Conus catus 81 ttaactttgc gctgcgcaac ttacggaaaa ccttgtggta ttcaaaacga ctgctgcaat 60 acatgcgatc cagccagaaa gacatgtacg tagctgatcc ggcgtctgat ctcccccctt 120 ctgtgctcta tccttttctg cctgagtcct ccttacctga gagtggtcat gaaccactca 180 tcacctgctc ctctggaggc ctcgggggag ctacattgaa ataaaagccg cattgc 236 82 30 PRT Conus catus 82 Leu Thr Leu Arg Cys Ala Thr Tyr Gly Lys Pro Cys Gly Ile Gln Asn 1 5 10 15 Asp Cys Cys Asn Thr Cys Asp Pro Ala Arg Lys Thr Cys Thr 20 25 30 83 26 PRT Conus catus PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 83 Cys Ala Thr Xaa Gly Lys Xaa Cys Gly Ile Gln Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Xaa Ala Arg Lys Thr Cys Thr 20 25 84 229 DNA Conus catus 84 tcgactcgct gccggggtag aggaggacca tgtactaagg ctatgtttaa ctgctgcagc 60 ggttcttgca acagaggtag atgtggctga tccagcgcct gatcttcccc cttctgtgct 120 ctatcctttt ctgcctgagt cctccttaac tgagagtagt catgaaccac tcatcaccta 180 ctcctctgga ggcctcagag aagcatcatt gaaataaaag ccgcattgc 229 85 29 PRT Conus catus 85 Ser Thr Arg Cys Arg Gly Arg Gly Gly Pro Cys Thr Lys Ala Met Phe 1 5 10 15 Asn Cys Cys Ser Gly Ser Cys Asn Arg Gly Arg Cys Gly 20 25 86 25 PRT Conus catus PEPTIDE (1)..(25) Xaa at residue 7 is Pro or Hyp 86 Cys Arg Gly Arg Gly Gly Xaa Cys Thr Lys Ala Met Phe Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Asn Arg Gly Arg Cys 20 25 87 374 DNA Conus circumcisus 87 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acgacctgtc aactcatcac agctgatgac tccagaggta cgcaggagca tcgtgccctg 120 aggtcggaca ccaaactccc catgtcgact cgctgcaagg gtaaaggagc atcatgtcgt 180 aagactatgt ataactgctg cagcggttct tgcagcaacg gtagatgtgg ctgatccagc 240 gcctgatctt cccccttctg ctgctctatc cttttctgcc tgagtcctcc ttacctgaga 300 gctggtcatg aaccactcat cacctgctcc tctggaggcc cagaggagct acattgaaat 360 aaaagccgca ttgc 374 88 71 PRT Conus circumcisus 88 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Thr 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Glu His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Pro Met Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Ala Ser Cys Arg Lys Thr Met Tyr Asn Cys Cys Ser Gly Ser 50 55 60 Cys Ser Asn Gly Arg Cys Gly 65 70 89 25 PRT Conus circumcisus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 89 Cys Lys Gly Lys Gly Ala Ser Cys Arg Lys Thr Met Xaa Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Ser Asn Gly Arg Cys 20 25 90 379 DNA Conus circumcisus 90 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acgacctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcggcca ccaaagtctc caagtcgact agctgcatgg aagccggatc ttattgccgc 180 tctactacga gaacctgctg cggttattgc tcttatttca gcaaaaaatg tattgacttt 240 cccagcaact gatcttcccc ctactgtgct ctatcctttt ctgcctgagt cctccttacc 300 tgagagtggt catgaaccac tcatcaccct actcctctgg aggcccagag gagctacatt 360 gaaataaaag ccgcattgc 379 91 77 PRT Conus circumcisus 91 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Thr 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Ala Thr Lys Val Ser Lys Ser Thr Ser Cys Met Glu 35 40 45 Ala Gly Ser Tyr Cys Arg Ser Thr Thr Arg Thr Cys Cys Gly Tyr Cys 50 55 60 Ser Tyr Phe Ser Lys Lys Cys Ile Asp Phe Pro Ser Asn 65 70 75 92 35 PRT Conus circumcisus PEPTIDE (1)..(35) Xaa at residue 6 is Glu or gamma-carboxy Glu; Xaa at residue 33 is Pro or Hyp; Xaa at residue 10, 21 and 24 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 92 Ser Thr Ser Cys Met Xaa Ala Gly Ser Xaa Cys Arg Ser Thr Thr Arg 1 5 10 15 Thr Cys Cys Gly Xaa Cys Ser Xaa Phe Ser Lys Lys Cys Ile Asp Phe 20 25 30 Xaa Ser Asn 35 93 379 DNA Conus circumcisus 93 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acgacctgtc aactcatcac agctgatgac tccagaggta cgcaggagca tcgtgccctg 120 aggtcggaca ccaaactccc catgtcgact cgctgcaaga gtaaaggagc aaaatgttca 180 aggcttatgt atgactgctg cagcggttct tgcagcaggt actcaggtag atgtggctga 240 tccagcgcct gatcttcccc cttctgctgc tctatccttt tctgcctgag tcctccttac 300 ctgagagtgg tcatgaacca ctcatcacct actcctctgg aggcccagag gagctacatt 360 gaaataaaag ccgcattgc 379 94 73 PRT Conus circumcisus 94 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Thr 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Glu His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Pro Met Ser Thr Arg Cys Lys Ser 35 40 45 Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys Ser Gly Ser 50 55 60 Cys Ser Arg Tyr Ser Gly Arg Cys Gly 65 70 95 27 PRT Conus circumcisus PEPTIDE (1)..(27) Xaa at residue 13 and 23 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 95 Cys Lys Ser Lys Gly Ala Lys Cys Ser Arg Leu Met Xaa Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Ser Arg Xaa Ser Gly Arg Cys 20 25 96 379 DNA Conus circumcisus 96 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acgacctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgttccctg 120 acgtcggcca ccaaagtctc caagtcgact ggctgcatga aagccggatc ttattgccgc 180 tctactacga gaacttgctg cggttattgc gcttatttcg gcaaaaaatg tattgactat 240 cccagcaact gatcttcccc ctactgtgct ctatcctttt ctgcctaagt cctccttacc 300 tgagagtggt catgaaccac tcatcaccct actcctctgg aggcccagag gagctacatt 360 gaaataaaag ccgcattgc 379 97 77 PRT Conus circumcisus 97 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Thr 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Thr Ser Ala Thr Lys Val Ser Lys Ser Thr Gly Cys Met Lys 35 40 45 Ala Gly Ser Tyr Cys Arg Ser Thr Thr Arg Thr Cys Cys Gly Tyr Cys 50 55 60 Ala Tyr Phe Gly Lys Lys Cys Ile Asp Tyr Pro Ser Asn 65 70 75 98 35 PRT Conus circumcisus PEPTIDE (1)..(35) Xaa at residue 33 is Pro or Hyp; Xaa at residue 10, 21, 24 and 32 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 98 Ser Thr Gly Cys Met Lys Ala Gly Ser Xaa Cys Arg Ser Thr Thr Arg 1 5 10 15 Thr Cys Cys Gly Xaa Cys Ala Xaa Phe Gly Lys Lys Cys Ile Asp Xaa 20 25 30 Xaa Ser Asn 35 99 362 DNA Conus consors 99 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcctc 60 acagctgatg actccagagg tacgcagaag catcgtgccc tgaagtctta caccaaactc 120 tccatgttaa ctttgcgctg cgcatcttac ggaaaacctt gtggtattga caacgactgc 180 tgcaatacat gcgatccagc cagaaagaca tgtacgtagc tgatccggcg tctgatcttc 240 ccccttctgt gctctatcct tttctgcctg agtcctcctt acctgagagt ggtcatgaac 300 cactcatcac ctagctcctc tggaggcttc agaggagcta caatgaaata aaagcgcatt 360 gc 362 100 72 PRT Conus consors 100 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Leu Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Lys Ser Tyr Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Ala 35 40 45 Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn Thr Cys 50 55 60 Asp Pro Ala Arg Lys Thr Cys Thr 65 70 101 26 PRT Conus consors PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 101 Cys Ala Ser Xaa Gly Lys Xaa Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Xaa Ala Arg Lys Thr Cys Thr 20 25 102 237 DNA Conus consors 102 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcctc 60 acagctgatg actccagagg tacgcagaag catcgtgccc tgaggtcgga caccaaactc 120 tccatgtcga ctcgctgcaa gggtacagga aaaccatgca gtaggattgc gtataactgc 180 tgcaccggtt cttgcagatc aggtaaatgt ggctgatcca gcgcctgatc tcccccc 237 103 71 PRT Conus consors 103 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Leu Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Thr Gly Lys Pro Cys Ser Arg Ile Ala Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Arg Ser Gly Lys Cys Gly 65 70 104 25 PRT Conus consors PEPTIDE (1)..(25) Xaa at residue 7 is Pro or Hyp; Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo- Tyr, O-sulpho-Tyr or O-phospho-Tyr 104 Cys Lys Gly Arg Gly Lys Xaa Cys Ser Arg Ile Ala Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 105 320 DNA Conus consors 105 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcatc 60 acagctgatg actccaaagg tacgcagaag catcgttccc tgaggtcgac caccaaagtc 120 tccaaggcga ctgactgcat tgaagccgga aattattgcg gacctactgt tatgaaaatc 180 tgctgcggct tttgcagtcc atacagcaaa atatgtatga actatcccca aaattgatct 240 tcccccttct gtgctctatc cttttctgcc tgagtcctcc ttacctgaga gtggtcatga 300 accactcatc acctcgtccc 320 106 78 PRT Conus consors 106 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Lys Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Arg Ser Thr Thr Lys Val Ser Lys Ala Thr Asp Cys Ile Glu 35 40 45 Ala Gly Asn Tyr Cys Gly Pro Thr Val Met Lys Ile Cys Cys Gly Phe 50 55 60 Cys Ser Pro Tyr Ser Lys Ile Cys Met Asn Tyr Pro Gln Asn 65 70 75 107 36 PRT Conus consors PEPTIDE (1)..(36) Xaa at residue 6 is Glu or gamma-carboxy Glu; Xaa at residue 13, 25 and 34 is Pro or Hyp; Xaa at residue 10, 26 and 33 is Tyr, 125 I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O- phospho-Tyr 107 Ala Thr Asp Cys Ile Xaa Ala Gly Asn Xaa Cys Gly Xaa Thr Val Met 1 5 10 15 Lys Ile Cys Cys Gly Phe Cys Ser Xaa Xaa Ser Lys Ile Cys Met Asn 20 25 30 Xaa Xaa Gln Asn 35 108 321 DNA Conus consors 108 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcctc 60 acagctgatg actccagagg tacgcagaag catcgtgccc tgaggtcgga caccaaactc 120 tccatgtcga ctcgctgcaa aggtaaagga gcatcatgta caaggcttat gtatgactgc 180 tgccacggtt cttgcagcag cagcaagggt agatgtggct gatccggcgc ctgatcttcc 240 cccttctgtg ctctatcctt ttctgcctga gtcctcctta cctgagaggt ggtcatgaac 300 cactcatcac ctgctcccct g 321 109 73 PRT Conus consors 109 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Leu Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Ala Ser Cys Thr Arg Leu Met Tyr Asp Cys Cys His Gly Ser 50 55 60 Cys Ser Ser Ser Lys Gly Arg Cys Gly 65 70 110 27 PRT Conus consors PEPTIDE (1)..(27) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 110 Cys Lys Gly Lys Gly Ala Ser Cys Thr Arg Leu Met Xaa Asp Cys Cys 1 5 10 15 His Gly Ser Cys Ser Ser Ser Lys Gly Arg Cys 20 25 111 292 DNA Conus consors 111 ggatccatga aactgacgtg catggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc gtgccctgag gtcggacacc 120 aaactctcca tgtcaactcg ctgcaagggt aaaggagcat catgtcatag gacttcgtat 180 gactgctgca ccggttcttg caacagaggt aaatgtggct gatccggcgc ctgatcttcc 240 cccttctgtg ctctatcctt ttctgcctga gtcatccata cctgtgctcg ag 292 112 71 PRT Conus consors 112 Met Lys Leu Thr Cys Met Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Ala Ser Cys His Arg Thr Ser Tyr Asp Cys Cys Thr Gly Ser 50 55 60 Cys Asn Arg Gly Lys Cys Gly 65 70 113 25 PRT Conus consors PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 113 Cys Lys Gly Lys Gly Ala Ser Cys His Arg Thr Ser Xaa Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Asn Arg Gly Lys Cys 20 25 114 299 DNA Conus consors 114 ggatccatga aactgacgtg cgtggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc gtgccctgaa gtcggacacc 120 aaactctcca tgttaacttt gcgctgcgca tcttacggaa aaccttgtgg tatttacaac 180 gactgctgca atacatgcga tccagccaga aagacatgta cgtagctgat ccggcgtctg 240 atcttccccc ttctgtgctc tatccttttc tgcctgagtc atccatacct gtgctcgag 299 115 72 PRT Conus consors 115 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Lys Ser Asp Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Ala 35 40 45 Ser Tyr Gly Lys Pro Cys Gly Ile Tyr Asn Asp Cys Cys Asn Thr Cys 50 55 60 Asp Pro Ala Arg Lys Thr Cys Thr 65 70 116 26 PRT Conus consors PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 and 11 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 116 Cys Ala Ser Xaa Gly Lys Xaa Cys Gly Ile Xaa Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Xaa Ala Arg Lys Thr Cys Thr 20 25 117 434 DNA Conus consors misc_feature (1)..(434) n may be any nucleotide 117 ggatccatga aactgacgtg tgtggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc gtgccctgag gtcggacacc 120 aaactctcca tgtcgactcg ctgcaagggt acaggaaaac catgcagtag ggttgcgtat 180 aactgctgca ccggttcttg cagatcaggt aaatgtggct gatccagtgc ctgatcttcc 240 cccttctgtg ctctatcctt ttctgcctga gtcctcctta cctgagagtg gtcatgaacc 300 actcatcacc tgctcctctg gaggcttcag aggagctaca ttgaaataaa agccgcattg 360 cantgnanaa aannnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnggaaaaaa 420 aaaaaaaaaa aaaa 434 118 71 PRT Conus consors 118 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Thr Gly Lys Pro Cys Ser Arg Val Ala Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Arg Ser Gly Lys Cys Gly 65 70 119 25 PRT Conus consors PEPTIDE (1)..(25) Xaa at residue 7 is Pro or Hyp; Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo- Tyr, O-sulpho-Tyr or O-phospho-Tyr 119 Cys Lys Gly Thr Gly Lys Xaa Cys Ser Arg Val Ala Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 120 393 DNA Conus consors 120 ggatccatga aactgacgtg catggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc gttccctgag gtcgaccacc 120 aaagtctcca agtcgactag ctgcatgaaa gccgggtctt attgccgctc tactacgaga 180 acctgctgcg gttattgcgc ttatttcggc aaattttgta ttgactttcc cagcaactga 240 tcttccccct actgtgctct atccttttct gcctctgcct gagtcctcct tacctgagag 300 tggtcatgaa ccactcatca cctgctcccc tggaggcctc agaggagcta caatgaaata 360 aaagccgcat tgcaaaaaaa aaaaaaaaaa aaa 393 121 77 PRT Conus consors 121 Met Lys Leu Thr Cys Met Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Arg Ser Thr Thr Lys Val Ser Lys Ser Thr Ser Cys Met Lys 35 40 45 Ala Gly Ser Tyr Cys Arg Ser Thr Thr Arg Thr Cys Cys Gly Tyr Cys 50 55 60 Ala Tyr Phe Gly Lys Phe Cys Ile Asp Phe Pro Ser Asn 65 70 75 122 35 PRT Conus consors PEPTIDE (1)..(35) Xaa at residue 33 is Pro or Hyp; Xaa at residue 10, 21 and 24 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 122 Ser Thr Ser Cys Met Lys Ala Gly Ser Xaa Cys Arg Ser Thr Thr Arg 1 5 10 15 Thr Cys Cys Gly Xaa Cys Ala Xaa Phe Gly Lys Phe Cys Ile Asp Phe 20 25 30 Xaa Ser Asn 35 123 361 DNA Conus dalli 123 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgttcctg 60 acggcctgtc aactcatcac agctgatgac tccagaagta cgcagaagca tcgtgctctg 120 aggtcgacca tcaaacactc catgttgact aggagctgca cgcctcccgg aggaccttgt 180 ggttattata atgactgctg cagtcatcaa tgcaatataa gcagaaataa atgcgagtag 240 ctgatccggc atctgatctt ccccttctgt gctcgtccta acctgagagt ggtcatgaac 300 catcatcacc tactcctctg gaggcttcag aggagctaca tggaaataaa agccgcattg 360 c 361 124 73 PRT Conus dalli 124 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Ser Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Ile Lys His Ser Met Leu Thr Arg Ser Cys Thr 35 40 45 Pro Pro Gly Gly Pro Cys Gly Tyr Tyr Asn Asp Cys Cys Ser His Gln 50 55 60 Cys Asn Ile Ser Arg Asn Lys Cys Glu 65 70 125 28 PRT Conus dalli PEPTIDE (1)..(28) Xaa at residue 28 is Glu or gamma-carboxy Glu; Xaa at residue 4, 5 and 8 is Pro or Hyp; Xaa at residue 11 and 12 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 125 Ser Cys Thr Xaa Xaa Gly Gly Xaa Cys Gly Xaa Xaa Asn Asp Cys Cys 1 5 10 15 Ser His Gln Cys Asn Ile Ser Arg Asn Lys Cys Xaa 20 25 126 350 DNA Conus distans 126 accaaaacca tcatcaaaat gaaactgacg tgcgtgttga tcatcgccgt gctgttcctg 60 acggcctgtc aactcactag aggaaagctg gagcgtcctg ttctgaggtc gagcgaccaa 120 acctccgggt caacgaagag atgcgaagat cctggtgaac cttgcggaag tgatcattcc 180 tgctgcggcg gtagttgcaa ccacaacgtc tgcgcctgaa gctggtctgg catctgacca 240 ttccccttct gtactctatc tctattgcct gagtcatctt tacctgtgag tggtcatgaa 300 tctctcaata ccttctcccc tggaggcttc agaagaacta gattgaaata 350 127 66 PRT Conus distans 127 Met Lys Leu Thr Cys Val Leu Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Thr Arg Gly Lys Leu Glu Arg Pro Val Leu Arg Ser Ser 20 25 30 Asp Gln Thr Ser Gly Ser Thr Lys Arg Cys Glu Asp Pro Gly Glu Pro 35 40 45 Cys Gly Ser Asp His Ser Cys Cys Gly Gly Ser Cys Asn His Asn Val 50 55 60 Cys Ala 65 128 25 PRT Conus distans PEPTIDE (1)..(25) Xaa at residue 2 and 6 is Glu or gamma-carboxy Glu; Xaa at residue 4 and 7 is Pro or Hyp 128 Cys Xaa Asp Xaa Gly Xaa Xaa Cys Gly Ser Asp His Ser Cys Cys Gly 1 5 10 15 Gly Ser Cys Asn His Asn Val Cys Ala 20 25 129 309 DNA Conus ermineus 129 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcatc 60 acagctgacg actccagacg tacgcagaag catcgtgccc tgaggtcgac caccaaacgc 120 gccacgtcga atcgcccctg caagccgaaa ggacgaaaat gttttccgca tcagaaggac 180 tgctgcaata aaacgtgcac cagatcaaaa tgtccctgat cttccccctt ctgtgctgta 240 tccttttctg cctgagtcct ccttacctga gagtggtcag taaccactca tcaccatctc 300 ctctggagg 309 130 72 PRT Conus ermineus 130 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Arg Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Arg Ala Thr Ser Asn Arg Pro Cys Lys 35 40 45 Pro Lys Gly Arg Lys Cys Phe Pro His Gln Lys Asp Cys Cys Asn Lys 50 55 60 Thr Cys Thr Arg Ser Lys Cys Pro 65 70 131 27 PRT Conus ermineus PEPTIDE (1)..(27) Xaa at residue 1, 4, 11 and 27 is Pro or Hyp 131 Xaa Xaa Lys Xaa Lys Gly Arg Lys Cys Phe Xaa His Gln Lys Asp Cys 1 5 10 15 Cys Asn Lys Thr Cys Thr Arg Ser Lys Cys Xaa 20 25 132 308 DNA Conus ermineus 132 aactcatcac agctgatgac tccagaggta cgcagaacga tcgtgccctg aggtcgacca 60 ccaaactctc catgctgact cgggcctgct ggtcttccgg aacaccttgt ggtactgata 120 gtttatgctg cggtggatgc aatgtatcca aaagtaaatg taactagctg attcggcgtc 180 tgaacttccc ccttctgtgc tctatccttt tctgcccgag tcctccatac ctgagaatgg 240 tcatgaacca ctcatcacct actcctctgg agacctcaga agagctacac tgaaataaaa 300 gcgcttgc 308 133 54 PRT Conus ermineus 133 Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Asn Asp Arg Ala Leu 1 5 10 15 Arg Ser Thr Thr Lys Leu Ser Met Leu Thr Arg Ala Cys Trp Ser Ser 20 25 30 Gly Thr Pro Cys Gly Thr Asp Ser Leu Cys Cys Gly Gly Cys Asn Val 35 40 45 Ser Lys Ser Lys Cys Asn 50 134 27 PRT Conus ermineus PEPTIDE (1)..(27) Xaa at 8 residue is Pro or Hyp; Xaa at residue 3 is Trp or Bromo-Trp 134 Ala Cys Xaa Ser Ser Gly Thr Xaa Cys Gly Thr Asp Ser Leu Cys Cys 1 5 10 15 Gly Gly Cys Asn Val Ser Lys Ser Lys Cys Asn 20 25 135 385 DNA Conus geographus 135 ggatccatga aactgacgtg cgtggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc gtgccctggg gtcgaccacc 120 gaactctcct tgtcgactcg ctgcaagtca cccggatctt catgttcacc gactagttat 180 aattgctgca ggtcttgcaa tccatacgcc aaaagatgtt acggctaatc cagcgcctga 240 tcttccccct tctgtgctct atcccttcct gtctgagtcc tccttacctg agagtggtca 300 tgaaccactc ctcacctact tctctggagg cttcggagga gctacattga aataaaagcc 360 gcattgtaaa aaaaaaaaaa aaaaa 385 136 73 PRT Conus geographus 136 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Gly Ser Thr Thr Glu Leu Ser Leu Ser Thr Arg Cys Lys Ser 35 40 45 Pro Gly Ser Ser Cys Ser Pro Thr Ser Tyr Asn Cys Cys Arg Ser Cys 50 55 60 Asn Pro Tyr Ala Lys Arg Cys Tyr Gly 65 70 137 27 PRT Conus geographus PEPTIDE (1)..(27) Xaa at residue 4, 10 and 21 is Pro or Hyp; Xaa at residue 13, 22 and 27 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 137 Cys Lys Ser Xaa Gly Ser Ser Cys Ser Xaa Thr Ser Xaa Asn Cys Cys 1 5 10 15 Arg Ser Cys Asn Xaa Xaa Ala Lys Arg Cys Xaa 20 25 138 396 DNA Conus geographus 138 ggatccatga aactgacgtg tgtggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg cagaagcatc gtgccctgag gtcgtccacc 120 aaactcacct tgtcgactcg ctgcaaatca cccggaactc catgttcaag gggtatgcgt 180 gattgctgca cgccttgctt gttatacagc aacaaatgta ggcgctacta acccagcgcc 240 tgatcttccc ccttctgtgc tctattcctt tctgcctgag tcctccttac ctgaaagtgg 300 tcatgaacca ctcatcacct acttctctgg aggcttcaga agagctacat tgaaataaaa 360 gccgcattgc aatgacaaaa aaaaaaaaaa aaaaaa 396 139 74 PRT Conus geographus 139 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Ser Thr Lys Leu Thr Leu Ser Thr Arg Cys Lys Ser 35 40 45 Pro Gly Thr Pro Cys Ser Arg Gly Met Arg Asp Cys Cys Thr Pro Cys 50 55 60 Leu Leu Tyr Ser Asn Lys Cys Arg Arg Tyr 65 70 140 29 PRT Conus geographus PEPTIDE (1)..(29) Xaa at residue 4, 7 and 18 is Pro or Hyp; Xaa at residue 22 and 29 is Tyr, 125I-Tyr, mono- iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O- phospho-Tyr 140 Cys Lys Ser Xaa Gly Thr Xaa Cys Ser Arg Gly Met Arg Asp Cys Cys 1 5 10 15 Thr Xaa Cys Leu Leu Xaa Ser Asn Lys Cys Arg Arg Xaa 20 25 141 407 DNA Conus geographus 141 ggaattccgt ttctgcgctg cttcctttgg catcaccaaa accatcatca aaatgaaact 60 gacgtgtgtg gtgatcgtcg ccgtgctgct cctgacggcc tgtcaactca tcacagctga 120 tgactccaga ggtacgcaga agcatcgtgc cctggggtcg accaccgaac tctccttgtc 180 gactcgctgc aagtcacccg gatcttcatg ttcaccgact agttataatt gctgcaggtc 240 ttgcaatcca tacaccaaaa gatgttacgg ctaatccagc gcctgatctt ccctgctctg 300 agtcctcctt acctgagagt ggtcatgaac cactcatcac ctacttctct aggcggttcg 360 gaggagctac attgaaataa aagccgcatt gcaaaaaaaa aaaaaaa 407 142 73 PRT Conus geographus 142 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Gly Ser Thr Thr Glu Leu Ser Leu Ser Thr Arg Cys Lys Ser 35 40 45 Pro Gly Ser Ser Cys Ser Pro Thr Ser Tyr Asn Cys Cys Arg Ser Cys 50 55 60 Asn Pro Tyr Thr Lys Arg Cys Tyr Gly 65 70 143 27 PRT Conus geographus PEPTIDE (1)..(27) Xaa at residue 4, 10 and 21 is Pro or Hyp; Xaa at residue 13, 22 and 27 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 143 Cys Lys Ser Xaa Gly Ser Ser Cys Ser Xaa Thr Ser Xaa Asn Cys Cys 1 5 10 15 Arg Ser Cys Asn Xaa Xaa Thr Lys Arg Cys Xaa 20 25 144 28 PRT Conus geographus PEPTIDE (1)..(28) Xaa at residue 4, 10 and 21 is Pro or Hyp; Xaa at residue 13, 22 and 27 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 144 Cys Lys Ser Xaa Gly Ser Ser Cys Ser Xaa Thr Ser Xaa Asn Cys Cys 1 5 10 15 Arg Ser Cys Asn Xaa Xaa Thr Lys Arg Cys Xaa Gly 20 25 145 26 PRT Conus geographus PEPTIDE (1)..(26) Xaa at residue 4, 10 and 21 is Pro or Hyp; Xaa at residue 13 and 22 is Tyr, 125I-Tyr, mono- iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O- phospho-Tyr 145 Cys Lys Ser Xaa Gly Ser Ser Cys Ser Xaa Thr Ser Xaa Asn Cys Cys 1 5 10 15 Arg Ser Cys Asn Xaa Xaa Thr Lys Arg Cys 20 25 146 314 DNA Conus geographus 146 catcacagct gatgactcca gaggtacgca gaagcatcgt gccctgaggt cgtccaccaa 60 actcaccttg tcgactcgct gcaaatcacc cggaactcca tgttcaaggg gtatgcgtga 120 ttgctgcacg tcttgcttgt tatacagcaa caaatgtagg cgctactaac ccagcgcctg 180 atcttccccc ttctgtgctc tattcctttc tgcctgagtc ctccttacct gaaagtggtc 240 atgaaccact catcacctac ttctctggag gcttcagaag agctacattg aaataaaagc 300 cgcattgcaa tgac 314 147 55 PRT Conus geographus 147 Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg Ala Leu Arg 1 5 10 15 Ser Ser Thr Lys Leu Thr Leu Ser Thr Arg Cys Lys Ser Pro Gly Thr 20 25 30 Pro Cys Ser Arg Gly Met Arg Asp Cys Cys Thr Ser Cys Leu Leu Tyr 35 40 45 Ser Asn Lys Cys Arg Arg Tyr 50 55 148 29 PRT Conus geographus PEPTIDE (1)..(29) Xaa at residue 4 and 7 is Pro or Hyp; Xaa at residue 22 and 29 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 148 Cys Lys Ser Xaa Gly Thr Xaa Cys Ser Arg Gly Met Arg Asp Cys Cys 1 5 10 15 Thr Ser Cys Leu Leu Xaa Ser Asn Lys Cys Arg Arg Xaa 20 25 149 29 PRT Conus geographus PEPTIDE (1)..(29) Xaa at residue 4 and 7 is Pro or Hyp; Xaa at residue 22 and 29 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 149 Cys Lys Ser Xaa Gly Thr Xaa Cys Ser Arg Gly Met Arg Asp Cys Cys 1 5 10 15 Thr Ser Cys Leu Ser Xaa Ser Asn Lys Cys Arg Arg Xaa 20 25 150 380 DNA Conus laterculatus 150 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac cgctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcgacca ccaatctctc catgctgact cggaagtgct ggccttccgg aagctattgt 180 cgtgcgaata gtaaatgctg cagtggatgc gatcggaaca gaaataaatg ttactagctg 240 attcggcgtc tgaacttcct ccttctgtgc tctatccttt tctgcccgag tcctccatac 300 ctgagagtgg tcatgaacca ctcaactcct actcctctgg aggcctcaga agagctacat 360 tgaaataaaa gccgcattgc 380 151 72 PRT Conus laterculatus 151 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Asn Leu Ser Met Leu Thr Arg Lys Cys Trp 35 40 45 Pro Ser Gly Ser Tyr Cys Arg Ala Asn Ser Lys Cys Cys Ser Gly Cys 50 55 60 Asp Arg Asn Arg Asn Lys Cys Tyr 65 70 152 27 PRT Conus laterculatus PEPTIDE (1)..(27) Xaa at residue 4 is Pro or Hyp; Xaa at residue 3 is Trp or Bromo-Trp; Xaa at residue 8 and 27 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 152 Lys Cys Xaa Xaa Ser Gly Ser Xaa Cys Arg Ala Asn Ser Lys Cys Cys 1 5 10 15 Ser Gly Cys Asp Arg Asn Arg Asn Lys Cys Xaa 20 25 153 367 DNA Conus laterculatus 153 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcgacca ccaaactctc catatcgact cgctgccttc ctcccggatc atattgtaag 180 gcgacaacgg aagtctgctg ctcttcttgc cttcaattcg ctcagatatg ttcgggttga 240 tcttccctct tctgtgctct atccttttct gcctgagtcc tccatacctg agaatggtca 300 tgaaccactc aacatctact cctctggagg cctcagaaga gctatattga aataaaagcc 360 gcattgc 367 154 73 PRT Conus laterculatus 154 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Ser Ile Ser Thr Arg Cys Leu Pro 35 40 45 Pro Gly Ser Tyr Cys Lys Ala Thr Thr Glu Val Cys Cys Ser Ser Cys 50 55 60 Leu Gln Phe Ala Gln Ile Cys Ser Gly 65 70 155 27 PRT Conus laterculatus PEPTIDE (1)..(27) Xaa at residue 13 is Glu or gamma-carboxy Glu; Xaa at residue 3 and 4 is Pro or Hyp; Xaa at residue 7 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 155 Cys Leu Xaa Xaa Gly Ser Xaa Cys Lys Ala Thr Thr Xaa Val Cys Cys 1 5 10 15 Ser Ser Cys Leu Gln Phe Ala Gln Ile Cys Ser 20 25 156 373 DNA Conus laterculatus 156 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcgacca ccaatctctc catgtcgact cgctgcaagt ctcccggatc atcatgtagc 180 gtgtctatgc gtaactgctg cacttcttgc aattcacgca ccaagaaatg tacgcgacgt 240 ggctgaactt cccccttctg tgctctatcc ttttctgccc gagtcctcca tacctgagag 300 tggtcatgaa ccactcaaca tctactcctc tggaggcctc agaagagcta tattgaaata 360 aaagccgcat tgc 373 157 75 PRT Conus laterculatus 157 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Asn Leu Ser Met Ser Thr Arg Cys Lys Ser 35 40 45 Pro Gly Ser Ser Cys Ser Val Ser Met Arg Asn Cys Cys Thr Ser Cys 50 55 60 Asn Ser Arg Thr Lys Lys Cys Thr Arg Arg Gly 65 70 75 158 29 PRT Conus laterculatus PEPTIDE (1)..(29) Xaa at residue 3 is Pro or Hyp 158 Cys Lys Ser Xaa Gly Ser Ser Cys Ser Val Ser Met Arg Asn Cys Cys 1 5 10 15 Thr Ser Cys Asn Ser Arg Thr Lys Lys Cys Thr Arg Arg 20 25 159 330 DNA Conus laterculatus 159 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcgacaa ccaaactctc catgctgact cggacctgct ggccttccgg aacagcttgt 180 ggtattgata gtaactgctg cagtggatgc aatgtatcca gaagtaaatg taactagctg 240 attcggcgtc taaacttcct ccttctgcct gagtcctcca tacctgagag tggtcatgaa 300 ccacatcatc acctcatctc tggaggcctc 330 160 72 PRT Conus laterculatus 160 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Ser Met Leu Thr Arg Thr Cys Trp 35 40 45 Pro Ser Gly Thr Ala Cys Gly Ile Asp Ser Asn Cys Cys Ser Gly Cys 50 55 60 Asn Val Ser Arg Ser Lys Cys Asn 65 70 161 27 PRT Conus laterculatus PEPTIDE (1)..(27) Xaa at residue 4 is Pro or Hyp; Xaa at residue 3 is Trp or Bromo-Trp 161 Thr Cys Xaa Xaa Ser Gly Thr Ala Cys Gly Ile Asp Ser Asn Cys Cys 1 5 10 15 Ser Gly Cys Asn Val Ser Arg Ser Lys Cys Asn 20 25 162 363 DNA Conus laterculatus 162 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcgacca ccaatctctc catgctgact cggaagtgct ggccttccgg aagctattgt 180 cgtgcgaata gtaaatgctg cagtggatgc gatcggaaca gaagtaaatg taactagctg 240 attcggcgtc taaacttcct ccttctgcct gagtcctcca tacctgagag tggtcatgaa 300 ccactcatca cctactcctc tggaggcctc aaaggagcta cattgaaata aaagccgcat 360 tgc 363 163 72 PRT Conus laterculatus 163 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Asn Leu Ser Met Leu Thr Arg Lys Cys Trp 35 40 45 Pro Ser Gly Ser Tyr Cys Arg Ala Asn Ser Lys Cys Cys Ser Gly Cys 50 55 60 Asp Arg Asn Arg Ser Lys Cys Asn 65 70 164 27 PRT Conus laterculatus PEPTIDE (1)..(27) Xaa at residue4 is Pro or Hyp; Xaa at residue 3 is Trp or Bromo-Trp; Xaa at residue 8 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho- Tyr or O-phospho-Tyr 164 Lys Cys Xaa Xaa Ser Gly Ser Xaa Cys Arg Ala Asn Ser Lys Cys Cys 1 5 10 15 Ser Gly Cys Asp Arg Asn Arg Ser Lys Cys Asn 20 25 165 391 DNA Conus leopardus misc_feature (1)..(391) n may be any nucleotide 165 atgaaactga cgtgtgtggt gatcgtagct gtgctgttcc tgacggcctg tcaactcact 60 acagctgaca tctccagagg tacgcggaag cgtcgtgctc tgaggtcgac caccaaactc 120 tccaggtcgc tctttgagtg cgcgccttcc ggtggacgtt gtggtttttt aaagtcctgc 180 tgcgaaggat attgcgatgg ggaaagcact tcatgtgtga gtggcccata cagcatctga 240 tcttcccgcc ttcagtgctc tatccttttc tgcctgagtc ctccatacct ctgagcggtc 300 atgaaccact caacacctac tcctctggag gcttcaggga actatattaa aataaagccg 360 cattgcaacg aaanaaaaaa aaaaaaaaaa a 391 166 79 PRT Conus leopardus 166 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Thr Thr Ala Asp Ile Ser Arg Gly Thr Arg Lys Arg Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Ser Arg Ser Leu Phe Glu Cys Ala 35 40 45 Pro Ser Gly Gly Arg Cys Gly Phe Leu Lys Ser Cys Cys Glu Gly Tyr 50 55 60 Cys Asp Gly Glu Ser Thr Ser Cys Val Ser Gly Pro Tyr Ser Ile 65 70 75 167 37 PRT Conus leopardus PEPTIDE (1)..(37) Xaa at residue 4, 20 and 26 is Glu or gamma- carboxy Glu; Xaa at residue 7 and 34 is Pro or Hyp; Xaa at residue 22 and 35 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho- Tyr or O-phospho-Tyr 167 Ser Leu Phe Xaa Cys Ala Xaa Ser Gly Gly Arg Cys Gly Phe Leu Lys 1 5 10 15 Ser Cys Cys Xaa Gly Xaa Cys Asp Gly Xaa Ser Thr Ser Cys Val Ser 20 25 30 Gly Xaa Xaa Ser Ile 35 168 365 DNA Conus leopardus 168 atgaaactga cgtgtgtggt gatcgtcgct gtgctgttcc tgacggcctg tcaactcact 60 acagctgaca tctccagagg tacgtggaag catcgtggtg tggggtcgac caccggactc 120 tccccgtggc ccttggactg cacggctccc agtcaacctt gtggttattt tcctaggtgc 180 tgtggacatt gcgatgtacg cagggtatgt acgagtggct gatccggcgt ctgatctttc 240 cgccttctgt gctgtatcct tttctgcctg agtcctccat acccgtgagt ggtcatgaac 300 cactcaacac ctactcctct ggaggcttca gaggaactat attaaaataa agccgcattg 360 caatg 365 169 73 PRT Conus leopardus 169 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Thr Thr Ala Asp Ile Ser Arg Gly Thr Trp Lys His Arg 20 25 30 Gly Val Gly Ser Thr Thr Gly Leu Ser Pro Trp Pro Leu Asp Cys Thr 35 40 45 Ala Pro Ser Gln Pro Cys Gly Tyr Phe Pro Arg Cys Cys Gly His Cys 50 55 60 Asp Val Arg Arg Val Cys Thr Ser Gly 65 70 170 30 PRT Conus leopardus PEPTIDE (1)..(30) Xaa at residue 2, 8, 11 and 16 is Pro or Hyp; Xaa at residue 1 is Trp or Bromo-Trp; Xaa at residue 14 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 170 Xaa Xaa Leu Asp Cys Thr Ala Xaa Ser Gln Xaa Cys Gly Xaa Phe Xaa 1 5 10 15 Arg Cys Cys Gly His Cys Asp Val Arg Arg Val Cys Thr Ser 20 25 30 171 381 DNA Conus leopardus 171 atgaaactga cgtgtgtggt gatcgtcgct gtgctgttcc tgacggcctg tcaactcact 60 acagctgaca tctccagagg tacgcggaag catcgtgctc tgaggtcgac caccaaactc 120 tccaggtcgc cctctaggtg catgtctccc ggtggaattt gtggtgattt tggtgactgc 180 tgcgaaattt gcaatgtgta cggtatatgt gtgagtgact tacccggcat ctgatctttc 240 cgccttctgt gctctatcct tttctgcctg agtcctccat acccctgagt ggtcatggac 300 cactcaacac ctactcctct ggaggcttca gaggaactac attaaaataa agccgcattg 360 caaaaaaaaa aaaaaaaaaa a 381 172 77 PRT Conus leopardus 172 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Thr Thr Ala Asp Ile Ser Arg Gly Thr Arg Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Ser Arg Ser Pro Ser Arg Cys Met 35 40 45 Ser Pro Gly Gly Ile Cys Gly Asp Phe Gly Asp Cys Cys Glu Ile Cys 50 55 60 Asn Val Tyr Gly Ile Cys Val Ser Asp Leu Pro Gly Ile 65 70 75 173 31 PRT Conus leopardus PEPTIDE (1)..(31) Xaa at residue 16 is Glu or gamma-carboxy Glu; Xaa at residue 4 and 29 is Pro or Hyp; Xaa at residue 21 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 173 Cys Met Ser Xaa Gly Gly Ile Cys Gly Asp Phe Gly Asp Cys Cys Xaa 1 5 10 15 Ile Cys Asn Val Xaa Gly Ile Cys Val Ser Asp Leu Xaa Gly Ile 20 25 30 174 404 DNA Conus leopardus 174 atgaaactga cgtgtgtggt gatcgtcgct gtgctgttcc tgacggcctg tcaactcact 60 acagctgatg attccagagg tacacggaag catcgtgctc tgaggtcaac caccaaactc 120 tccaggtggc ccaggtactg cgcgcctccc ggtggagctt gtgggttttt tgatcactgc 180 tgcggatatt gcgaaacgtt ttacaatacg tgtagatgag ttggctgatc cggcgcttga 240 tctttccgcc ttctgttgct ctatcttttt ctgcctgagt cctcccatac cccgttgagt 300 ggtccatgaa ccactccaac acctactccc tccttggaag cttccaaagg aaacgacatt 360 taaaataaat tccccattgc aattggaaaa aaaaaaaaaa aaaa 404 175 72 PRT Conus leopardus 175 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Thr Thr Ala Asp Asp Ser Arg Gly Thr Arg Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Ser Arg Trp Pro Arg Tyr Cys Ala 35 40 45 Pro Pro Gly Gly Ala Cys Gly Phe Phe Asp His Cys Cys Gly Tyr Cys 50 55 60 Glu Thr Phe Tyr Asn Thr Cys Arg 65 70 176 27 PRT Conus leopardus PEPTIDE (1)..(27) Xaa at residue 20 is Glu or gamma-carboxy Glu; Xaa at residue 4 and 5 is Pro or Hyp; Xaa at residue 1, 18 and 23 is Tyr, 125I-Tyr, mono- iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O- phospho-Tyr 176 Xaa Cys Ala Xaa Xaa Gly Gly Ala Cys Gly Phe Phe Asp His Cys Cys 1 5 10 15 Gly Xaa Cys Xaa Thr Phe Xaa Asn Thr Cys Arg 20 25 177 292 DNA Conus lynceus 177 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcatc 60 acagctgatg actccagacg tacacagaag catcgtgccc tgaggtcgac caccaatctc 120 tccatgtcga ctcgctgcaa gtctcccgga tcaccatgta gtgtgacatc gtataactgc 180 tgcacttttt gctcttcata cactaagaaa tgtcgggcct ctttatgaac cactcatcac 240 ctactcctct ggaggcctca gaagagctac actgaaataa aagccgcatt gg 292 178 75 PRT Conus lynceus 178 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Arg Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Asn Leu Ser Met Ser Thr Arg Cys Lys Ser 35 40 45 Pro Gly Ser Pro Cys Ser Val Thr Ser Tyr Asn Cys Cys Thr Phe Cys 50 55 60 Ser Ser Tyr Thr Lys Lys Cys Arg Ala Ser Leu 65 70 75 179 30 PRT Conus lynceus PEPTIDE (1)..(30) Xaa at residue 4 and 7 is Pro or Hyp; Xaa at residue 13 and 22 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 179 Cys Lys Ser Xaa Gly Ser Xaa Cys Ser Val Thr Ser Xaa Asn Cys Cys 1 5 10 15 Thr Phe Cys Ser Ser Xaa Thr Lys Lys Cys Arg Ala Ser Leu 20 25 30 180 355 DNA Conus lynceus 180 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctcc tgacggcctg tcaactcatc 60 acagctgatg actccagagg tacgcagaag catcgtgccc tgaggtcgac caccaaacta 120 tccatgtata ctcgctgcgc aggtccagga gcaatttgtc ctaatagggt atgctgcggt 180 tattgcagta aaagaacaca tctatgtcat tcgcgaactg gctgatcttc ccccttctgt 240 gctctatcct ttttctgcct gagtcctcca tacctgagaa tggtcatgaa ccactcatca 300 cctactcctc ttggagacct cagaggagct acactgaaat aaaagccgca ttggc 355 181 74 PRT Conus lynceus 181 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Ser Met Tyr Thr Arg Cys Ala Gly 35 40 45 Pro Gly Ala Ile Cys Pro Asn Arg Val Cys Cys Gly Tyr Cys Ser Lys 50 55 60 Arg Thr His Leu Cys His Ser Arg Thr Gly 65 70 182 28 PRT Conus lynceus PEPTIDE (1)..(28) Xaa at residue 4 and 9 is Pro or Hyp; Xaa at residue 16 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 182 Cys Ala Gly Xaa Gly Ala Ile Cys Xaa Asn Arg Val Cys Cys Gly Xaa 1 5 10 15 Cys Ser Lys Arg Thr His Leu Cys His Ser Arg Thr 20 25 183 361 DNA Conus lynceus 183 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgctgc tagcggcctg tcaactacta 60 cacgctgatg actccagagg tacgcagaag actgctgccc gaggtcgacc accaaaactc 120 tccatgctga ctcgggcctg ctggtcttcc ggaacacctt gtggtactga tagtttatgc 180 tgcggtggat gcaatgtatc caaaagtaaa tgtaactagc tgattcggcg tctgaacttc 240 ccccttctgt gctctatcct tttctgcccg agtcctccat acctgagaat ggtcatgaac 300 cactcatcac ctactcctct ggagacctca gaagagctac actgaaataa aagcgcattg 360 c 361 184 72 PRT Conus lynceus 184 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Ala Ala 1 5 10 15 Cys Gln Leu Leu His Ala Asp Asp Ser Arg Gly Thr Gln Lys Thr Ala 20 25 30 Ala Arg Gly Arg Pro Pro Lys Leu Ser Met Leu Thr Arg Ala Cys Trp 35 40 45 Ser Ser Gly Thr Pro Cys Gly Thr Asp Ser Leu Cys Cys Gly Gly Cys 50 55 60 Asn Val Ser Lys Ser Lys Cys Asn 65 70 185 27 PRT Conus lynceus PEPTIDE (1)..(27) Xaa at residue 8 is Pro or Hyp; Xaa at residue 3 is Trp or Bromo-Trp 185 Ala Cys Xaa Ser Ser Gly Thr Xaa Cys Gly Thr Asp Ser Leu Cys Cys 1 5 10 15 Gly Gly Cys Asn Val Ser Lys Ser Lys Cys Asn 20 25 186 364 DNA Conus lynceus 186 atgaaactga cgtgtgtggt gatcgtcgcc gagctactcc taacggcctg tcaactcatc 60 acagctgatg actccagagg tacgcagaag catcgtgccc tgaggtcgac caccaatctc 120 tccatgctga ctcggaagtg ctggtctccc ggaacctatt gtcgtgcgca tagtaaatgc 180 tgccgtggat gcgatcagaa cagaaataaa tgttactagc tgattcggcg tctgaacttc 240 ctccttctgt gctctatcct ttttctgcct gagtcctcca tacctgagaa tggtcatgaa 300 ccactcatca cctactcctc tggaggcctc agaggagcct acactgaaat aaaagccgca 360 ttgg 364 187 72 PRT Conus lynceus 187 Met Lys Leu Thr Cys Val Val Ile Val Ala Glu Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Asn Leu Ser Met Leu Thr Arg Lys Cys Trp 35 40 45 Ser Pro Gly Thr Tyr Cys Arg Ala His Ser Lys Cys Cys Arg Gly Cys 50 55 60 Asp Gln Asn Arg Asn Lys Cys Tyr 65 70 188 27 PRT Conus lynceus PEPTIDE (1)..(27) Xaa at residue 5 is Pro or Hyp; Xaa at residue 3 is Trp or Bromo-Trp; Xaa at residue 8 and 27 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 188 Lys Cys Xaa Ser Xaa Gly Thr Xaa Cys Arg Ala His Ser Lys Cys Cys 1 5 10 15 Arg Gly Cys Asp Gln Asn Arg Asn Lys Cys Xaa 20 25 189 318 DNA Conus magus 189 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcggaca ccaaactctc catgtcgact cgctgcaagg gtacaggaaa accatgcagt 180 aggattgcgt ataactgctg caccggttct tgcagatcag gtaaatgtgg ctgatccagt 240 gcctgatctt cccccttctg tgctctatcc tttttctgcc tgagtcctcc ttacctgaga 300 gtggtcatga accactca 318 190 71 PRT Conus magus 190 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Thr Gly Lys Pro Cys Ser Arg Ile Ala Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Arg Ser Gly Lys Cys Gly 65 70 191 25 PRT Conus magus PEPTIDE (1)..(25) Xaa at residue 7 is Pro or Hyp; Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo- Tyr, O-sulpho-Tyr or O-phospho-Tyr 191 Cys Lys Gly Thr Gly Lys Xaa Cys Ser Arg Ile Ala Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 192 259 DNA Conus magus 192 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aagtcggaca ccaaactctc catgttaact ttgcgctgcg catcttacgg aaaaccttgt 180 ggtatttaca acgactgctg caatacatgc gatccagcca gaaagacatg tacgtagctg 240 atccggcgtc tgatcttcc 259 193 72 PRT Conus magus 193 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Lys Ser Asp Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Ala 35 40 45 Ser Tyr Gly Lys Pro Cys Gly Ile Tyr Asn Asp Cys Cys Asn Thr Cys 50 55 60 Asp Pro Ala Arg Lys Thr Cys Thr 65 70 194 26 PRT Conus magus PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 and 11 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 194 Cys Ala Ser Xaa Gly Lys Xaa Cys Gly Ile Xaa Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Xaa Ala Arg Lys Thr Cys Thr 20 25 195 254 DNA Conus magus 195 gaattttcag catcaccaaa accatcatca aaatgaaact gacgtgtgtg gtgatcgtcg 60 ccgtgctgct cctgacggcc tgtcaactca tcacagctga tgactccaga ggtacgcaga 120 agcatcgtgc cctgaggtcg gacaccaaac tctccatgtc aactcgctgc aagggtaaag 180 gagcatcatg tcataggact tcgtatgact gctgcaccgg ttcttgcaac agaggtaaat 240 ttggctgatc cgcc 254 196 71 PRT Conus magus 196 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Ala Ser Cys His Arg Thr Ser Tyr Asp Cys Cys Thr Gly Ser 50 55 60 Cys Asn Arg Gly Lys Phe Gly 65 70 197 25 PRT Conus magus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 197 Cys Lys Gly Lys Gly Ala Ser Cys His Arg Thr Ser Xaa Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Asn Arg Gly Lys Cys 20 25 198 358 DNA Conus miles 198 ggatccatga aactgacgtg cgtggtgatc atcgccatgc tgttcctgac agcctatcaa 60 ctcgctacag ctgcgagcta cgccaaaggt aaacagaagc atcgtgctct gaggccagct 120 gacaaacacc tcaggttgac caagcgttgc aatgatcgcg gtggaggttg cagtcaacat 180 cctcactgct gcggtggaac ttgcaataag cttattggcg tatgtctgta aagctggtct 240 gccgtctgat attccctttc tgtgcttcat cctcttttgc ctgagtcatc catacctgtg 300 aatggttaag agccactcaa tacctattcc tctgggggct tcagaggaac tactttac 358 199 74 PRT Conus miles 199 Met Lys Leu Thr Cys Val Val Ile Ile Ala Met Leu Phe Leu Thr Ala 1 5 10 15 Tyr Gln Leu Ala Thr Ala Ala Ser Tyr Ala Lys Gly Lys Gln Lys His 20 25 30 Arg Ala Leu Arg Pro Ala Asp Lys His Leu Arg Leu Thr Lys Arg Cys 35 40 45 Asn Asp Arg Gly Gly Gly Cys Ser Gln His Pro His Cys Cys Gly Gly 50 55 60 Thr Cys Asn Lys Leu Ile Gly Val Cys Leu 65 70 200 27 PRT Conus arenatus PEPTIDE (1)..(27) Xaa at residue 12 is Pro or Hyp 200 Cys Asn Asp Arg Gly Gly Gly Cys Ser Gln His Xaa His Cys Cys Gly 1 5 10 15 Gly Thr Cys Asn Lys Leu Ile Gly Val Cys Leu 20 25 201 292 DNA Conus monachus 201 accaaaacca tcatcaaaat gaaactgacg agtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcggaca ccaaactctc catatcgact cgctgcaagt ctacaggaaa atcatgcagt 180 aggattgcgt ataactgctg caccggttct tgcagatcag gtaaatgtgg ctgatccagc 240 gcctgatctt cccccttctg tgctctatcc ttttctgcct gagtcctcct ta 292 202 71 PRT Conus monachus 202 Met Lys Leu Thr Ser Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Ile Ser Thr Arg Cys Lys Ser 35 40 45 Thr Gly Lys Ser Cys Ser Arg Ile Ala Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Arg Ser Gly Lys Cys Gly 65 70 203 25 PRT Conus monachus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 203 Cys Lys Ser Thr Gly Lys Ser Cys Ser Arg Ile Ala Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 204 258 DNA Conus monachus 204 accaaaacca tcatcaaaat gaaactgacg agtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcggaca ccaacctctc catgtcgact cgctgcaagg gtaaaggatc ttcatgtagt 180 aggaccatgt ataactgctg caccggttct tgcaacagag gtaaatgtgg ctgatccagc 240 gcctgatctt cccccttc 258 205 71 PRT Conus monachus 205 Met Lys Leu Thr Ser Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Asn Leu Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Ser Ser Cys Ser Arg Thr Met Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Asn Arg Gly Lys Cys Gly 65 70 206 25 PRT Conus monachus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 206 Cys Lys Gly Lys Gly Ser Ser Cys Ser Arg Thr Met Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Asn Arg Gly Lys Cys 20 25 207 258 DNA Conus obscurus 207 ctctctctct ctctgctgga caggtcgcct ccctgcatga aaggcggatc gtcatgccgc 60 ggtactacgg gagtctgttg cggtttttgc agtgatttcg gctataaatg tagggactat 120 ccccaaaact gatcttcccc cttctgtgct ctatcctttt ctgtccgagt cctcctgacc 180 tgagagtggt catgaaccac tcatcaccta cccctctggg gcttcacagg atctacattg 240 aaataaaagc cgcattgc 258 208 39 PRT Conus obscurus 208 Leu Leu Asp Arg Ser Pro Pro Cys Met Lys Gly Gly Ser Ser Cys Arg 1 5 10 15 Gly Thr Thr Gly Val Cys Cys Gly Phe Cys Ser Asp Phe Gly Tyr Lys 20 25 30 Cys Arg Asp Tyr Pro Gln Asn 35 209 35 PRT Conus obscurus PEPTIDE (1)..(35) Xaa at residue 2, 3 and 33 is Pro or Hyp; Xaa at residue 27 and 32 is Tyr, 125I-Tyr, mono- iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O- phospho-Tyr 209 Ser Xaa Xaa Cys Met Lys Gly Gly Ser Ser Cys Arg Gly Thr Thr Gly 1 5 10 15 Val Cys Cys Gly Phe Cys Ser Asp Phe Gly Xaa Lys Cys Arg Asp Xaa 20 25 30 Xaa Gln Asn 35 210 259 DNA Conus obscurus 210 ctctctctct ctctgctgga caggtcgact cgctgcttgc ctgacggaac gtcttgcctt 60 tttagtagga tcagatgctg cggtacttgc agttcaatct taaagtcatg tgtgagctga 120 tccagcggtt gatcttcctc cctctgtgct ccatcctttt ctgcctgagt tctccttacc 180 tgagagtggt catgaaccac tcatcaccta ctcttctgga ggcttcagag gagctacatt 240 gaaataaaag ccgcattgc 259 211 32 PRT Conus obscurus 211 Arg Ser Thr Arg Cys Leu Pro Asp Gly Thr Ser Cys Leu Phe Ser Arg 1 5 10 15 Ile Arg Cys Cys Gly Thr Cys Ser Ser Ile Leu Lys Ser Cys Val Ser 20 25 30 212 28 PRT Conus monachus PEPTIDE (1)..(28) Xaa at residue 3 is Pro or Hyp 212 Cys Leu Xaa Asp Gly Thr Ser Cys Leu Phe Ser Arg Ile Arg Cys Cys 1 5 10 15 Gly Thr Cys Ser Ser Ile Leu Lys Ser Cys Val Ser 20 25 213 330 DNA Conus pulicarius misc_feature (1)..(330) n may be any nucleotide 213 atgaaactga cgtgtgtggt gatcatcgcc gtgctgttcc tgacggcctg tcaactcatt 60 acagctgaga cttactccag aggtaagcag aagcaccgtg ctttgaggtc aactgacaaa 120 aactccaagt tgactaggca gtgctcgcct aacggtggat cttgttctcg tcattttcac 180 tgctgcagcc tctattgcaa taaaaatact ggcgtatgta ttgcaaccta atacccgtgt 240 gtggtcatga accactcaat accctctcct ctggaggctt cagaggaact gcattgaaat 300 aaaactgcat tgcnttgacc aaaaaaaaaa 330 214 76 PRT Conus pulicarius 214 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Lys Gln Lys His 20 25 30 Arg Ala Leu Arg Ser Thr Asp Lys Asn Ser Lys Leu Thr Arg Gln Cys 35 40 45 Ser Pro Asn Gly Gly Ser Cys Ser Arg His Phe His Cys Cys Ser Leu 50 55 60 Tyr Cys Asn Lys Asn Thr Gly Val Cys Ile Ala Thr 65 70 75 215 30 PRT Conus pulicarius PEPTIDE (1)..(30) Xaa at residue 1 is Gln or pyro-Glu; Xaa at residue 4 is Pro or Hyp; Xaa at residue 19 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 215 Xaa Cys Ser Xaa Asn Gly Gly Ser Cys Ser Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Xaa Cys Asn Lys Asn Thr Gly Val Cys Ile Ala Thr 20 25 30 216 282 DNA Conus purpurascens 216 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgttcc tgacggcctg tcaactcatc 60 acagctgatg actccagacg tacgcagaag catcgtgccc tgaggtcgac caccaaaggc 120 gccacgtcga atcgcccctg caagacaccc ggacgaaaat gttttccgca tcagaaggac 180 tgctgcggtc gagcgtgcat catcacaata tgtccctgat cttccccctt ctgtgctgta 240 tccttttctg cctgagtctc cttacctgag agtggtcatg aa 282 217 72 PRT Conus purpurascens 217 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Arg Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Gly Ala Thr Ser Asn Arg Pro Cys Lys 35 40 45 Thr Pro Gly Arg Lys Cys Phe Pro His Gln Lys Asp Cys Cys Gly Arg 50 55 60 Ala Cys Ile Ile Thr Ile Cys Pro 65 70 218 27 PRT Conus purpurascens PEPTIDE (1)..(27) Xaa at residue 1, 5, 11 and 27 is Pro or Hyp 218 Xaa Cys Lys Thr Xaa Gly Arg Lys Cys Phe Xaa His Gln Lys Asp Cys 1 5 10 15 Cys Gly Arg Ala Cys Ile Ile Thr Ile Cys Xaa 20 25 219 340 DNA Conus purpurascens 219 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcgacca ccaaactctt cacgtcgaaa agctgcaagc ttcccggagc atattgtaat 180 gcagaagatt atgactgctg ccttagatgc aaagttggag gtacatgtgg ctgatccagt 240 gcctgatctt cccccttctg tgctctatcc ttttctgcct gagtcctcct tacctaagag 300 tggtcatgaa ccactcatca ccttctcctc tggaggcttc 340 220 71 PRT Conus purpurascens 220 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Leu Phe Thr Ser Lys Ser Cys Lys Leu 35 40 45 Pro Gly Ala Tyr Cys Asn Ala Glu Asp Tyr Asp Cys Cys Leu Arg Cys 50 55 60 Lys Val Gly Gly Thr Cys Gly 65 70 221 26 PRT Conus purpurascens PEPTIDE (1)..(26) Xaa at residue 12 is Glu or gamma-carboxy Glu; Xaa at residue 5 is Pro or Hyp; Xaa at residue 8 and 14 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 221 Ser Cys Lys Leu Xaa Gly Ala Xaa Cys Asn Ala Xaa Asp Xaa Asp Cys 1 5 10 15 Cys Leu Arg Cys Lys Val Gly Gly Thr Cys 20 25 222 317 DNA Conus purpurascens 222 atgaaactga cgtgtgtggt gatcgtcgcc gtgctgttcc tgacggcctg tcaactcatc 60 acagctgatg actccagacg tacgcagaag catcgtgccc tgaggtcgac caccaaacgc 120 gccacgtcga atcgcccctg caagaaaacc ggacgaaaat gttttccgca tcagaaggac 180 tgctgcggtc gagcgtgcat catcacaata tgtccctgat cttccccctt ctgtgctgta 240 tccttttctg cctgagtcct ccttacctga gagtggtcat gaaccactca tcaccttctc 300 ctctggaggc ttcagag 317 223 72 PRT Conus purpurascens 223 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Arg Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys Arg Ala Thr Ser Asn Arg Pro Cys Lys 35 40 45 Lys Thr Gly Arg Lys Cys Phe Pro His Gln Lys Asp Cys Cys Gly Arg 50 55 60 Ala Cys Ile Ile Thr Ile Cys Pro 65 70 224 27 PRT Conus purpurascens PEPTIDE (1)..(27) Xaa at residue 1, 11 and 27 is Pro or Hyp 224 Xaa Cys Lys Lys Thr Gly Arg Lys Cys Phe Xaa His Gln Lys Asp Cys 1 5 10 15 Cys Gly Arg Ala Cys Ile Ile Thr Ile Cys Xaa 20 25 225 328 DNA Conus radiatus 225 gctgatgcct gatcttcatc gttcttccct gtctcctttg gcatcaccaa aaccatcatc 60 aaaatgaaac tgacgtgtgt ggtgatcgtc gccgtgctgg tcctgacggc ctgtcaactc 120 atcacagctg atgactccag aggtatgcag aaacatcatg ccctggggtc gatcagcagt 180 ctctttaagt cgacccgtca tggctgcaaa cccctcaaac gtcgttgttt caatgataaa 240 gaatgctgca gcaaattttg caattcagtc cgaaagcagt gtggataaat ggctaaaaaa 300 ctgaataaaa gccgcattgc aaaaaaaa 328 226 74 PRT Conus radiatus 226 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Val Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Met Gln Lys His His 20 25 30 Ala Leu Gly Ser Ile Ser Ser Leu Phe Lys Ser Thr Arg His Gly Cys 35 40 45 Lys Pro Leu Lys Arg Arg Cys Phe Asn Asp Lys Glu Cys Cys Ser Lys 50 55 60 Phe Cys Asn Ser Val Arg Lys Gln Cys Gly 65 70 227 28 PRT Conus radiatus PEPTIDE (1)..(28) Xaa at residue 15 is Glu or gamma-carboxy Glu; Xaa at residue 5 is Pro or Hyp 227 His Gly Cys Lys Xaa Leu Lys Arg Arg Cys Phe Asn Asp Lys Xaa Cys 1 5 10 15 Cys Ser Lys Phe Cys Asn Ser Val Arg Lys Gln Cys 20 25 228 250 DNA Conus radiatus 228 gaaatgaaac tgacgtgtgt ggtgatcgtc gccgtgctgg tcctgacggc ctgtcaactc 60 atcacagctg atgactccag aggtatgcag aaacatcatg ccctggggtc gatcagcagt 120 ctctttaagt cgacccgtcg tggctgcaaa cccctcaaac gtcgttgttt caatgataaa 180 gaatgctgca gcaaattttg caattcagtc cgaaaccagt gtggataaat ggctaaaaac 240 tgaataaaag 250 229 74 PRT Conus radiatus 229 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Val Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Met Gln Lys His His 20 25 30 Ala Leu Gly Ser Ile Ser Ser Leu Phe Lys Ser Thr Arg Arg Gly Cys 35 40 45 Lys Pro Leu Lys Arg Arg Cys Phe Asn Asp Lys Glu Cys Cys Ser Lys 50 55 60 Phe Cys Asn Ser Val Arg Asn Gln Cys Gly 65 70 230 28 PRT Conus radiatus PEPTIDE (1)..(28) Xaa at residue 15 is Glu or gamma-carboxy Glu; Xaa at residue 5 is Pro or Hyp 230 Arg Gly Cys Lys Xaa Leu Lys Arg Arg Cys Phe Asn Asp Lys Xaa Cys 1 5 10 15 Cys Ser Lys Phe Cys Asn Ser Val Arg Asn Gln Cys 20 25 231 435 DNA Conus radiatus 231 ggaattccgc ttgcacggcg aacctgactt catctttctt ccctgcctcc tttggcatca 60 ccaaaaccat catcaaaatg aaactgacgt gtgtggtgat cgtcgccgtg ctggtcctga 120 cggcctgtca actcatcaca gctgatgact ccagaggtat gcagaagcat catgccctga 180 ggtcgatcac caaactctcc ctgtcgactc gctgcaaacc tcccggatca ccatgtagag 240 tttcttcgta taactgctgc tcttcttgca aatcatacaa caagaaatgt ggctgaactt 300 ccccttctgt gctctatcct tttcctgccc gagtcctcca tacctgagag tagtcatgaa 360 ccactgatta cctactcctc tggagggcct cagaggagct actttgaaat aaaagcccgc 420 attgcaaaaa aaaaa 435 232 72 PRT Conus radiatus 232 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Val Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Met Gln Lys His His 20 25 30 Ala Leu Arg Ser Ile Thr Lys Leu Ser Leu Ser Thr Arg Cys Lys Pro 35 40 45 Pro Gly Ser Pro Cys Arg Val Ser Ser Tyr Asn Cys Cys Ser Ser Cys 50 55 60 Lys Ser Tyr Asn Lys Lys Cys Gly 65 70 233 27 PRT Conus radiatus PEPTIDE (1)..(27) Xaa at residue 3, 4 and 7 is Pro or Hyp; Xaa at residue 13 and 22 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 233 Cys Lys Xaa Xaa Gly Ser Xaa Cys Arg Val Ser Ser Xaa Asn Cys Cys 1 5 10 15 Ser Ser Cys Lys Ser Xaa Asn Lys Lys Cys Gly 20 25 234 392 DNA Conus rattus 234 ggatccatga aactgacgtg catggtgatc atcgccgtgc tgttcctgac agcctgtcaa 60 ttcgatacag ctgcgagcta cgacaaaggt aagcagaaac ctcctactct gaggccagct 120 gacaaacaca tcaggttgac caagcgttgc aatgctcgca atgatggttg cagtcaacat 180 tctcaatgct gcagtggatc ttgcaataag actgcaggcg tatgtctgta aagctggtct 240 gccgtctgat attccctttc tgtgctttat cctcttttgc ctgagtcatc catacctgtg 300 aatggttaag agccactcaa tacctactcc tctgggggct tcagaggaac tacattaaat 360 aaagccacat tgcaaaaaaa aaaaaaaaaa aa 392 235 74 PRT Conus rattus 235 Met Lys Leu Thr Cys Met Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Phe Asp Thr Ala Ala Ser Tyr Asp Lys Gly Lys Gln Lys Pro 20 25 30 Pro Thr Leu Arg Pro Ala Asp Lys His Ile Arg Leu Thr Lys Arg Cys 35 40 45 Asn Ala Arg Asn Asp Gly Cys Ser Gln His Ser Gln Cys Cys Ser Gly 50 55 60 Ser Cys Asn Lys Thr Ala Gly Val Cys Leu 65 70 236 27 PRT Conus rattus 236 Cys Asn Ala Arg Asn Asp Gly Cys Ser Gln His Ser Gln Cys Cys Ser 1 5 10 15 Gly Ser Cys Asn Lys Thr Ala Gly Val Cys Leu 20 25 237 395 DNA Conus rattus 237 ggatccatga aactgacgtg cgtggtgatc atcgccgtgc tgttcctgac agcctgtcaa 60 ctcgatgcag ctgcgagcta cgacaaaggt aagcagaaac ctcctactct gaggccagct 120 gacaaacact tcaggttgat caagcgttgc aatgctcgca atagtggttg cagtcaacat 180 cctcaatgct gcagtggatc ttgcaataag actgcaggcg tatgtctgta aagctggtct 240 gccgtctgat attccctttc tgtgctttat cctcttttgc ctgagtcatc catacctgtg 300 aatggttaag agccactcaa tacctactcc tctgggggct tcagaggaac tacattaaat 360 aaagccacat tgcaacgaaa aaaaaaaaaa aaaaa 395 238 74 PRT Conus rattus 238 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Asp Ala Ala Ala Ser Tyr Asp Lys Gly Lys Gln Lys Pro 20 25 30 Pro Thr Leu Arg Pro Ala Asp Lys His Phe Arg Leu Ile Lys Arg Cys 35 40 45 Asn Ala Arg Asn Ser Gly Cys Ser Gln His Pro Gln Cys Cys Ser Gly 50 55 60 Ser Cys Asn Lys Thr Ala Gly Val Cys Leu 65 70 239 27 PRT Conus rattus PEPTIDE (1)..(27) Xaa at residue 12 is Pro or Hyp 239 Cys Asn Ala Arg Asn Ser Gly Cys Ser Gln His Xaa Gln Cys Cys Ser 1 5 10 15 Gly Ser Cys Asn Lys Thr Ala Gly Val Cys Leu 20 25 240 390 DNA Conus rattus 240 ggatccatga aactgacgtg tgtggtgatc atcgccgtgc tgttcctgac agcctgtcaa 60 ttcgatacag ctgcgagcta cgacaaaggt aagcagaaac ctcctactct gaggccagct 120 gacaaacact tcaggttgat caagcgttgc aatgctcgca atagtggttg cagtcaacat 180 cctcaatgct gcagtggatc ttgcaataag actttgggcg tatgtctgta aagctggtct 240 gccgtctgat attccctttc tgtgctttat cctcttttgc ctgagtcatc catacctgtg 300 aatggttaag agccactcaa tacctactcc tctgggggct tcagaggaac tacattaaat 360 aaagccacat tgaaaaaaaa aaaaaaaaaa 390 241 74 PRT Conus rattus 241 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Phe Asp Thr Ala Ala Ser Tyr Asp Lys Gly Lys Gln Lys Pro 20 25 30 Pro Thr Leu Arg Pro Ala Asp Lys His Phe Arg Leu Ile Lys Arg Cys 35 40 45 Asn Ala Arg Asn Ser Gly Cys Ser Gln His Pro Gln Cys Cys Ser Gly 50 55 60 Ser Cys Asn Lys Thr Leu Gly Val Cys Leu 65 70 242 27 PRT Conus rattus PEPTIDE (1)..(27) Xaa at residue 12 is Pro or Hyp 242 Cys Asn Ala Arg Asn Ser Gly Cys Ser Gln His Xaa Gln Cys Cys Ser 1 5 10 15 Gly Ser Cys Asn Lys Thr Leu Gly Val Cys Leu 20 25 243 379 DNA Conus stercusmuscarum 243 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcgaaga ccaaactctc catgtcgact cgctgcaaga gtaaaggagc aaaatgttca 180 aggcttatgt atgactgctg cagcggttct tgcagcggct acacaggtag atgtggctga 240 tccagcgcct gatcttcccc cttctgtgct ctatcctttt ctgcctgggt cctccttacc 300 tgagagtggt catgaaccac tcatcaccta ctcctctgga ggcctcagag gagttacaat 360 gaaataaaag ccgcattgc 379 244 73 PRT Conus stercusmuscarum 244 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Lys Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Ser 35 40 45 Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys Ser Gly Ser 50 55 60 Cys Ser Gly Tyr Thr Gly Arg Cys Gly 65 70 245 27 PRT Conus stercusmuscarum PEPTIDE (1)..(27) Xaa at residue 13 and 23 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 245 Cys Lys Ser Lys Gly Ala Lys Cys Ser Arg Leu Met Xaa Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Ser Gly Xaa Thr Gly Arg Cys 20 25 246 35 PRT Conus stercusmuscarum PEPTIDE (1)..(35) Xaa at residue 33 is Pro or Hyp; Xaa at residue 10, 21, 24 and 32 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 246 Thr Thr Ser Cys Met Gln Ala Gly Ser Xaa Cys Gly Ser Thr Thr Arg 1 5 10 15 Ile Cys Cys Gly Xaa Cys Ala Xaa Phe Gly Lys Lys Cys Ile Asp Xaa 20 25 30 Xaa Ser Asn 35 247 380 DNA Conus stercusmuscarum 247 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acgacctgtc aactcatcac agctgatgac tccagaggta cgcaggagca tcgtgccctg 120 aggtcgaaga ccaaactctc catgttaact ttgcgctgcg catcttacgg aaaaccttgt 180 ggtattgaca acgactgctg caatgcatgc gatccagcca gaaatatatg tacgtagctg 240 atccggcgtc tgatcttccc ccttctgtgc tctatccttt tctgcctgag tcctccttac 300 ctgagagtgg tcatgaacca ctcatcatct actctcctgg aggcctcaga ggagctacaa 360 tgaaataaaa gccgcattgc 380 248 72 PRT Conus stercusmuscarum 248 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Thr 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Glu His Arg 20 25 30 Ala Leu Arg Ser Lys Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Ala 35 40 45 Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn Ala Cys 50 55 60 Asp Pro Ala Arg Asn Ile Cys Thr 65 70 249 26 PRT Conus stercusmuscarum PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 249 Cys Ala Ser Xaa Gly Lys Xaa Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Xaa Ala Arg Asn Ile Cys Thr 20 25 250 388 DNA Conus stercusmuscarum 250 ggatccatga aactgacgtg tgtggtgatt gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg caggagcatc gtgccctgag gtcgaagacc 120 aaactctcca tgttaacttt gcgctgcgta tcttacggaa aaccttgtgg tattgacaac 180 gactgctgca atgcatgcga tccagccaga aatatatgta cgtagctgat ccggcgtctg 240 atcttccccc ttctgtgctc tatccttttc tgcctgggtc ctccttacct gagagtggtc 300 atgaaccact catcacctac tcctctggag gcctcagagg agttacaatg aaataaaagc 360 cgcattgcaa aaaaaaaaaa aaaaaaaa 388 251 72 PRT Conus stercusmuscarum 251 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Glu His Arg 20 25 30 Ala Leu Arg Ser Lys Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Val 35 40 45 Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn Ala Cys 50 55 60 Asp Pro Ala Arg Asn Ile Cys Thr 65 70 252 26 PRT Conus stercusmuscarum PEPTIDE (1)..(26) Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 252 Cys Val Ser Xaa Gly Lys Xaa Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Xaa Ala Arg Asn Ile Cys Thr 20 25 253 264 DNA Conus striatus 253 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgttccctg 120 aggtcgacca ccaaagtctc caaggcgact gactgcattg aagccggaaa ttattgcgga 180 cctactgtta tgaaaatctg ctgcggcttt tgcagtccat acagcaaaat atgtatgaac 240 tatcccaaaa attgatcttc cccc 264 254 78 PRT Conus striatus 254 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Arg Ser Thr Thr Lys Val Ser Lys Ala Thr Asp Cys Ile Glu 35 40 45 Ala Gly Asn Tyr Cys Gly Pro Thr Val Met Lys Ile Cys Cys Gly Phe 50 55 60 Cys Ser Pro Tyr Ser Lys Ile Cys Met Asn Tyr Pro Lys Asn 65 70 75 255 36 PRT Conus striatus PEPTIDE (1)..(36) Xaa at residue 6 is Glu or gamma-carboxy Glu; Xaa at residue 13, 25 and 34 is Pro or Hyp; Xaa at residue 10, 26 and 33 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 255 Ala Thr Asp Cys Ile Xaa Ala Gly Asn Xaa Cys Gly Xaa Thr Val Met 1 5 10 15 Lys Ile Cys Cys Gly Phe Cys Ser Xaa Xaa Ser Lys Ile Cys Met Asn 20 25 30 Xaa Xaa Lys Asn 35 256 233 DNA Conus striatus 256 gtcgactcgc tgcaagctta aaggacaatc atgtcgtagg actatgtatg actgctgcag 60 cggttcttgc ggcaggagag gtaaatgtgg ctgatccagc gcctgatctc cccccttctg 120 tgctctatcc ttttctgcct gggtcctcct tacctgagag tggtcatgaa ccactcatca 180 cctactcctc tggaggcctc agaggagcta caatgaaata aaagccgcat tgc 233 257 30 PRT Conus striatus 257 Ser Thr Arg Cys Lys Leu Lys Gly Gln Ser Cys Arg Arg Thr Met Tyr 1 5 10 15 Asp Cys Cys Ser Gly Ser Cys Gly Arg Arg Gly Lys Cys Gly 20 25 30 258 26 PRT Conus striatus PEPTIDE (1)..(26) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 258 Cys Lys Leu Lys Gly Gln Ser Cys Arg Arg Thr Met Xaa Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Gly Arg Arg Gly Lys Cys 20 25 259 310 DNA Conus striatus 259 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcagaagca tcgtgccctg 120 aggtcggaca ccaaactctc catgtcgact cgctgcaagg ctgcaggaaa atcatgcagt 180 aggattgcgt ataactgctg caccggttct tgcagatcag gtaaatgcgg ctgatccagc 240 gcctgatctt cccccttctg tgctctatcc tttctgcctg agtcctctta cctgagagtg 300 gtcatgaacc 310 260 71 PRT Conus striatus 260 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Ala 35 40 45 Ala Gly Lys Ser Cys Ser Arg Ile Ala Tyr Asn Cys Cys Thr Gly Ser 50 55 60 Cys Arg Ser Gly Lys Cys Gly 65 70 261 25 PRT Conus striatus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 261 Cys Lys Ala Ala Gly Lys Ser Cys Ser Arg Ile Ala Xaa Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 262 256 DNA Conus striatus 262 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc aactcatcac agctgatgac tccagaggta cgcaggagca tcgtgccctg 120 aggtcggaca ccaaactctc catgttaact ttgcgctgcg aatcttacgg aaaaccttgt 180 ggtatttaca acgactgctg caatgcatgc gatccagcca aaaagacatg tacgtagctg 240 atccggcgtc tgatct 256 263 72 PRT Conus striatus 263 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Glu His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Leu Thr Leu Arg Cys Glu 35 40 45 Ser Tyr Gly Lys Pro Cys Gly Ile Tyr Asn Asp Cys Cys Asn Ala Cys 50 55 60 Asp Pro Ala Lys Lys Thr Cys Thr 65 70 264 26 PRT Conus striatus PEPTIDE (1)..(26) Xaa at residue 2 is Glu or gamma-carboxy Glu; Xaa at residue 7 and 20 is Pro or Hyp; Xaa at residue 4 and 11 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 264 Cys Xaa Ser Xaa Gly Lys Xaa Cys Gly Ile Xaa Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Xaa Ala Lys Lys Thr Cys Thr 20 25 265 229 DNA Conus striatus 265 tctaggtcct ccggcagccc ctgtggtgtt actagtatat gctgtggtag atgctatagg 60 ggtaaatgta cgtagctcat cgggcgtctg atcttccccc ttctgtgctc catccttttc 120 tgcctgagtc ctccttacct gagagtggtc gtgaaccact catcgcctac tcctctggag 180 gcttcagagg ggctacacta aaataaaagc tatattgcaa tgaaaaaaa 229 266 24 PRT Conus striatus 266 Cys Arg Ser Ser Gly Ser Pro Cys Gly Val Thr Ser Ile Cys Cys Gly 1 5 10 15 Arg Cys Tyr Arg Gly Lys Cys Thr 20 267 24 PRT Conus striatus PEPTIDE (1)..(24) Xaa at residue 7 is Pro or Hyp; Xaa at residue 19 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo- Tyr, O-sulpho-Tyr or O-phospho-Tyr 267 Cys Arg Ser Ser Gly Ser Xaa Cys Gly Val Thr Ser Ile Cys Cys Gly 1 5 10 15 Arg Cys Xaa Arg Gly Lys Cys Thr 20 268 26 PRT Conus striatus PEPTIDE (1)..(26) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O -sulpho-Tyr or O-phospho- Tyr 268 Cys Lys Leu Lys Gly Gln Ser Cys Arg Lys Thr Ser Xaa Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Gly Arg Ser Gly Lys Cys 20 25 269 292 DNA Conus striolatus 269 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgtctt gctgctcctg 60 acgacctgtc gtctcatcac agctgatgac tccagaggta cgcagaagca tcgttccctg 120 aggtcgacta ctaaagtctc catgtcgact cgctgcaagg gtaaaggagc atcatgtctt 180 aggactgcgt atgactgctg caccggttct tgcaacagag gtagatgtgg ctgatccagc 240 gtctgatctt cccccttctg tgctctatcc ttttctgctt gagtcctcct ta 292 270 71 PRT Conus striolatus 270 Met Lys Leu Thr Cys Val Val Ile Val Val Leu Leu Leu Leu Thr Thr 1 5 10 15 Cys Arg Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Arg Ser Thr Thr Lys Val Ser Met Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Ala Ser Cys Leu Arg Thr Ala Tyr Asp Cys Cys Thr Gly Ser 50 55 60 Cys Asn Arg Gly Arg Cys Gly 65 70 271 25 PRT Conus striolatus PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 271 Cys Lys Gly Lys Gly Ala Ser Cys Leu Arg Thr Ala Xaa Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Asn Arg Gly Arg Cys 20 25 272 259 DNA Conus striolatus 272 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt tctgctgacg 60 gcgtgtcaac tcatcacagc tgaggactcc agaggtacac agaagcatcg taccctgagg 120 tcgaccgtca gacgctccaa gtccgagttg actacgagat gcaggccttc aggatccaac 180 tgtggtaata ttagtatctg ctgtggtaga tgcgttaaca gaagatgtac gtagctcatc 240 gggcgtctga tctttcccc 259 273 71 PRT Conus striolatus 273 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Thr Ala Cys 1 5 10 15 Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr Gln Lys His Arg Thr 20 25 30 Leu Arg Ser Thr Val Arg Arg Ser Lys Ser Glu Leu Thr Thr Arg Cys 35 40 45 Arg Pro Ser Gly Ser Asn Cys Gly Asn Ile Ser Ile Cys Cys Gly Arg 50 55 60 Cys Val Asn Arg Arg Cys Thr 65 70 274 24 PRT Conus striolatus PEPTIDE (1)..(24) Xaa at residue 3 is Pro or Hyp 274 Cys Arg Xaa Ser Gly Ser Asn Cys Gly Asn Ile Ser Ile Cys Cys Gly 1 5 10 15 Arg Cys Val Asn Arg Arg Cys Thr 20 275 280 DNA Conus striolatus 275 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt tctgttcctg 60 acggcgtgtc aactcatcac agctgaggac tccagaggta cacagaagca tcgttccctg 120 aggtcgacta ccaaagtctc caagtcgact agctgcatga aagccgggtc ttattgcgtc 180 gctactacga gaatctgctg cggttattgc gcttatttcg gcaaaatatg tattgactat 240 cccaaaaact gatcttcccc ctactgtgct ctatcctttt 280 276 77 PRT Conus striolatus 276 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ser Leu Arg Ser Thr Thr Lys Val Ser Lys Ser Thr Ser Cys Met Lys 35 40 45 Ala Gly Ser Tyr Cys Val Ala Thr Thr Arg Ile Cys Cys Gly Tyr Cys 50 55 60 Ala Tyr Phe Gly Lys Ile Cys Ile Asp Tyr Pro Lys Asn 65 70 75 277 35 PRT Conus striolatus PEPTIDE (1)..(35) Xaa at residue 33 is Pro or Hyp; Xaa at residue 10, 21, 24 and 32 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 277 Ser Thr Ser Cys Met Lys Ala Gly Ser Xaa Cys Val Ala Thr Thr Arg 1 5 10 15 Ile Cys Cys Gly Xaa Cys Ala Xaa Phe Gly Lys Ile Cys Ile Asp Xaa 20 25 30 Xaa Lys Asn 35 278 174 DNA Conus textile 278 gttgactcgg tactgcacgc ctcatggagg acattgtggt tatcataatg actgctgcag 60 tcatcaatgc aatataaaca gaaataaatg tgagtagctg atctggcatc tgatctgtgc 120 tcgtccttac ctgagagtgg tcatgaacca ctcatcacct actcctctgg aggc 174 279 31 PRT Conus textile 279 Leu Thr Arg Tyr Cys Thr Pro His Gly Gly His Cys Gly Tyr His Asn 1 5 10 15 Asp Cys Cys Ser His Gln Cys Asn Ile Asn Arg Asn Lys Cys Glu 20 25 30 280 28 PRT Conus textile PEPTIDE (1)..(28) Xaa at residue 28 is Glu or gamma-carboxy Glu; Xaa at residue 4 is Pro or Hyp; Xaa at residue 1 and 11 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 280 Xaa Cys Thr Xaa His Gly Gly His Cys Gly Xaa His Asn Asp Cys Cys 1 5 10 15 Ser His Gln Cys Asn Ile Asn Arg Asn Lys Cys Xaa 20 25 281 28 PRT Conus textile PEPTIDE (1)..(28) Xaa at residue 28 is Glu or gamma-carboxy Glu; Xaa at residue 4 is Pro or Hyp; Xaa at residue 1 and 11 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 281 Xaa Cys Thr Xaa Xaa Gly Gly His Cys Gly Xaa His Asn Asp Cys Cys 1 5 10 15 Ser His Gln Cys Asn Ile Asn Arg Asn Lys Cys Xaa 20 25 282 379 DNA Conus tulipa 282 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcatcac agctctgcac tccagaggta cgcagaagca tcgtgccctg 120 gggcggacca ccaaactcac cttgtcgact cgctgcaaat cacccggatc tccatgttca 180 ccgactagtt ataattgctg ctggtcttgc agtccataca gaaaaaaatg taggggctaa 240 tccagcgcct gattttcccc cttctgtgct ctattccttt ctgcctgagt cctccttacc 300 tgaaagtggt catgaaccac tcatcaccta cttctctgga ggcttcggag gagctacatt 360 gaaataaaag ccgcattgc 379 283 73 PRT Conus tulipa 283 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Leu His Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Gly Arg Thr Thr Lys Leu Thr Leu Ser Thr Arg Cys Lys Ser 35 40 45 Pro Gly Ser Pro Cys Ser Pro Thr Ser Tyr Asn Cys Cys Trp Ser Cys 50 55 60 Ser Pro Tyr Arg Lys Lys Cys Arg Gly 65 70 284 27 PRT Conus tulipa PEPTIDE (1)..(27) Xaa at residue 3, 7, 10 and 21 is Pro or Hyp; Xaa at residue 17 is Trp or Bromo Trp; Xaa at residue 13 and 22 is Tyr, 125I-Tyr, mono- iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 284 Cys Lys Ser Xaa Gly Ser Xaa Cys Ser Xaa Thr Ser Xaa Asn Cys Cys 1 5 10 15 Xaa Ser Cys Ser Xaa Xaa Arg Lys Lys Cys Arg 20 25 285 379 DNA Conus tulipa 285 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcatcac agctctgcac tccagaggta cgcagaagca tcgtgccctg 120 gggtcgacca ccaaactcac cttgtcgact cgctgcttgt cacccggatc ttcatgttca 180 ccgactagtt ataattgctg caggtcttgc aatccataca gcagaaaatg taggggctaa 240 tccagcgcct gatcttcccc cttctgtgct ctattccttt ctgcctgagt cctccttacc 300 tgaaagtggt catgaaccac tcatcaccta cttctctgga ggcttcggag gagctacatt 360 gaaataaaag ccgcattgc 379 286 73 PRT Conus tulipa 286 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Leu His Ser Arg Gly Thr Gln Lys His Arg 20 25 30 Ala Leu Gly Ser Thr Thr Lys Leu Thr Leu Ser Thr Arg Cys Leu Ser 35 40 45 Pro Gly Ser Ser Cys Ser Pro Thr Ser Tyr Asn Cys Cys Arg Ser Cys 50 55 60 Asn Pro Tyr Ser Arg Lys Cys Arg Gly 65 70 287 27 PRT Conus tulipa PEPTIDE (1)..(27) Xaa at residue 4, 10 and 21 is Pro or Hyp; Xaa at residue 13 and 22 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 287 Cys Leu Ser Xaa Gly Ser Ser Cys Ser Xaa Thr Ser Xaa Asn Cys Cys 1 5 10 15 Arg Ser Cys Asn Xaa Xaa Ser Arg Lys Cys Arg 20 25 288 401 DNA Conus viola 288 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgatgac tccagaggta cgcagttgca tcgtgccctg 120 aggaaggcca ccaaactccc cgtgtcgact cgctgcatta ctttaggaac acgatgtaag 180 gttccgagtc aatgctgcag atcttcttgc aagaacggtc gttgtgctcc atcccctgaa 240 gaatggtaaa tgtggctgat ccagcgcctg atcttccccc ttctgactgt ctccgacctt 300 ttctgcctga gtcctcctta cctgagaggt gtcatgaacc actcatcacc tactcccctg 360 gaagcttcag aggagctaca ttgaaataaa agccgcattg c 401 289 76 PRT Conus viola 289 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Leu His Arg 20 25 30 Ala Leu Arg Lys Ala Thr Lys Leu Pro Val Ser Thr Arg Cys Ile Thr 35 40 45 Leu Gly Thr Arg Cys Lys Val Pro Ser Gln Cys Cys Arg Ser Ser Cys 50 55 60 Lys Asn Gly Arg Cys Ala Pro Ser Pro Glu Glu Trp 65 70 75 290 31 PRT Conus viola PEPTIDE (1)..(31) Xaa at residue 29 and 30 is Glu or gamma- carboxy Glu; Xaa at residue 11, 26 and 28 is Pro or Hyp; Xaa at residue 31 is Trp or Bromo- Trp 290 Cys Ile Thr Leu Gly Thr Arg Cys Lys Val Xaa Ser Gln Cys Cys Arg 1 5 10 15 Ser Ser Cys Lys Asn Gly Arg Cys Ala Xaa Ser Xaa Xaa Xaa Xaa 20 25 30 291 372 DNA Conus viola 291 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattat agctggggac tccagaggta cgcagttgca tcgtgccctg 120 aggaaggcca ccaaactctc cgtgtcgact cgctgcaaga gtagaggatc atcatgtcgt 180 aggacttcgt atgactgctg cacgggttct tgcagaaatg gtaaatgtgg ctgatccagc 240 gcctgatctt cccccttctg tgctccatcc ttttctgcct gagtcctcct tacctgagag 300 tgggcatgaa ccactcatca cctactccct ggaagcttca gaggagctac attgaaataa 360 aagccgcatt gc 372 292 71 PRT Conus viola 292 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Ile Ala Gly Asp Ser Arg Gly Thr Gln Leu His Arg 20 25 30 Ala Leu Arg Lys Ala Thr Lys Leu Ser Val Ser Thr Arg Cys Lys Ser 35 40 45 Arg Gly Ser Ser Cys Arg Arg Thr Ser Tyr Asp Cys Cys Thr Gly Ser 50 55 60 Cys Arg Asn Gly Lys Cys Gly 65 70 293 25 PRT Conus viola PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 293 Cys Lys Ser Arg Gly Ser Ser Cys Arg Arg Thr Ser Xaa Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Asn Gly Lys Cys 20 25 294 380 DNA Conus viola 294 accaaaacca tcatcaaaat gaaactgacg tgtgtggcga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgaagac tccagaggta cgcatgagca tcttgccctg 120 aagtcgacct ccaaagtctc caagtcgact agctgcatgg aagccagatc ttattgcgga 180 cctgctacta cgaaaatctg ctgcgatttt tgcagtccat tcagcgatag atgtatgaac 240 aatcccaaca attgatcttc ccccttgtgt gctccatctt ttctgcctga gtcctcctta 300 cctgagagtg gtcatgaacc actcatcacc tactcctctg gaggcttcag aggagttaca 360 ttgaaataaa agccgcatgc 380 295 78 PRT Conus viola 295 Met Lys Leu Thr Cys Val Ala Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr His Glu His Leu 20 25 30 Ala Leu Lys Ser Thr Ser Lys Val Ser Lys Ser Thr Ser Cys Met Glu 35 40 45 Ala Arg Ser Tyr Cys Gly Pro Ala Thr Thr Lys Ile Cys Cys Asp Phe 50 55 60 Cys Ser Pro Phe Ser Asp Arg Cys Met Asn Asn Pro Asn Asn 65 70 75 296 36 PRT Conus viola PEPTIDE (1)..(36) Xaa at residue6 is Glu or gamma-carboxy Glu; Xaa at residue 13, 25 and 34 is Pro or Hyp; Xaa at residue 10 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 296 Ser Thr Ser Cys Met Xaa Ala Arg Ser Xaa Cys Gly Xaa Ala Thr Thr 1 5 10 15 Lys Ile Cys Cys Asp Phe Cys Ser Xaa Phe Ser Asp Arg Cys Met Asn 20 25 30 Asn Xaa Asn Asn 35 297 373 DNA Conus viola 297 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgctcctg 60 acggcctgtc agctcattac agctgaggac tccagaggta cgcagttgca tcgtgccctg 120 aggaagacca ccaaactctc cttgtcgact cgctgcaagg gtccaggagc catatgtata 180 aggattgcgt ataactgctg caagtattct tgcggaaatg gtaaatgtgg ctgatccagc 240 gcctgatctt cccccttgtg tgctccatcc tttttctgcc tgagtcctcc ttacctgaga 300 gtggtcatga accactcatc acctactcct ctggaggctt cagaggagct acattgaaat 360 aaaagccgca tgc 373 298 71 PRT Conus viola 298 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Asp Ser Arg Gly Thr Gln Leu His Arg 20 25 30 Ala Leu Arg Lys Thr Thr Lys Leu Ser Leu Ser Thr Arg Cys Lys Gly 35 40 45 Pro Gly Ala Ile Cys Ile Arg Ile Ala Tyr Asn Cys Cys Lys Tyr Ser 50 55 60 Cys Gly Asn Gly Lys Cys Gly 65 70 299 25 PRT Conus viola PEPTIDE (1)..(25) Xaa at residue 3 is Pro or Hyp; Xaa at residue 13 and 18 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 299 Cys Lys Gly Xaa Gly Ala Ile Cys Ile Arg Ile Ala Xaa Asn Cys Cys 1 5 10 15 Lys Xaa Ser Cys Gly Asn Gly Lys Cys 20 25 300 353 DNA Conus viola 300 accaaaacca tcatcaaaat gaaactgacg tgtgtggtga tcgtcgccgt gctgttcctg 60 acggcctgtc aattcatcac agctgatgac tccagaagta cgcagaagca tcgtgccctg 120 aggtcgacca ccaaacactt tatgttgact tggtactgca cgccttatgg aggacattgt 180 ggttattata atgactgctg cagtcatcaa tgcaatataa acagaaataa atgtgagtag 240 ctgatccggc atctgatctg tgctcgccct aacctgagag tggtcatgaa ccactcatca 300 tctactcctc tggaggcttc agaggagcta catggaaata aaagccgcat tgc 353 301 73 PRT Conus viola 301 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Phe Ile Thr Ala Asp Asp Ser Arg Ser Thr Gln Lys His Arg 20 25 30 Ala Leu Arg Ser Thr Thr Lys His Phe Met Leu Thr Trp Tyr Cys Thr 35 40 45 Pro Tyr Gly Gly His Cys Gly Tyr Tyr Asn Asp Cys Cys Ser His Gln 50 55 60 Cys Asn Ile Asn Arg Asn Lys Cys Glu 65 70 302 28 PRT Conus viola PEPTIDE (1)..(28) Xaa at residue 28 is Glu or gamma-carboxy Glu; Xaa at residue 4 is Pro or Hyp; Xaa at residue 1, 5, 11 and 12 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 302 Xaa Cys Thr Xaa Xaa Gly Gly His Cys Gly Xaa Xaa Asn Asp Cys Cys 1 5 10 15 Ser His Gln Cys Asn Ile Asn Arg Asn Lys Cys Xaa 20 25 303 294 DNA Conus pulicarius 303 ggatccatga aactgacgtg cgtggtgatt atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcattacag ctgagactta ctccagaggt aagcagatgc accgtgctct gaggtcaact 120 gacaaaaact ccaagttgac cagggaatgc acacctccag atggagcttg tggtttacct 180 acacactgct gcgggttttg cgatatggca aacaacagat gtctgtaaag cgtctgatat 240 tccccttctg tgctctatcc tctttggcct gagtcatcca tacctgtgct cgag 294 304 73 PRT Conus pulicarius 304 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Lys Gln Met His 20 25 30 Arg Ala Leu Arg Ser Thr Asp Lys Asn Ser Lys Leu Thr Arg Glu Cys 35 40 45 Thr Pro Pro Asp Gly Ala Cys Gly Leu Pro Thr His Cys Cys Gly Phe 50 55 60 Cys Asp Met Ala Asn Asn Arg Cys Leu 65 70 305 27 PRT Conus pulicarius PEPTIDE (1)..(27) Xaa at residue 1 is Glu or gamma-carboxy Glu; Xaa at residue 4, 5 and 12 is Pro or Hyp 305 Xaa Cys Thr Xaa Xaa Asp Gly Ala Cys Gly Leu Xaa Thr His Cys Cys 1 5 10 15 Gly Phe Cys Asp Met Ala Asn Asn Arg Cys Leu 20 25 306 294 DNA Conus pulicarius 306 ggatccatga aactgacgtg cgtggtgatt atcgccgtgc tgttcctgac ggcctgtcaa 60 ctcattacag ctgagactta ctccagaggt aagcagatgc accgtgctct gaggtcaact 120 gacaaaaact cccagttgac cagggaatgc acacctccag gtggagcttg tggtttacct 180 acacactgct gcgggttttg cgatatggca aacaacagat gtctgtaaag cgtctgatat 240 tccccttctg tgctctatcc tctttggcct gagtcatcca tacctgtgct cgag 294 307 73 PRT Conus pulicarius 307 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Glu Thr Tyr Ser Arg Gly Lys Gln Met His 20 25 30 Arg Ala Leu Arg Ser Thr Asp Lys Asn Ser Gln Leu Thr Arg Glu Cys 35 40 45 Thr Pro Pro Gly Gly Ala Cys Gly Leu Pro Thr His Cys Cys Gly Phe 50 55 60 Cys Asp Met Ala Asn Asn Arg Cys Leu 65 70 308 27 PRT Conus pulicarius PEPTIDE (1)..(27) Xaa at residue 1 is Glu or gamma-carboxy Glu; Xaa at residue 4, 5 and 12 is Pro or Hyp 308 Xaa Cys Thr Xaa Xaa Gly Gly Ala Cys Gly Leu Xaa Thr His Cys Cys 1 5 10 15 Gly Phe Cys Asp Met Ala Asn Asn Arg Cys Leu 20 25 309 307 DNA Conus rattus 309 ggatccatga aactgacgtg tgtggtgatc atcgccgtgc tgttcctggc agcctgtcaa 60 cctgttacaa ctgagacttt ctccagaggt aaggagaagc gtcgtgctct gaggtcaact 120 gacggcaact cccggttgac cagggcatgc acgcctgaag gtggagcctg tagtagtggg 180 cgtcactgct gcggcttttg cgataacgtg tcccacacgt gctatggtga aacaccatct 240 ctccactgat gtttcccctt ctgtgctcta tcttcttttg cctgagtcat ccatacctgt 300 gctcgag 307 310 80 PRT Conus rattus 310 Met Lys Leu Thr Cys Val Val Ile Ile Ala Val Leu Phe Leu Ala Ala 1 5 10 15 Cys Gln Pro Val Thr Thr Glu Thr Phe Ser Arg Gly Lys Glu Lys Arg 20 25 30 Arg Ala Leu Arg Ser Thr Asp Gly Asn Ser Arg Leu Thr Arg Ala Cys 35 40 45 Thr Pro Glu Gly Gly Ala Cys Ser Ser Gly Arg His Cys Cys Gly Phe 50 55 60 Cys Asp Asn Val Ser His Thr Cys Tyr Gly Glu Thr Pro Ser Leu His 65 70 75 80 311 34 PRT Conus rattus PEPTIDE (1)..(34) Xaa at residue 5 and 29 is Glu or gamma-carboxy Glu; Xaa at residue 4 and 31 is Pro or Hyp; Xaa at residue 27 is Tyr, 125I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 311 Ala Cys Thr Xaa Xaa Gly Gly Ala Cys Ser Ser Gly Arg His Cys Cys 1 5 10 15 Gly Phe Cys Asp Asn Val Ser His Thr Cys Xaa Gly Xaa Thr Xaa Ser 20 25 30 Leu His 312 342 DNA Conus stercusmuscarum misc_feature (1)..(342) n may be any nucleotide 312 agatccatga aactgacgtg cgtggtgatc gtcgccgtgc tgctcctgac ggcctgtcaa 60 ctcatcacag ctgatgactc cagaggtacg caggagcatc gtgccctgag gtcggacacc 120 aaactcccca tatcgactcg ctgcaagggt aaaggagcat catgtcataa gactatgtat 180 gactgctgca gcggttcctg caccagaggt agatgtggct gatccagcgc ctgatcttcc 240 cccttctgtg ctctatcctt ttctgcctga gtcatcatac ctgtgctcga gcgttactag 300 tggatccgag ctcggtacca agcttggcgt aatcataaaa nc 342 313 71 PRT Conus stercusmuscarum 313 Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala 1 5 10 15 Cys Gln Leu Ile Thr Ala Asp Asp Ser Arg Gly Thr Gln Glu His Arg 20 25 30 Ala Leu Arg Ser Asp Thr Lys Leu Pro Ile Ser Thr Arg Cys Lys Gly 35 40 45 Lys Gly Ala Ser Cys His Lys Thr Met Tyr Asp Cys Cys Ser Gly Ser 50 55 60 Cys Thr Arg Gly Arg Cys Gly 65 70 314 25 PRT Conus stercusmuscarum PEPTIDE (1)..(25) Xaa at residue 13 is Tyr, 125I-Tyr, mono-iodo- Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr 314 Cys Lys Gly Lys Gly Ala Ser Cys His Lys Thr Met Xaa Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Thr Arg Gly Arg Cys 20 25 315 33 PRT Conus arenatus 315 Gln Cys Ser Ala Asn Gly Gly Ser Cys Thr Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Tyr Cys Asn Lys Asp Ser Ser Val Cys Val Ala Thr Ser Tyr 20 25 30 Pro 316 28 PRT Conus arenatus 316 Thr Cys Asn Thr Pro Thr Glu Tyr Cys Thr Leu His Arg His Cys Cys 1 5 10 15 Ser Gly Tyr Cys His Lys Thr Ile Gln Ala Cys Ser 20 25 317 33 PRT Conus arenatus 317 Gln Cys Thr Pro Asn Gly Gly Ser Cys Ser Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Tyr Cys Asn Lys Ser Thr Gly Val Cys Ile Ala Thr Ser Tyr 20 25 30 Pro 318 33 PRT Conus arenatus 318 Gln Cys Thr Pro Asn Gly Gly Ser Cys Ser Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Tyr Cys Asn Lys Ser Thr Gly Val Cys Ile Ala Thr Ser Tyr 20 25 30 Pro 319 27 PRT Conus arenatus 319 Glu Cys Thr Pro Pro Gly Gly Ala Cys Gly Leu Pro Thr His Cys Cys 1 5 10 15 Gly Phe Cys Asp Thr Ala Asn Asn Arg Cys Leu 20 25 320 28 PRT Conus arenatus 320 Thr Cys Asn Thr Pro Thr Glu Tyr Cys Thr Leu His Gln His Cys Cys 1 5 10 15 Ser Gly His Cys His Lys Thr Ile Gln Ala Cys Ala 20 25 321 30 PRT Conus arenatus 321 Gln Cys Ser Pro Ile Gly Gly Tyr Cys Thr Leu His Ile His Cys Cys 1 5 10 15 Ser Asn His Cys Ile Lys Pro Ile Gly Arg Cys Val Ala Thr 20 25 30 322 30 PRT Conus arenatus 322 Gln Cys Leu Pro Asn Gly Gly Tyr Cys Thr Leu His Ile His Cys Cys 1 5 10 15 Ser Asp His Cys Ile Lys Pro Ile Asp Arg Cys Val Ala Thr 20 25 30 323 25 PRT Conus aurisiacus 323 Cys Lys Gly Lys Gly Lys Pro Cys Ser Arg Ile Ser Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 324 32 PRT Conus aurisiacus 324 Cys Met Glu Ala Gly Ser Tyr Cys Gly Ser Thr Thr Arg Ile Cys Cys 1 5 10 15 Gly Phe Cys Ala Tyr Phe Gly Lys Lys Cys Ile Asp Tyr Pro Ser Asn 20 25 30 325 25 PRT Conus aurisiacus 325 Cys Lys Ala Lys Gly Lys Pro Cys Ser Arg Ile Ala Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 326 26 PRT Conus aurisiacus 326 Cys Ala Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Pro Gly Arg Asn Ile Cys Thr 20 25 327 36 PRT Conus bullatus 327 Ser Thr Ser Cys Met Glu Ala Gly Ser Tyr Cys Gly Pro Ala Thr Thr 1 5 10 15 Lys Ile Cys Cys Asp Phe Cys Ser Pro Phe Ser Asp Arg Cys Met Asn 20 25 30 Asn Pro Asn Asn 35 328 31 PRT Conus bullatus 328 Cys Ile Thr Pro Gly Thr Arg Cys Lys Val Pro Ser Gln Cys Cys Arg 1 5 10 15 Gly Pro Cys Lys Asn Gly Arg Cys Thr Pro Ser Pro Ser Glu Trp 20 25 30 329 26 PRT Conus bullatus 329 Cys Ala Thr Tyr Gly Lys Pro Cys Gly Ile Gln Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Pro Ala Arg Arg Thr Cys Thr 20 25 330 25 PRT Conus bullatus 330 Cys Lys Gly Pro Gly Ala Ser Cys Ile Arg Ile Ala Tyr Asn Cys Cys 1 5 10 15 Lys Tyr Ser Cys Arg Asn Gly Lys Cys 20 25 331 36 PRT Conus bullatus 331 Ser Thr Ser Cys Met Ala Ala Gly Ser Tyr Cys Gly Pro Ala Thr Thr 1 5 10 15 Asn Ile Cys Cys Asp Phe Cys Ser Pro Phe Ser Asp Arg Cys Met Lys 20 25 30 Lys Pro Asn Asn 35 332 25 PRT Conus bullatus 332 Cys Lys Ser Lys Gly Ser Ser Cys His Arg Thr Ser Tyr Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Asn Gly Arg Cys 20 25 333 25 PRT Conus catus 333 Cys Lys Ser Thr Gly Ala Ser Cys Arg Arg Thr Ser Tyr Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Arg Cys 20 25 334 25 PRT Conus catus 334 Cys Gln Gly Arg Gly Ala Ser Cys Arg Lys Thr Met Tyr Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Asn Arg Gly Ser Cys 20 25 335 28 PRT Conus catus 335 Cys Leu Pro Ala Gly Glu Ser Cys Leu Phe Ser Arg Ile Arg Cys Cys 1 5 10 15 Gly Thr Cys Ser Ser Val Leu Lys Ser Cys Val Ser 20 25 336 25 PRT Conus catus 336 Cys Gln Gly Arg Gly Gly Pro Cys Thr Lys Ala Val Phe Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Asn Arg Gly Arg Cys 20 25 337 26 PRT Conus catus 337 Cys Ala Thr Tyr Gly Lys Pro Cys Gly Ile Gln Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Pro Ala Arg Lys Thr Cys Thr 20 25 338 25 PRT Conus catus 338 Cys Arg Gly Arg Gly Gly Pro Cys Thr Lys Ala Met Phe Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Asn Arg Gly Arg Cys 20 25 339 33 PRT Conus caracteristicus 339 Gln Cys Ser Ala Asn Gly Gly Ser Cys Thr Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Tyr Cys Asn Lys Asp Ser Ser Val Cys Val Ala Thr Ser Tyr 20 25 30 Pro 340 26 PRT Conus consors 340 Cys Ala Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Pro Ala Arg Lys Thr Cys Thr 20 25 341 25 PRT Conus consors 341 Cys Lys Gly Thr Gly Lys Pro Cys Ser Arg Ile Ala Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 342 36 PRT Conus consors 342 Ala Thr Asp Cys Ile Glu Ala Gly Asn Tyr Cys Gly Pro Thr Val Met 1 5 10 15 Lys Ile Cys Cys Gly Phe Cys Ser Pro Tyr Ser Lys Ile Cys Met Asn 20 25 30 Tyr Pro Gln Asn 35 343 27 PRT Conus catus 343 Cys Lys Gly Lys Gly Ala Ser Cys Thr Arg Leu Met Tyr Asp Cys Cys 1 5 10 15 His Gly Ser Cys Ser Ser Ser Lys Gly Arg Cys 20 25 344 25 PRT Conus consors 344 Cys Lys Gly Lys Gly Ala Ser Cys His Arg Thr Ser Tyr Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Asn Arg Gly Lys Cys 20 25 345 26 PRT Conus consors 345 Cys Ala Ser Tyr Gly Lys Pro Cys Gly Ile Tyr Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Pro Ala Arg Lys Thr Cys Thr 20 25 346 25 PRT Conus consors 346 Cys Lys Gly Thr Gly Lys Pro Cys Ser Arg Val Ala Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 347 35 PRT Conus consors 347 Ser Thr Ser Cys Met Lys Ala Gly Ser Tyr Cys Arg Ser Thr Thr Arg 1 5 10 15 Thr Cys Cys Gly Tyr Cys Ala Tyr Phe Gly Lys Phe Cys Ile Asp Phe 20 25 30 Pro Ser Asn 35 348 25 PRT Conus circumcisus 348 Cys Lys Gly Lys Gly Ala Ser Cys Arg Lys Thr Met Tyr Asn Cys Cys 1 5 10 15 Ser Gly Ser Cys Ser Asn Gly Arg Cys 20 25 349 35 PRT Conus circumcisus 349 Ser Thr Ser Cys Met Glu Ala Gly Ser Tyr Cys Arg Ser Thr Thr Arg 1 5 10 15 Thr Cys Cys Gly Tyr Cys Ser Tyr Phe Ser Lys Lys Cys Ile Asp Phe 20 25 30 Pro Ser Asn 35 350 27 PRT Conus circumcisus 350 Cys Lys Ser Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Ser Arg Tyr Ser Gly Arg Cys 20 25 351 35 PRT Conus circumcisus 351 Ser Thr Gly Cys Met Lys Ala Gly Ser Tyr Cys Arg Ser Thr Thr Arg 1 5 10 15 Thr Cys Cys Gly Tyr Cys Ala Tyr Phe Gly Lys Lys Cys Ile Asp Tyr 20 25 30 Pro Ser Asn 35 352 28 PRT Conus dalli 352 Ser Cys Thr Pro Pro Gly Gly Pro Cys Gly Tyr Tyr Asn Asp Cys Cys 1 5 10 15 Ser His Gln Cys Asn Ile Ser Arg Asn Lys Cys Glu 20 25 353 25 PRT Conus distans PEPTIDE (1)..(25) Xaa is Hyp 353 Cys Glu Asp Xaa Gly Glu Xaa Cys Gly Ser Asp His Ser Cys Cys Gly 1 5 10 15 Gly Ser Cys Asn His Asn Val Cys Ala 20 25 354 27 PRT Conus ermineus 354 Pro Cys Lys Pro Lys Gly Arg Lys Cys Phe Pro His Gln Lys Asp Cys 1 5 10 15 Cys Asn Lys Thr Cys Thr Arg Ser Lys Cys Pro 20 25 355 27 PRT Conus ermineus 355 Ala Cys Trp Ser Ser Gly Thr Pro Cys Gly Thr Asp Ser Leu Cys Cys 1 5 10 15 Gly Gly Cys Asn Val Ser Lys Ser Lys Cys Asn 20 25 356 27 PRT Conus geographus 356 Cys Lys Ser Pro Gly Ser Ser Cys Ser Pro Thr Ser Tyr Asn Cys Cys 1 5 10 15 Arg Ser Cys Asn Pro Tyr Ala Lys Arg Cys Tyr 20 25 357 29 PRT Conus geographus 357 Cys Lys Ser Pro Gly Thr Pro Cys Ser Arg Gly Met Arg Asp Cys Cys 1 5 10 15 Thr Pro Cys Leu Leu Tyr Ser Asn Lys Cys Arg Arg Tyr 20 25 358 30 PRT Unknown unknown Conus species 358 Cys Leu Ser Pro Gly Ser Arg Cys His Lys Thr Met Arg Asn Cys Cys 1 5 10 15 Thr Ser Cys Ser Ser Tyr Lys Gly Lys Cys Arg Pro Arg Lys 20 25 30 359 27 PRT Unknown unknown Conus species 359 Cys Lys Pro Pro Gly Arg Lys Cys Leu Asn Arg Lys Asn Glu Cys Cys 1 5 10 15 Ser Lys Phe Cys Asn Glu His Leu His Met Cys 20 25 360 26 PRT Unknown unknown Conus species 360 Cys Lys Pro Pro Arg Arg Lys Cys Leu Lys Ile Lys Asp Lys Cys Cys 1 5 10 15 Asn Phe Cys Asn Thr His Leu Asn Met Cys 20 25 361 28 PRT Unknown unknown Conus species 361 Cys Ala Gly Pro Gly Thr Ile Cys Pro Asn Arg Val Cys Cys Gly Tyr 1 5 10 15 Cys Ser Lys Arg Thr His Leu Cys His Ser Arg Thr 20 25 362 27 PRT Conus laterculatus 362 Lys Cys Trp Pro Ser Gly Ser Tyr Cys Arg Ala Asn Ser Lys Cys Cys 1 5 10 15 Ser Gly Cys Asp Arg Asn Arg Asn Lys Cys Tyr 20 25 363 27 PRT Conus laterculatus 363 Cys Leu Pro Pro Gly Ser Tyr Cys Lys Ala Thr Thr Glu Val Cys Cys 1 5 10 15 Ser Ser Cys Leu Gln Phe Ala Gln Ile Cys Ser 20 25 364 30 PRT Conus lynceus 364 Cys Lys Ser Pro Gly Ser Pro Cys Ser Val Thr Ser Tyr Asn Cys Cys 1 5 10 15 Thr Phe Cys Ser Ser Tyr Thr Lys Lys Cys Arg Ala Ser Leu 20 25 30 365 28 PRT Conus lynceus 365 Cys Ala Gly Pro Gly Ala Ile Cys Pro Asn Arg Val Cys Cys Gly Tyr 1 5 10 15 Cys Ser Lys Arg Thr His Leu Cys His Ser Arg Thr 20 25 366 27 PRT Conus lynceus 366 Ala Cys Trp Ser Ser Gly Thr Pro Cys Gly Thr Asp Ser Leu Cys Cys 1 5 10 15 Gly Gly Cys Asn Val Ser Lys Ser Lys Cys Asn 20 25 367 27 PRT Conus lynceus 367 Lys Cys Trp Ser Pro Gly Thr Tyr Cys Arg Ala His Ser Lys Cys Cys 1 5 10 15 Arg Gly Cys Asp Gln Asn Arg Asn Lys Cys Tyr 20 25 368 29 PRT Conus laterculatus 368 Cys Lys Ser Pro Gly Ser Ser Cys Ser Val Ser Met Arg Asn Cys Cys 1 5 10 15 Thr Ser Cys Asn Ser Arg Thr Lys Lys Cys Thr Arg Arg 20 25 369 27 PRT Conus laterculatus 369 Thr Cys Trp Pro Ser Gly Thr Ala Cys Gly Ile Asp Ser Asn Cys Cys 1 5 10 15 Ser Gly Cys Asn Val Ser Arg Ser Lys Cys Asn 20 25 370 27 PRT Conus laterculatus 370 Lys Cys Trp Pro Ser Gly Ser Tyr Cys Arg Ala Asn Ser Lys Cys Cys 1 5 10 15 Ser Gly Cys Asp Arg Asn Arg Ser Lys Cys Asn 20 25 371 37 PRT Conus leopardus 371 Ser Leu Phe Glu Cys Ala Pro Ser Gly Gly Arg Cys Gly Phe Leu Lys 1 5 10 15 Ser Cys Cys Glu Gly Tyr Cys Asp Gly Glu Ser Thr Ser Cys Val Ser 20 25 30 Gly Pro Tyr Ser Ile 35 372 30 PRT Conus leopardus 372 Trp Pro Leu Asp Cys Thr Ala Pro Ser Gln Pro Cys Gly Tyr Phe Pro 1 5 10 15 Arg Cys Cys Gly His Cys Asp Val Arg Arg Val Cys Thr Ser 20 25 30 373 31 PRT Conus leopardus 373 Cys Met Ser Pro Gly Gly Ile Cys Gly Asp Phe Gly Asp Cys Cys Glu 1 5 10 15 Ile Cys Asn Val Tyr Gly Ile Cys Val Ser Asp Leu Pro Gly Ile 20 25 30 374 27 PRT Conus leopardus 374 Tyr Cys Ala Pro Pro Gly Gly Ala Cys Gly Phe Phe Asp His Cys Cys 1 5 10 15 Gly Tyr Cys Glu Thr Phe Tyr Asn Thr Cys Arg 20 25 375 25 PRT Conus magus 375 Cys Lys Gly Thr Gly Lys Pro Cys Ser Arg Ile Ala Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 376 26 PRT Conus magus 376 Cys Ala Ser Tyr Gly Lys Pro Cys Gly Ile Tyr Asn Asp Cys Cys Asn 1 5 10 15 Thr Cys Asp Pro Ala Arg Lys Thr Cys Thr 20 25 377 27 PRT Conus miles 377 Cys Asn Asp Arg Gly Gly Gly Cys Ser Gln His Pro His Cys Cys Gly 1 5 10 15 Gly Thr Cys Asn Lys Leu Ile Gly Val Cys Leu 20 25 378 25 PRT Conus monachus 378 Cys Lys Ser Thr Gly Lys Ser Cys Ser Arg Ile Ala Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 379 25 PRT Conus monachus 379 Cys Lys Gly Lys Gly Ser Ser Cys Ser Arg Thr Met Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Asn Arg Gly Lys Cys 20 25 380 35 PRT Conus obscurus 380 Ser Pro Pro Cys Met Lys Gly Gly Ser Ser Cys Arg Gly Thr Thr Gly 1 5 10 15 Val Cys Cys Gly Phe Cys Ser Asp Phe Gly Tyr Lys Cys Arg Asp Tyr 20 25 30 Pro Gln Asn 35 381 28 PRT Conus obscurus 381 Cys Leu Pro Asp Gly Thr Ser Cys Leu Phe Ser Arg Ile Arg Cys Cys 1 5 10 15 Gly Thr Cys Ser Ser Ile Leu Lys Ser Cys Val Ser 20 25 382 27 PRT Conus purpurascens PEPTIDE (1)..(27) Xaa is Hyp 382 Xaa Cys Lys Thr Xaa Gly Arg Lys Cys Phe Xaa His Gln Lys Asp Cys 1 5 10 15 Cys Gly Arg Ala Cys Ile Ile Thr Ile Cys Pro 20 25 383 26 PRT Conus purpurascens PEPTIDE (1)..(26) Xaa at residue 5 is Hyp; Xaa at residue 12 is gamma-carboxy-Glu 383 Ser Cys Lys Leu Xaa Gly Ala Tyr Cys Asn Ala Xaa Asp Tyr Asp Cys 1 5 10 15 Cys Leu Arg Cys Lys Val Gly Gly Thr Cys 20 25 384 27 PRT Conus purpurascens 384 Pro Cys Lys Lys Thr Gly Arg Lys Cys Phe Pro His Gln Lys Asp Cys 1 5 10 15 Cys Gly Arg Ala Cys Ile Ile Thr Ile Cys Pro 20 25 385 30 PRT Conus pulicarius 385 Gln Cys Ser Pro Asn Gly Gly Ser Cys Ser Arg His Phe His Cys Cys 1 5 10 15 Ser Leu Tyr Cys Asn Lys Asn Thr Gly Val Cys Ile Ala Thr 20 25 30 386 27 PRT Conus pulicarius 386 Glu Cys Thr Pro Pro Asp Gly Ala Cys Gly Leu Pro Thr His Cys Cys 1 5 10 15 Gly Phe Cys Asp Met Ala Asn Asn Arg Cys Leu 20 25 387 27 PRT Conus pulicarius 387 Glu Cys Thr Pro Pro Gly Gly Ala Cys Gly Leu Pro Thr His Cys Cys 1 5 10 15 Gly Phe Cys Asp Met Ala Asn Asn Arg Cys Leu 20 25 388 28 PRT Conus radiatus 388 His Gly Cys Lys Pro Leu Lys Arg Arg Cys Phe Asn Asp Lys Glu Cys 1 5 10 15 Cys Ser Lys Phe Cys Asn Ser Val Arg Lys Gln Cys 20 25 389 28 PRT Conus radiatus 389 Arg Gly Cys Lys Pro Leu Lys Arg Arg Cys Phe Asn Asp Lys Glu Cys 1 5 10 15 Cys Ser Lys Phe Cys Asn Ser Val Arg Asn Gln Cys 20 25 390 27 PRT Conus rattus 390 Cys Asn Ala Arg Asn Asp Gly Cys Ser Gln His Ser Gln Cys Cys Ser 1 5 10 15 Gly Ser Cys Asn Lys Thr Ala Gly Val Cys Leu 20 25 391 27 PRT Conus rattus 391 Cys Asn Ala Arg Asn Ser Gly Cys Ser Gln His Pro Gln Cys Cys Ser 1 5 10 15 Gly Ser Cys Asn Lys Thr Ala Gly Val Cys Leu 20 25 392 27 PRT Conus rattus 392 Cys Asn Ala Arg Asn Ser Gly Cys Ser Gln His Pro Gln Cys Cys Ser 1 5 10 15 Gly Ser Cys Asn Lys Thr Leu Gly Val Cys Leu 20 25 393 34 PRT Conus rattus 393 Ala Cys Thr Pro Glu Gly Gly Ala Cys Ser Ser Gly Arg His Cys Cys 1 5 10 15 Gly Phe Cys Asp Asn Val Ser His Thr Cys Tyr Gly Glu Thr Pro Ser 20 25 30 Leu His 394 36 PRT Conus striatus 394 Ala Thr Asp Cys Ile Glu Ala Gly Asn Tyr Cys Gly Pro Thr Val Met 1 5 10 15 Lys Ile Cys Cys Gly Phe Cys Ser Pro Tyr Ser Lys Ile Cys Met Asn 20 25 30 Tyr Pro Lys Asn 35 395 26 PRT Conus striatus 395 Cys Lys Leu Lys Gly Gln Ser Cys Arg Arg Thr Met Tyr Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Gly Arg Arg Gly Lys Cys 20 25 396 25 PRT Conus striatus 396 Cys Lys Ala Ala Gly Lys Ser Cys Ser Arg Ile Ala Tyr Asn Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 397 26 PRT Conus striatus 397 Cys Glu Ser Tyr Gly Lys Pro Cys Gly Ile Tyr Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Pro Ala Lys Lys Thr Cys Thr 20 25 398 27 PRT Conus stercusmuscarum 398 Cys Lys Ser Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Ser Gly Tyr Thr Gly Arg Cys 20 25 399 35 PRT Conus stercusmuscarum 399 Thr Thr Ser Cys Met Gln Ala Gly Ser Tyr Cys Gly Ser Thr Thr Arg 1 5 10 15 Ile Cys Cys Gly Tyr Cys Ala Tyr Phe Gly Lys Lys Cys Ile Asp Tyr 20 25 30 Pro Ser Asn 35 400 26 PRT Conus stercusmuscarum 400 Cys Ala Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Pro Ala Arg Asn Ile Cys Thr 20 25 401 26 PRT Conus stercusmuscarum 401 Cys Val Ser Tyr Gly Lys Pro Cys Gly Ile Asp Asn Asp Cys Cys Asn 1 5 10 15 Ala Cys Asp Pro Ala Arg Asn Ile Cys Thr 20 25 402 25 PRT Conus stercusmuscarum 402 Cys Lys Gly Lys Gly Ala Ser Cys His Lys Thr Met Tyr Asp Cys Cys 1 5 10 15 Ser Gly Ser Cys Thr Arg Gly Arg Cys 20 25 403 25 PRT Conus striolatus 403 Cys Lys Gly Lys Gly Ala Ser Cys Leu Arg Thr Ala Tyr Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Asn Arg Gly Arg Cys 20 25 404 24 PRT Conus striolatus 404 Cys Arg Pro Ser Gly Ser Asn Cys Gly Asn Ile Ser Ile Cys Cys Gly 1 5 10 15 Arg Cys Val Asn Arg Arg Cys Thr 20 405 35 PRT Conus striolatus 405 Ser Thr Ser Cys Met Lys Ala Gly Ser Tyr Cys Val Ala Thr Thr Arg 1 5 10 15 Ile Cys Cys Gly Tyr Cys Ala Tyr Phe Gly Lys Ile Cys Ile Asp Tyr 20 25 30 Pro Lys Asn 35 406 28 PRT Conus textile 406 Tyr Cys Thr Pro His Gly Gly His Cys Gly Tyr His Asn Asp Cys Cys 1 5 10 15 Ser His Gln Cys Asn Ile Asn Arg Asn Lys Cys Glu 20 25 407 31 PRT Conus viola 407 Cys Ile Thr Leu Gly Thr Arg Cys Lys Val Pro Ser Gln Cys Cys Arg 1 5 10 15 Ser Ser Cys Lys Asn Gly Arg Cys Ala Pro Ser Pro Glu Glu Trp 20 25 30 408 25 PRT Conus viola 408 Cys Lys Ser Arg Gly Ser Ser Cys Arg Arg Thr Ser Tyr Asp Cys Cys 1 5 10 15 Thr Gly Ser Cys Arg Asn Gly Lys Cys 20 25 409 36 PRT Conus viola 409 Ser Thr Ser Cys Met Glu Ala Arg Ser Tyr Cys Gly Pro Ala Thr Thr 1 5 10 15 Lys Ile Cys Cys Asp Phe Cys Ser Pro Phe Ser Asp Arg Cys Met Asn 20 25 30 Asn Pro Asn Asn 35 410 25 PRT Conus viola 410 Cys Lys Gly Pro Gly Ala Ile Cys Ile Arg Ile Ala Tyr Asn Cys Cys 1 5 10 15 Lys Tyr Ser Cys Gly Asn Gly Lys Cys 20 25 411 28 PRT Conus viola 411 Tyr Cys Thr Pro Tyr Gly Gly His Cys Gly Tyr Tyr Asn Asp Cys Cys 1 5 10 15 Ser His Gln Cys Asn Ile Asn Arg Asn Lys Cys Glu 20 25 412 27 PRT Conus textile 412 Cys Thr Pro Tyr Gly Gly His Cys Gly Tyr Asn His Asp Cys Cys Ser 1 5 10 15 His Gln Cys Asn Ile Asn Arg Asn Lys Cys Glu 20 25 413 26 PRT Conus tulipa PEPTIDE (1)..(26) Xaa is Hyp 413 Cys Lys Ser Trp Gly Ser Xaa Cys Ser Xaa Thr Ser Thr Asn Cys Cys 1 5 10 15 Trp Ser Cys Ser Pro Tyr Arg Lys Lys Cys 20 25 

What is claimed is:
 1. An isolated peptide selected from the group consisting of: (a) a peptide set forth in Table 2 (b) a derivative of the peptide in (a); and (c) a propeptide set forth in Table
 1. 2. The isolated peptide of claim 1, wherein Xaa₁ is Lys, Xaa₂ is Tyr, Xaa₃ is Glu and Xaa₅ is Trp.
 3. An isolated nucleic acid encoding an ω-conopeptide propeptide having an amino acid sequence set forth in Table
 1. 4. The isolated nucleic acid of claim 3, wherein the nucleic acid comprises a nucleotide sequence set forth in Table
 1. 5. An isolated conopeptide propeptide having an amino acid sequence set forth in Table
 1. 6. A method for treating or preventing disorders associated with voltage gated ion channel disorders which comprises administering to a patient in need thereof a therapeutically effective amount of an active agent selected from the group consisting of peptides (a) and (b) of claim 1 or a pharmaceutically acceptable salt thereof.
 7. The method of claim 6, wherein said disorder is a neurologic disorder.
 8. The method of claim 7, wherein said neurologic disorder is a seizure.
 9. The method of claim 8, wherein said seizure is seizure is associated with epilepsy.
 10. The method of claim 7, wherein said neurologic disorder is a neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia.
 11. The method of claim 10, wherein said neurotoxic injury is associated with stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drownings, suffocation, perinatal asphyxia, or hypoglycemic events.
 12. The method of claim 6, wherein said disorder is pain.
 13. The method of claim 12, wherein said pain is migraine, acute pain, persistent pain, neuropathic pain or nociceptive pain.
 14. The method of claim 6, wherein said disorder is inflammation.
 15. The method of claim 6, wherein said disorder is a cardiovascular disorder. 